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Diabetes mellitus (DM) is a developing issue around the world. This 
cutting-edge plague is one of the world's oldest sicknesses, specified 
in authentic records of ancient civilizations, for example, those found 
in old Egypt, Persian Empire, and India [1-3]. The International 
Diabetes Federation estimates that ∼415 million individuals over the 
globe were experiencing diabetes in 2015 and about 642 million 
individuals are assessed to be diabetic by 2040 [4]. Mortality 
identified with DM and its complexities results in 3.8 million passings 
yearly, representing 6% of the overall mortality [5]. Lately, records 
propose the overall prevalence of diabetes is 9.2% in females and 
9.8% in males [6].  
There are two primary types of diabetes, type 1 (T1DM) and type 2 
(T2DM), in spite of the fact that diabetes may likewise happen during 
pregnancy and under different conditions, for example, medication 
or compound poisonous quality, endocrinopathies and in a 
relationship with insulin disregluation and pancreatic exocrine 
infections [7]. The increased fasting levels of glucose, named 
hyperglycemia, is the major indicative parameter that is found in the 
two kinds of diabetes [8, 9] which can be caused by constant or 
relative insulin inadequacy [10].  
T1DM is 100% insulin dependence, and in T2DM, upwards of half of 
patients expect insulin to control hyperglycemia [8]. T1DM is caused 
by autoimmune ablation of pancreatic beta cells inside the islets of 
Langerhans, which abrogates insulin production and affects 
associated metabolic entanglements [11]. Various hereditary 
determinants of T1DM, for example, alleles of the real 
histocompatibility locus (HLA) at the HLA-DRB1, DQB1 loci [12], and 
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HLA-B*39 locus [13] represent 40% – half of the familial grouping of 
this issue. T2DM represents about 90% of all analyzed cases [14]. 
what's more, is related to both fringe insulin protection and 
hindered insulin discharge. The most sensitive tissues respect to 
instigated insulin incorporates skeletal muscle, liver, and fat tissue by 
reason of the particular necessities for glucose take-up and 
digestion. The confirmations recommend that mitochondria assume 
a part of the two procedures [15]. 
 
2. Complications of Diabetes 
Diabetes is a noteworthy reason for mortality and (co)morbidity due 
to its vascular complications. Vascular dysfunction is a causative 
factor in the etiology of essential optional difficulties of DM which 
are gathered under "microvascular sickness" (because of harm to 
small blood vessels) and "macrovascular inflammation" (because of 
harm to the arteries). Microvascular entanglements incorporate eye 
ailment named "retinopathy," kidney ailment as "nephropathy," and 
neural damage or "neuropathy". The major macrovascular 
entanglements incorporate quickened cardiovascular inflammation 
causing myocardial infarction and cerebrovascular disease showing 
as strokes [16-23]. The danger of the difficulties in T1DM as indicated 
by the Diabetes Control and Complications Cohort (DCCT) and 
Epidemiology of Diabetes Interventions and Complications (EDIC) 
[24] are 47% for retinopathy, 17% for nephropathy, and 14% for 
cardiovascular illness. For T2DM, there are more constrained 
information [25]. Contrasted to people without complications, the 
risk of retinopathy was related to ∼1.7-fold expanded hazard for 
cardiovascular occurrence and more than two-fold expanded hazard 
for coronary events in T2DM [26]. 
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3. Diabetic Retinopathy 
Diabetic retinopathy (DR) influences around 33% of all people who 
experience the disease effects of DM [27]. The longer the patient has 
diabetes, the higher the possibility of contracting DR [25]. Half of the 
patients with T1DM show features of retinopathy within 10– 15 
years after diagnosis. This increments to 75– 95% following 15 years 
and 100% following 30 years. 60% of patients with T2DM show signs 
of retinopathy within 16 years [28]. DR has two overlapping phases 
i.e. non-proliferative diabetic retinopathy (NPDR) and proliferative 
diabetic retinopathy (PDR) [29, 30]. Diabetics with NPDR, generally 
have normal visual acuity. The most punctual clinical indications of 
NPDR are microaneurysms and retinal hemorrhaging. Improvement 
of cotton-wool spots, venous bleeding and intraretinal microvascular 
abnormalities are signs of progressive capillary profusion [31].  
The severity of DR ranges from non-proliferative and pre-
proliferative to all the more extremely proliferative, in which the 
anomalous development of new vessels occurs [32]. The new vessels 
are fragile and very permeable. They pass through the optic disc and 
develop along the surface of the retina and into the scaffold of the 
back hyaloid face. The vessels themselves do not disable vision, yet 
are disturbed effortlessly by vitreous traction and hemorrhage into 
the vitreous cavity [31, 33].  
This procedure of the disease with neovascularization and 
accumulation of liquid and protein inside the retina, is termed 
diabetic macular edema (DME), and significantly contributes to the 
visual weakness. In more serious cases, bleeding may occur with 
related contorting of the retinal structure including improvement of 
a fibro-vascular membrane which can, therefore, prompt retinal 
detachment [34]. Though in T1DM the fundamental vision 
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undermining retinal issue has all the hallmarks of PDR, in T2DM 
there is a higher frequency of macular edema [35].  
As indicated by the World health organization, DR represents around 
5% of worldwide visual impairment among grown-ups matured 20–
74 years [36]. 
 
4. Current Treatment of DR 
The beginning stage of retinopathy, most of the time goes unnoticed 
as it does not have noteworthy pathological signs. In any case, 
advanced retinopathy is sought after of treatment. Currently, there 
is no technique to prevent or treat DR and accessible methods have 
just restricted accomplishment in controlling its overwhelming 
outcomes. 
4.1. Primary Prevention 
Hypertension, hyperglycemia, and diabetes term are the major risk 
factor for DR, in particular their combined occurrence [9, 37]. The 
early phases of the retinopathy can be alleviated by control of blood 
glucose levels [38, 39], blood pressure, and lipids [39-41]. Tight 
glucose and blood pressure control can postpone the beginning of 
retinopathy by means of suppression of its progression [37]. 
Importantly, application of glycemic control can cause brief declines, 
generally because of the advancement of small arteriolar infarctions 
which result in the cotton wool spots. Specifically, patients merit 
cautious observation previously and at 3-month to month interims 
after practice of intensified control for no less than 1 year [42]. In 
animal models of diabetes, exogenous insulin treatment may retard 
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development of both micro and macrovascular diabetic co-
morbidities [43, 44]. 
4.2. Secondary Prevention 
Treatment to restrain advanced phases of retinopathy essentially 
manages vascular changes primarily. Current methods incorporate 
laser and vitrectomy, anti-angiogenesis treatments joined with 
steroids, and anti-inflammation drugs. Laser photocoagulation and 
vitrectomy have enhanced the personal satisfaction for patients with 
DR and the danger of serious visual misfortune by 50 – 60% [37]. This 
includes focal laser photocoagulation for areas of focal blood retinal 
barrier (BRB) breakdown in diabetes, grid photocoagulation for DME, 
and scatter photocoagulation as a prophylaxis in contradiction of 
neovascularization in PDR [45]. Pan retinal photocoagulation (PRP) 
therapy may get its impact by diminishing the host of angiogenic and 
permeability factors that have accumulated in the photoreceptor 
layer of the retina [46]. A few endeavors have been made to modify 
laser procedures to diminish their side-effects, for example, 
diminished visual sharpness, peripheral field misfortune, and 
compounding of macular edema [47]. This process likewise affects 
night vision and requires repeated treatment [48-50]. Late studies 
have demonstrated that antiangiogenic methods joined with laser 
treatment, result in preferable visual outcomes over laser alone [51]. 
It has been demonstrated that people with PDR have elevated levels 
of intravitreal vascular endothelial growth factor (VEGF), and that 
laser photocoagulation treatment altogether decreases these levels 
[51, 52].  
Presently, blocking VEGF can keep the improvement of PDR in 
murine models [53]. There are three principle components by which 
anti-angiogenesis specialists are utilized for the treatment of PDR: (a) 
Inhibition of VEGF through direct binding; (b) Inhibition of VEGF 
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signaling; and (c) Inhibition of VEGF synthesis. Pegaptanib, 
Bevacizumab, Ranibizumab, and VEGF Trap are utilized for the 
management of PDR by sterically hindering of VEGF isomers through 
direct binding [54]. The issue with block of VEGF isomers is in reality 
the reduction of physiologic revascularization, which is imperative in 
avoiding exacerbated PDR [55]. A considerable part of intraocular 
anti-VEGF could diffuse into the systemic circulation [56-58]. Anti-
VEGF treatment requires repeated intravitreal infusions for quite a 
while with conceivable inconveniences [50].  
In addition, hypertension (because of the expanded vasoconstriction 
) and proteinuria (because of glomerular dysfunction) are the most 
widely recognized symptoms of fundamental VEGF block [59]. 
Vitreous hemorrhage, tractional retinal detachment (TRD) [60], 
endophthalmitis, cataract, and potential loss of neural retinal cells 
[61] may likewise seem separated from nearby side-effects of Anti-
VEGF treatment. Twisting of the eye amid intravitreal infusion with 
conceivable interference of the vitreous in the sclera, may bring 
about vitreoretinal traction [62]. Steroids strongly inhibit 
angiogenesis, proliferation, apoptosis, and inflammation. In the eye 
the impact of most steroids is temporary, demanding repeated or 
nonstop administration to keep up the supportive impact [63]. 
 
5. Pathology of DR 
It is amply acknowledged that DR builds up first by vascular cell 
dysfunction and apoptosis, pericyte loss, thickening of the basement 
membrane (BM), and compromised BRB permeability [64]. The 
expression "pericyte ghosts" alludes to pericytes which left pockets 
in the BM and vanished from the capillary wall [65]. Pericyte dropout 
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in the diabetic retinal vasculature is identified by the existence of 
ghosts as seen in transmission electron microscopy micrographs [66]. 
Pericytes harbor anti-apoptotic support for the endothelium [67], in 
this way, the loss of pericytes in DR might be lenient for endothelial 
cells (EC) development [49].  
EC are additionally lost in DR, bringing about acellular capillaries that 
comprise exclusively of BM sleeves. BM thickening originates from 
gathering and lessened corruption of BM modules. The synthesis of 
BM is as yet not fully understood, in any case it is realized that 
collagen type IV, fibronectin, laminin, and heparan sulfate 
proteoglycan are included [68-70]. The associations of these portions 
are expanded by hyperglycemic conditions. Hyperglycemia enhances 
fibronectin, collagen IV, and laminin gene expression [71-73].  
In diabetes, the vascular BM achieves a thickness that is often a few 
times more than the ordinary vascular BM [74, 75]. One of the early 
events in DR is the modification of the BRB which increases the 
permeability of vessels. The barrier function of retinal EC is also 
affected, because gap junction intercellular communication (GJIC) 
are reduced in number and function, as a result of changed connexin 
expression in various tissues [76]. GJIC are essential for the 
intercellular transport of various small molecules and ions, for 
example, ATP, Na+, and K+ that are fundamental for cell viability 
[77]. Also, onset and development of DR correlates with the 
diminished GJIC in the retina. Interestingly, retinal EC are more 
prone to dysfunction caused by oxidative stress than other EC types 
a result of which is increased permeability [78]. Hyperglycemia 
induces increased plasma levels of tumor necrosis factor alpha (TNF-
α), interleukin (IL)-6, and IL-8 [79]. Increased leukostasis, cytokines, 
and growth factors direct the breakdown of the BRB in diabetes [80-
82]. Specifically, the proliferative phase is portrayed by the 
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formation of new defective vessels spreading without normal 
configuration i.e. pericyte coverage, on the retinal surface which may 
lead to fibrosis, and tractional retinal detachment [83]. 
6. Animal models of DR  
Animal models are suitable to replicate specific phases or processes 
of the onset and development of human disease such as diabetes 
and DR. This allows to dissect the pathophysiology and assess 
treatment modalities prior to clinical trials. There have been several 
animal species and strains examined to model human DR, including 
mice, rats and monkeys [84]. Mammalian models build up the 
beginning stages of retinopathy, which incorporates degeneration of 
retinal vessels. Also, degeneration of retinal neuronal cells in diabetic 
mice [85] and rats [86]. The most regularly utilized diabetes models 
are instigated by chemical toxins, for example, streptozotocin (STZ) 
or alloxan which destruct the insulin-producing beta cells in the 
islands of Langerhans in the pancreas. Thus, both chemicals induce 
T1DM more than insulin resistance-based T2DM [87]. Be that as it 
may, toxin-incited diabetes in mice is highly strain-variable as a result 
of strain-subordinate protection from STZ [88].  
Preretinal neovascularization is not found in any rodent animal 
model, probably because of their short lifespan. This has brought 
about the development of various nondiabetic models of retinal 
complications where neovascularization is counted as the secondary 
complication, for example, hypoxia-induced models like oxygen-
induced retinopathy (OIR) also known as retinopathy of premature 
(ROP) in newborn mice[89], or models with overexpression of VEGF 
[90] and insulin-like growth factor I (IGF-I) [91] in the eye. Rodent 
pups have an immature retinal vasculature at birth [92].  
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Therefore, development of the intraretinal vasculature happens 
postnatally in mice which can be seen and controlled tentatively 
[93]. 
 
6.1. OIR mouse model  
Mouse model of OIR, is a standout amongst the most generally 
utilized animal models with in excess of 15,000 publications since it 
was first distributed in 1994 [94]. In a word, neonatal mice are 
presented to 75% oxygen from postnatal (P) day 7 until P12 and 
came back to room air (21% oxygen) from P12 to P17. Amid the 
primary hyperoxic stage, retinal vessels constrict to control oxygen 
levels [95]. What's more, immature vessels of the central retina 
relapse prompting a central zone of vaso-obliteration (VO). On 
return to room air at P12, the VO retinal area turns hypoxic and a 
huge upregulation of HIF-1α-dependent proangiogenic pathways 
ensues. From P17 on, neovessels begin to relapse, until at P25 [96, 
97]. 
6.2. Ins2Akita mouse model 
The Mody4 locus on chromosome 7 has a mutation in the insulin 2 
gene, now alluded to as the Ins2Akita allele. This mutation induces 
protein changes, prompting its collection in the endoplasmic 
reticulum of pancreatic β cells and leads to β-cell apoptosis. 
Heterozygous mice with this mutation develop increased 
hypoinsulinemia and hyperglycemia during their life span and thus 
represent a rodent model for human diabetes. The various studies 
bolster the utilization of the Ins2Akita mouse as a suitable model of 
early stage of DR [98]. 
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6.3. Akimba mouse model 
The Akimba is another basic experimental model which is a cross 
between the hyperglycemic Akita mouse and the Kimba mouse 
(overexpresses human VEGF in photoreceptor cells of the retina). 
The merger of these two makes a mouse with hallmarks of PDR, such 
as neovascularization and retinal edema [99, 100]. The outcomes 
from animal model studies must be taken with alert, recalling the 
impediments of these models with general reference back to the 
human state, which is basic for characterizing the significance of 
these discoveries. 
 
7. Pericyte  
Pericytes were depicted by Charles-Marie Benjamin Rouget in 1873 
for the first time as cells with contractile properties that envelop 
capillary EC [64]. Pericytes are particular perivascular cells [101], 
derived from the vascular smooth muscle lineage. Pericytes of the 
capillaries are connected to the abluminal side of EC [102]. Pericytes 
share a BM with the EC and straightforwardly interaction these 
through gaps in the BM. These heterologous peg-and-socket 
contacts include tight and gap junctions [103, 104]. Pericytes 
express mesenchymal markers such as neuron-glial antigen 2 
(NG2), regulator of G-protein signaling 5 (RGS5), N-Cadherin 
(CDH2), Platelet-derived growth factor receptor beta (PDGFRβ) and 
CD146 and lack hematopoietic markers such as CD45 or CD34. 
Despite the fact that pericytes share numerous markers with 
smooth muscle cells (SMC), they can be recognized from SMC by 
expanded PDGFRβ and diminished alpha smooth muscle actin 
(αSMA). In vivo, the typical way to distinguish pericytes remains 
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their morphology and anatomical restriction [105]. In fact, the 
operational definition of a pericyte is a matrix-embedded cell that 
surrounds small arterioles and capillaries. The highest density of 
pericytes i.e. pericyte to EC ratio is in neural tissues, particularly the 
retina, perhaps because of its high metabolic action and its 
prerequisite of a tightly-controlled blood retinal barrier (BRB).  
The pericyte to EC ratio in retina is 1:1. This is as opposed to the 
skeletal muscles where the pericyte to EC ratio is approximately 1:10 
[64, 102]. This extraordinary quantity of pericytes in retina, may 
mirror their commitment to the BRB, in which they are proposed to 
constitute a guardian and sentinel cellular layer [106]. 
 
8. Pericyte Function 
Pericytes are contractile cells that assist to control local perfusion 
[107]. Pericytes contract when exposed to hyperoxia [108], ATP, 
endothelin1, angiotensin 2 [109] and they relax upon exposure to 
nitric oxide (NO) [110], CO2 [111] and adenosine [112].  
They are likewise known to keep up the integrity of the BRB by 
prompting the zonula occludens-1 (ZO-1) and occludin expression 
between EC under normoxia and reversing the occludin decrease 
that happens under hypoxia [113]. Pericytes support the 
stabilization, remodeling, and maturation of vessels. Moreover, 
pericytes are in charge of providing an anti-angiogenic and anti-
inflammatory environment for EC and actually cause endothelial 
quiescence [114]. The construction of the BRB relies on the 
connection of the vascular EC with pericytes and glial cells in the so-
called neurovascular unit or NVU [115].  
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Procedures supporting angiogenesis organized by the principle 
physical or paracrine communications amongst EC and pericytes. 
This connection is controlled by the crosstalk between a few 
ligands/receptors, the principle of which is specified in Table.1 




Ligand/receptor Consequence Ref 
Ang1/Tie2 Vessel stabilization  [117] 
TGFβ/ALK-1/5 EC proliferation and migration (ALK-1) [118] 
Vessel maturation (ALK-5) 
PDGF-BB/PDGFR-β Pericyte recruitment and proliferation [119] 
Vessel stabilization [117] 
VEGFA/VEGFR2 EC survival [114] 
Vessel stabilization [114] 
Angiogenesis sprouting [120] 
N-Cadherin/N-
Cadherin 
Pericyte recruitment [121] 
Vessel maturation 
Jagged1/Notch Vessel maturation and stabilization [122] 
Angiogenesis sprouting 
 
Table. 1. The principle communications between EC and pericytes amongst 
angiogenesis [116]. 
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9. Pericytes in DR 
Pericytes are associated with the pathogenesis of the DR [123]. 
Studies on retinal vessels uncovered that the loss of pericytes is the 
principal morphological conversion in a diabetic retina. EC in this way 
vanish, giving rise to acellular vessels, which are obviously not 
functional and non-perfused [124, 125]. The reason for pericyte 
apoptosis in DR is not understood to date. Some conceivable 
mechanisms relate pericyte apoptosis with prolonged oxidative 
stress [126] followed by nuclear factor-kappa B (NF-κB) activation. 
Hyperglycemia activates NF-κB in retinal pericytes which activates 
apoptotic pathways [127].  
Apoptosis may occur independent of NF-κB. Downstream of the 
hyperglycemia-induced PKC activation and expanded the protein 
tyrosine phosphate called Src homology-2 domain– containing 
phosphatase-1 (SHP1) expression, dephosphorylates activated 
PDGFRβ. Downregulation of the pericyte's PDGF signaling suppresses 
survival signals in these cells [128]. Interruption of PDGFB/PDGFRβ 
signaling has been proposed a part in of the pericyte apoptosis [49]. 
Angiopoietin-1 (Ang-1) is additionally one pericyte-delivered factor 
that is essential for the pericyte's balancing function [129]. Ang-1 
exerts anti-inflammatory and anti-apoptotic properties, and loss of 
Ang-1 increases expression of angiopoietin-2 (Ang-2) [130]. 
Angiopoitin-2 (Ang-2) is an antagonist of Ang-1 by hindering the Ang-
1 induced-autophosphorylation of Tie-2 [131], which can meddle 
with Tie-2 receptor signaling, which causes the reduced survival of 
EC and pericytes [132, 133]. While Ang-2 induces neovascularization, 
Ang-1 supports vascular maturation, thus both molecules require to 
be well-balanced under normal physiology [134].  
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The angiopoietin/Tie-2 signaling has a critical part in the 
pathogenesis of PDR [132, 135]. Ang-2 injection into the retina of 
wild type mice causes pericyte loss [136]. Cytokines, for example, 
TNF-α cause pericyte apoptosis and restraint of TNF-α inhibited 
pericyte ghost appearance caused by T1DM and T2DM [137].  
Chronic hyperglycemic exposure for 2-12 days broadly raised IL-1β , 
NF-κB, VEGF, TNF-α, transforming growth factor beta (TGF β), and 
intercellular adhesion molecule-1 (ICAM-1) gene expression and 
protein concentration in retinal pericytes, and these changes 
continued even after reclamation to normalglycemia [138]. VEGF is 
another pivotal factor associated with the breakdown of the BRB and 
increased permeability of the retinal vessels [139]. Peroxisome 
proliferator-activated receptor-gamma (PPAR-γ) agonists can inhibit 
VEGF signaling. Blocking of tyrosine kinase action can bring about 
remarkable suppression of the VEGF-induced neovascularization 
[140].  
Downmodulation of pathological neovascularization in DR, is a 
therapeutic goal [141, 142]. Pericytes from diabetic patients have an 
alteration in the secretion of pro-angiogenic factors, like VEGF [143]. 
Likewise, mitochondria in pericytes are influenced by hyperglycemia 
which disturbed mitochondrial network. Changes in mitochondrial 
metabolism and morphology underlies pericyte apoptosis [144]. The 
prevention of the earliest events in the pathogenesis of DR, for 
instance, pericyte loss, will keep the ensuing improvement of DR. 
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10. EC in DR 
Hyperglycemia-induced reactive oxygen species (ROS) is the best-
known critical factor in diabetic vascular complications. NADPH 
oxidases (NOX) are the main producer of ROS in the vessels. Under 
hyperglycemia, stimulation of mitochondrial uncoupling protein 2 
(UCP2) diminishes the mitochondrial membrane potential which 
leads to a lowered release of ROS and protection of EC [145]. 
Hyperglycemia causes mitochondrial fragmentation and membrane 
potential heterogeneity in rodent retinal EC. Bioenergetics analysess 
shows that hyperglycemia causes a higher extracellular acidification 
and a lower steady state and maximal oxygen consumption under in 
these retinal EC [146]. Human umbilical vein endothelial cells 
(HUVEC) under hyperglycemia also had elevated ROS formation and 
upregulated vascular adhesion molecule-1 (VCAM1) expression 
[147].  
Upregulation of ICAM-1 on retinal EC has been shown in diabetes by 
others too [148]. Also in human microvascular endothelial cell lines 
such as EA.hy926, hyperglycemia induces ROS both by activated NOX 
and a dysfunctional mitochondrial respiratory chain [149].  
Moreover, hyperglycemically challenged HUVEC and EA.hy926 cells 
had a misbalance between oxidative stress and nitric oxide-cyclic 
guanosine monophosphate (NO-cGMP) pathway i.e. uncoupled 
endothelial nitric oxide synthase (eNOS) activity. In spite of the fact 
that, in hyperglycemic condition EA.hy926 cells showed more 
proliferation [150].  
Toll-like receptors (TLRs) are pathogen-associated molecular pattern 
receptors (PAMPs), broadly expressed by several cell types, which a 
part of the native immune response [151, 152]. Toll-like receptors 
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signal via myeloid differentiation primary response 88 (MyD88) and 
NF-B and upregulate pro-inflammatory mediators. In fact, TLRs are 
regulated by NF-B and thus sensitive to hyperglycemically-induced 
ROS. TLR2 and TLR4 mRNA and protein expression in human 
microvascular retinal endothelial cells (HMVREC) is increased under 
hyperglycemia.  
Additionally, increased NF-κB, MyD88 and non-MyD88 pathways and 
monocyte adhesion are shown in this condition. Noteworthy, altered 
TLR2 and TLR4 expression can be treated by antioxidant which is 
followed by downstream inflammatory markers [153].  
Hyperglycemia significantly elevated NO and prostaglandin E2 (PGE2) 
in bovine retinal endothelial cells (BREC) [154]. Reduced expression 
of connexin 43 [155], occludin (through the activation of VEGF and 
IGF-1) [156] and ZO-1 [157] levels caused of hyperglycemia in the 
retinal EC may lead to the increased BRB breakdown. 
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11. The main contributors of DR  
11.1.  Impaired Glucose Metabolism 
A considerable collection of evidence from in vivo and in vitro studies 
offer four biochemical irregularities in the development of micro and 
macro-vascular complexities in DM as demonstrated by: (a) 
increased polyol pathway flux [158, 159]; (b) hyperactivation of 
isoform(s) of protein kinase C (PKC) [160, 161]; (c) increased 
oxidative stress [162]; and (d) increased deposit of advanced 
glycation end-products (AGEs) [163-166]. These apparently irrelevant 
pathways share a single factor: overproduction of mitochondrial 
superoxides. These metabolic pathways are related to excessive ROS 
[167]. Aldose reductase (AR) is the main compound and the first step 
in the polyol pathway. In a hyperglycemic condition, AR inhibits 
nicotinamide adenine dinucleotide phosphate (NADPH)-dependent 
conversion of glucose to sorbitol. The second step of the pathway is 
oxidation of sorbitol to fructose by the sorbitol dehydrogenase 
enzyme. Generating the intracellular antioxidant glutathione (GSH) 
depends on NADPH consumption. Consequently, a decline in the 
accessibility of NADPH impairs intracellular oxidative stress. An 
increased enzymatic activity of AR by hyperglycemia worsens the 
state of DR [163, 168]. Thus, inhibition of AR may limit progress of 
DR [169, 170]. AGEs and its receptor, RAGE, can also induce oxidative 
stress and ROS [171]. Similar to AR, the inhibition AGE and RAGE 
signaling offers therapeutic prospects to treat DR [172, 173]. 
Hyperglycemia induces accumulation of glyceraldehyde-3 phosphate 
which additionally causes the ROS overproduction and stimulates the 
collection of poly(ADP-ribose) polymerase-1 (PARP), which triggers 
the PKC pathway activation followed by increased deposition of 
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AGEs [174]. Taken together, these pathways initiate DR through ROS-
induced vascular permeability and ischemia [168, 175, 176]. 
 
11.2. Oxidative Stress 
The imbalance between the generation of ROS and the capacity to 
scavenge ROS by endogenous antioxidants states is called oxidative 
stress. The retina is profoundly vulnerable to oxidative stress-
induced damage. Neural tissue, in particular the retina, has the 
highest oxygen consumption in the body [177], thus this high oxygen 
demand of the retina likely generates ROS if not properly controlled 
[178].  
Superoxide anion (O2•-), perhydroxyl radical (hydroperoxyl radical, 
HO2) and hydroxyl radical (OH•) are relevant ROS. Superoxide is 
formed non-enzymatically via mitochondrial respiration or by the 
enzymatic oxygen decline of NOX. Superoxide is enzymatically 
converted into hydrogen peroxide (H2O2) via superoxide dismutase 
(SOD) or non-enzymatically to H2O2 and single oxygen [179]. 
Oxidation of the guanidine gathering of L-arginine by the nitric oxide 
synthase (NOS) produces NO.  
NO as a free radical react with superoxide and create an oxidant 
named peroxynitrite (ONOO), one of the reactive nitrogen species 
(RNS) [180]. The enzymatic antioxidants, for example, manganese 
superoxide dismutase (MnSOD), copper/zinc superoxide dismutase 
(Cu/Zn SOD), catalase, and glutathione peroxidase (GPx) and 
nonenzymatic antioxidants like ascorbic acid (vitamin C), α-
tocopherol (vitamin E), GSH, and β-carotene can proficiently 
scavenge ROS. Superoxide can be converted to H2O2 by MnSOD and 
Cu/Zn SOD, which is then effectively converted to water by GPx or 
catalase [181].  
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The ROS overproduction can disturb the normal capacity of cells by 
damaging the lipids, proteins and DNA of the cells. Intracellularly, 
ROS can damage mitochondria by opening the mitochondrial 
membrane permeability transition pores (PTPs), which may leads to 
additional ROS production [182]. Releasing of ROS-induced 
Cytochrome-c, further prompting apoptosis in the cells [183, 184]. 
11.3. Mitochondrial Dysfunction 
In the diabetic retina before histopathology signs can be recognized, 
dysfunctional mitochondria, damaged DNA (mtDNA) and increases 
apoptotic cells are seen. The fact that is showing the role of 
mitochondria in the development of DR [185-187]. The typical shape 
of mitochondria in the cells is tubular, and balanced between 
mitochondrial fission and fusion dedicates mitochondrial shape 
[188]. Mitochondrial function is additionally controlled by cycle of 
fusion and fission, and changes in shape and mitochondrial structure 
are considered as a sign of dysfunctional mitochondria [189]. 
Mitochondrial fission is associated with apoptosis and mitochondrial 
fusion with inhibition of apoptosis. Hyperglycemia-induced ROS 
causes mitochondrial fragmentation [190, 191].  
Oxidative phosphorylation is the basic function of mitochondria 
through its five enzyme complexes, assigned as complex I, II, III, IV 
and ATP synthase. In 1966, for the first time, mitochondria were 
reported as the ROS generators. NADH dehydrogenase at complex I, 
and the interface amongst co-enzyme Q and complex III are principle 
culprits that generate superoxide in mitochondria [192]. 
Dysfunctional mitochondria cause low respiration rate and formation 
of superoxide [193-196]. Under physiological conditions, electron 
exchange through complexes I, III and IV expels protons outwards 
into the intermembrane space, creating a proton gradient that drives 
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ATP synthase as protons go back through the inner membrane into 
the matrix. Interestingly, in diabetic cells under hyperglycemic 
conditions, there is more oxidation of glucose-derived pyruvate in 
the tricarboxylic acid (TCA) cycle (oxidative phosphorylation), which 
increases the flux of NADH and FADH2 (electron donors) into the 
electron transport chain. The mitochondrial membrane’s potential 
increases till the point when a critical threshold is reached. At this 
point, electron exchange inside complex III is blocked, making the 
electrons go down to coenzyme Q, which gives the electrons each 
one in turn to molecular oxygen, subsequently creating superoxide 
[197].  
Thenoyltrifluoroacetone (TTFA, complex II inhibitor) and carbonyl 
cyanide m-chlorophenylhydrazone (CCCP, an uncoupler), totally 
prevent the impact of hyperglycemia. Overexpression of 
mitochondrial antioxidants, uncoupling protein-1 (UCP1) and 
MnSOD, likewise prevent the hyperglycemia impact [198, 199]. 
Mitochondrial dysfunction induces the oxidation of unsaturated fat, 
bringing about expanded intracellular fatty acyl-CoA and 
diacylglycerol content which leads to PKC inhibition [200]. Damaged 
oxidative phosphorylation [201]; disabled ATP synthesis [202]; 
reduced density of mitochondria; expanded intracellular lipids with 
diminished glucose metabolism [203]; and reduced TCA-cycle 
substrate oxidation [204] are observed in T2DM. The function of 
antioxidants, such as SOD, glutathione reductase, glutathione 
peroxidase, and catalase to scavenge ROS and maintain a proper 
redox homeostasis, are compromised in the diabetic retina [205].  
Vitamin C, vitamin E, and β-carotene control the redox homeostasis 
and are also compromised by hyperglycemia [206]. Moreover, inside 
the retinal mitochondria, reduced activity of complex III is reported 
in diabetic rodents [207]. In spite of the fact that mitochondrial 
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dysfunction might be the main indicator of the disease, the loss of 
ATP generation is likely adding to apoptosis in the later phases of DR 
[208, 209]. 
11.4. Inflammation 
The previous sections hinted already that hyperglycemia activates 
NF-B signaling and renders the retina in a pro-inflammatory state; 
therefore DR is a chronic inflammation. Interestingly, as early as in 
1964, it was noticed that diabetics with rheumatoid arthritis who 
took high dose aspirin (a cyclooxygenase inhibitor), showed a 
reduction in severity of PDR [210]. 
 Inflammation is composed by several factors that include release of 
pro-inflammatory cytokines, chemokines, and upregulation of 
adhesion molecules. Inflammation is a first line activated defense 
and a reaction to damage that connects leukocytes and the 
endothelium and conducts leukocyte migration towards damaged 
area. Inflammation has advantageous effects on an acute damage, 
however can have negative impacts if chronically [211]. The immune 
system boosts a repair response of damaged tissue which includes 
the eradication of unwanted pathogens or removal of undesirable 
molecules. Endothelium and immune cells, but also a host of other 
tissue cells, are equipped with pathogen and damage-associated 
molecular pattern (PAMP resp. DAMP) receptors. These include the 
before mentioned TLRs and the receptor for AGE (RAGE). Activation 
of pattern recognition receptors causes pro-inflammatory activation 
and induces expression of pro-inflammatory proteins [212].  
The expression of a host of pro-inflammatory proteins is controlled 
through the activation of pro-inflammatory transcription factors, 
including NF-κB, p38 MAPkinase, and TAK1 and sustains a feed 
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forward loop of synthesis of cytokines, chemokines, and 
inflammatory molecules [212]. Leukocytes bind to ICAM-1 on the 
surface of endothelium during inflammation. ICAM-1 is upregulated 
by VEGF, PARP, dyslipidemia and oxidative stress via NF-κB [148]. 
Upregulated expression of E-Selectin, ICAM-1 and VCAM-1 is also 
detected in diabetic retinal vasculature [213]. ICAM-1, VCAM-1 and 
E-selectins assist recruitment of leukocytes and enable their 
infiltration into the damaged tissue [214]. Blockade of ICAM-1 may 
prevent or reduce the disruption breakdown of the BRB, as well as 
prevent capillary occlusion and EC damage in DR [148, 215].  
Expression of ICAM-1 is promoted by VEGF in EC. This leads to 
leukocyte activation and cytokine release, along these lines 
generating additional VEGF and amplification of the inflammatory 
reaction. Suppression of retinal leukostasis and BRB breakdown has 
shown followed by particular blockade of endogenous VEGF in 
diabetes [216]. In retinas of diabetic mice the activity of caspase-1 is 
increased. Caspase-1, also known as IL-1 converting enzyme (ICE), 
generates IL-1β from its precursor. IL-1β activity is mediated by 
binding to IL-1R1 on the cell surface [217, 218]. The increased level 
of the cytokines TNF-α, IL-1β [219], IL-6 [220] and the chemokine (C-
C motif) ligand 2 (CCL2) [221], CCL5 [222], C-X-C motif chemokine 8 
(CXCL8), CXCL10, CXCL12 is reported in the serum and vitreous 
samples from DR patients [222-224]. This shows that during DR, local 
chronic inflammation exists. Additionally, expression of NF-κB is 
higher than ordinary in retinal membranes of patients with PDR 
[225]. Endothelial damage and even loss may associate with 
inflammation in DR via CCL2 that activates PKCα/ζ-mediated 
phosphorylation and translocation of ZO-1, ZO-2, occludin and 
claudin-5 which causes disruption of endothelial tight junctions and 
loss of the BRB barrier [226]. Remarkably, CXCL8 causes loss of 
membrane expression of VE-cadherin through phosphatidylinositol 
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3-kinases/Rac/p21 activated kinase signaling which increases 
endothelial permeability [227]. Prostanoids such as prostaglandins 
(PG) and thromboxane A2 (TXA2) are generated as part of the 
arachidonic acid (AA) pathway by plasma membrane bound 
phospholipases (PLAs). Pivotal enzymes in PG synthesis is the 
cyclooxygenase 1 and 2 (COX) and prostaglandin G/H synthase [228].  
In healthy tissues the production of prostaglandin is low, however 
this increases promptly during onset of acute inflammation and 
promotes the recruitment of leukocytes among others. In contrast to 
COX-1 which is expressed in a majority of cells, COX-2 is induced by 
inflammatory stimuli, hormones and growth factors. COX-2 is the 
main source of prostanoids during inflammation [229]. Both COX-2 
expression and extensive generation of prostaglandins occurs in 
retinas of diabetic animals. Similarly, COX-2 was shown in vascular EC 
in fibrovascular epiretinal membranes from patients in late phase DR 
[230].  
PGE2 synthesis in diabetic rat retinas was fundamentally abrogated 
by celecoxib (a specific COX-2 inhibitor) but not by a COX-1 inhibitor 
[231], which suggests that COX-2 is responsible for the increased 
retinal prostaglandin generation in diabetes. The COX enzymes are 
targeted by non-steroidal anti-inflammatory drugs (NSAIDs), for 
example, aspirin and salicylate [232]. While parenchymal cells are 
generally pro-inflammatory activated by PGE2, the function of 
immune cells including lymphocytes and macrophages is suppressed 
by PGE2. Thus PGE2 is both pro-inflammatory and anti-
inflammatory. This double role of PGE2 in tweaking the inflammation 
has been seen in various medical complications [233]. The 
cyclooxygenase/prostaglandin pathway is a common pathway in 
both neovascularization and inflammation [234]. Also, various 
Chapter 1 
32 
chemokines serve a double-role i.e. as leukocyte attractant and as 
angiogenic mediator on EC [235]. IL-1α, IL-1β, IL-6, TNF-α, and more 
pro-inflammatory cytokines invoke vascularization directly by 
targeting EC or indirectly by prompting leukocytes and EC to create 
additional proangiogenic mediators [236-238]. 
12. Stem Cells 
Stem cell (SC) [239] have two main properties: self-renewal and 
differentiation [240]. Preferably, stem cells which are applied for 
regenerative therapies ought should fulfill the following criteria: (a) 
available a high numbers, depending on the application from 
thousands to even millions; (b) can be collected by a minimally 
invasive procedure; (c) can be differentiated along different lineages, 
and (d) can be safely and efficiently administered to the patient 
[241]. Embryonic stem cells are the most versatile stem cells and 
capable to differentiate to all cells of the body. However, primarily 
ethical, legal and political concerns, render embryonic stem cells 
unsuitable for large-scale clinical applications [242, 243]. 
Hematopoietic stem cells (HSCs) have been used in experimental 
therapies for tissue repair for many decades, yet HSCs remain hard 
to isolate and have low yields in general  [244].  
Induced pluripotent stem cells (iPSC) are exceptionally encouraging, 
yet current procedures to generate iPSC virus or vector free are in 
their infancy and restrict clinical use [245, 246]. Endogenous stem 
cells derived from adult tissues such as brain, gut, lung, liver, adipose 
tissue and bone marrow [247], in general have the ability to self-
renew and differentiate into numerous cell types [248, 249]. 
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13. Mesenchymal Stem Cells 
Mesenchymal stem cells (MSC), also called multipotent 
mesenchymal stromal cells, are present in the connective tissue of 
every postnatal organ and tissue [250]. MSC have been isolated from 
adipose tissue [251], umbilical cord blood [252], dura mater [253], 
cartilage [254], compact bone [255], tonsil [256], synovial membrane 
[257], skin [258], hair [259], placenta [260] and dental pulp [261]. 
MSC, first distinguished in 1966 in the investigations of Friedenstein 
and Petrakova [262], these bone-forming cells were isolated from 
bone marrow of rats. To date, according to international society for 
cellular therapy (ISCT), MSC are characterized by the following three 
criteria [263]: (a) MSC adhere to plastic. MSC after isolation attach to 
plastic and expand in serum containing medium without extra 
prerequisites growth factors or cytokines;  
(b) MSC express variable levels of following molecules. CD44, CD90, 
CD166 (vascular cell adhesion molecule), CD54/CD102 (intracellular 
adhesion molecule), CD105 (SH2), CD73 (SH3/4), stromal antigen 1, 
and CD49 [263, 264]. Contrariwise, MSC do not express of surface 
markers of hematopoietic cells (i.e. CD14, CD45, and CD11a), EC 
marker (i.e. CD31) and erythrocytes marker (i.e. glycophorin An) 
[265]. MSC express very low levels of cell-surface HLA class I 
molecules and the absence expression of HLA class II, CD40, CD80 
and CD86 in these cells leading to reduced activation of immune 
reactions [266]. The absence of major histocompatibility complex II 
(MHCII) (encoded by HLA gene) expression in MSC marks them a 
reasonable choice for allogeneic transplantation [267, 268]. (c) MSC 
has differentiation potential: MSC can be differentiated into the 
trilineage comprising adipocytes, osteoblasts and chondrocytes in 
vitro [269, 270]. The efficacy of MSC in vivo has been credited to 
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various mechanisms counting differentiation to other cell lineage, 
release of paracrine factors to change microenvironment, balancing 
oxidative stress and immunomodulatory capacity [271].  
In 2005, international society for cellular therapy (ISCT) proposed 
that cells depicted as mesenchymal stem cells should be rephrase to 
multipotent mesenchymal stromal cells because most MSC types 
lack the capacity to self-renew, at least in vitro. As per the ISCT, the 
term mesenchymal stem cells ought to be held just for 
subpopulations with particular highlights of stem cells [272]. 
  
14. Immuno-modulating Properties of MSC 
The therapeutic efficacy of MSC has been shown in different 
inflammatory studies in three distinctive methodologies: (a) 
expressing the interleukin (IL)-1 receptor antagonist; (b) making a 
negative feedback loop where pro-inflammatory cytokines like TNF-α 
from local macrophages cause MSC to secrete the anti-inflammatory 
TNF-α stimulated gene/protein 6 (TSG-6). The TSG-6 at that point 
decreases NF-κB pathway and tweaks the inflammation; (c) making a 
negative feedback loop whereby damage-associated molecular 
patterns (DAMPs) or pathogen-associated molecular patterns 
(PAMPs), NO, lipopolysaccharide and TNF-α from local macrophages 
cause MSC to emit PGE2. The PGE2 changes macrophages to an anti-
inflammatory, so-called M2, phenotype that secretes IL-10 as well as 
anti-inflammatory TGFß, IP10, and PGE2 [273]. MSC require 
inflammatory activation such as by cytokines secreted by immune 
cells, to acquire. TNF-α, interferon (IFN)γ and IL1β appear to play a 
key role in this activation [274, 275]. Therefore, the inflammatory 
condition and the immunological status of administered therapeutic 
MSC are important and require optimization to reach optimal clinical 
Introduction and outline 
35 
 
efficacy. Immunosuppressive impact of MSC can be in two ways: (a) 
cell contact mechanisms (i.e. through Jagged1-Notch1) [276]; (b) 
paracrine impact via PGE2, indoleamine 2,3-dioxygenase (IDO) [277], 
IL-6, IL-10 [278], hepatocyte growth factor (HGF) [279], TGFβ1 [280], 
TSG6 [281], NO [282] and heme oxygenase-1 (HO-1) [283].  
MSC suppress production of cytokine and T-cell proliferation [282, 
284]. MSC-derived IL-6 constitutively polarizes macrophages towards 
the M2 phenotype [285]. This polarization is also accomplished via 
MSC-derived IDO and PGE2. MSC that do not secrete IL-6, drive 
polarization of macrophages towards the pro-inflammatory M1 
phenotype, which expresses IFNγ, TNF-α, and CD40L [286]. 
Promoted polarization of M2 by MSC, associates with a high 
expression of the mannose receptor CD206, increased production of 
IL-10 and a reduced production of pro-inflammatory cytokines and 
reduced phagocytic activity [287].  
The expression of co-stimulatory molecule CD86 and MHCII on 
macrophages is reduced by MSC thus diminishing their stimulatory 
potency of the adaptive immune system [288]. MSC suppress mast 
cells by their constitutive release of PGE2 upon pro-inflammatory 
COX-2 upregulation [289] and suppress expression of TNF-α and IL-6 
in activated macrophages [288]. The inhibition of natural killer cells 
(NK) is through IDO expression by MSC [290] which coincides with 
suppression of NK activating receptors [291]. MSC repress 
proliferation of B cells by arrest at the G0/G1 check point, without 
induction of apoptosis [292-294]. Preventing the allogeneic skin 
grafts rejection [295], ameliorating graft-versus-host disease (GvHD) 
[296], experimental autoimmune encephalomyelitis [297], collagen-
induced arthritis [298], sepsis [299] and colitis [300, 301] are all 




15. Adipose Tissue 
Adipose tissue, in mammals, has been grouped into: white adipose 
tissue (WAT), the storage of energy with adipokine secretory 
capacity which is morphologically described by the extensive lipid 
vacuoles in vivo. (b) brown adipose tissue (BAT), particular for energy 
consumption in fatty acids metabolism and providing heat [302] 
which is morphologically described by the small lipid vacuoles in 
vivo. BAT is closely associated with skeletal muscle as opposed to 
WAT that is found as visceral fat and subcutaneous fat depots [303, 
304]. Of note, there is a sub-type adipocyte called Beige adipocytes 
(distinguished as brown/white), with the possibility of energy 
storage and express UCP1, however this type is related to WAT 
[305]. WAT and BAT derives from various precursor cell populations. 
Finally, perivascular adipose tissue (PVAT) is found around large 
arteries and important for blood pressure regulation [306]. The 
phenotype of PVAT is intermediate between WAT and BAT. In 
adipogenesis, PPARγ heterodimerizes with retinoid X receptor (RXR) 
and drives the development of differentiated adipocytes by 
regulation of downstream target gene expression. The 
CCAAT/enhancer-binding proteins (C/EBP) family (α, β, δ) participate 
in adipogenesis in a feedback loop to control the expression of 
PPARγ [307, 308]. Progenitor cells of skeletal muscle i.e. satellite 
cells, can also differentiate into either muscle cells or BAT, but not 
WAT [304]. Adipocytes’ main endocrine function is the production of 
fat-derived systemic mediators such as adipokines, e.g. adiponectin, 
leptin, and resistin, but also retinol binding protein 4 (RBP4) and pro-
inflammatory TNFα, that together maintain a balanced systemic 
metabolism [309]. This endocrine capacity is maintained by both 
WAT and BAT. 




16. Adipose tissue-derived stromal cells (ASC) 
Several of names have been used to denote the plastic adherent cell 
population isolated from fat tissue after collagenase digestion. 
Adipose tissue-derived Stem/Stromal Cells (ASC); Adipose-Derived 
Adult Stem/Stromal (ADAS) Cells, Adipose-Derived Stromal Cells 
(ASC), Adipose Stromal Cells (ASC), Adipose Mesenchymal Stem Cells 
(AdMSC), Lipoblast, Pericyte, Pre-Adipocyte, Processed Lipoaspirate 
(PLA) Cells have all been used to distinguish the same cell population 
[310]. A current definition from the 2004 meeting of the 
International Fat Applied Technology Society (IFATS) has settled on 
the expression "adipose tissue-derived stem cells” (ASC) [311].  
However, because self-renewal has not been conclusively confirmed 
and, in concurrence with the announcement of ISCT [272], we use 
the term “stromal” instead of “stem”. First time, Zuk and his 
colleagues recognized ASC in 2001; they characterized the stem cell 
qualities of ASC by their capacity to differentiate into other 
mesenchymal lineages [312].  
ASC can be easily isolated from WAT [313]. A ubiquitous amount of 
ASC can be isolated from lipoaspirates, the waste result of 
liposuction operations. About 300mL of lipoaspirates may yield 
1×107 to 6×108 cells. Besides, ASC reach senescence upon prolonged 
passaging in vitro but (in general) can be cultured longer compared 
to bone marrow mesenchymal stem cells (BM-MSC) [314-316]. ASC 
are a promising choice for cell therapy. ASC can be harvested, 
propagated and handled effectively with relatively mild procedures. 
ASC have a pluripotency capacity equivalent to BM-MSC and the 
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harvesting process from donors i.e. lipoaspiration, requires just local 
anesthesia and a short recovery time [317].  
ASC are characterized by their capacity to adhere to plastic as all the 
MSC; ASC express certain cell surface markers, i.e.CD73, CD90 and 
CD105 whereas lacking the expression of CD34 and CD45; There 
have been references that affirm specific markers like CD49d, CD105, 
CD44 and CD29 are reliably upregulated in ASC culture [270, 318-
320]. Noteworthy, surface expression of CD49d, as known as integrin 
α4β1 or VLA, decreases in ASC culture significantly [312, 321]. At last, 
ASC require not be cultured long period of times to get desired 
number of cells to accomplish what is called as therapeutic threshold 
[310, 316, 322-324]. 
 
17. ASC Isolation 
In 1960, Rodbell and colleagues, established the first method to 
isolate cells from adipose tissue [325]. Briefly, the rat fat pads were 
minced and washed to get rid of mixed hematopoietic cells. The 
minced tissues were incubated with collagenase and centrifuged. 
Subsequently the floating population of mature adipocytes was 
separated from the pelleted so-called stromal vascular fraction (SVF). 
The last step comprised plating the SVF to select for the plastic 
adherent population which was presumed to contain pre-adipocytes. 
The liposuction aspiration procedure has no effect on the viability of 
isolated cells [326-328]. Virtually all presently used methods are 
adjusted from the Rodbell technique.  
The SVF derived from fat tissue is a mixed population of stroma i.e. 
vascular cells (EC, SMC, pericytes) and fibroblasts, as well as immune 
cells (macrophages and lymphocytes) and preadipocytes as known as 
ASC [329, 330]. The superficial location of fat tissue makes it visually 
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accessible and can be removed from a donor without serious harm 
[331].  
Worldwide survey published in 2002 demonstrates that in the 
vicinity of 1994 and 2000 zero mortality was reported in 66,570 
liposuction operations (serious adverse event rate of 0.068%) [332]. 
In comparison, lipoaspirates and bone marrow aspirates 
respectively, contain 2% and 0.002% MSC [333].  
The fat tissue from abdomen area has the higher ASC yield than the 
hip/thigh, albeit no distinction in differentiation capacity between 
the two origins were found [334]. 
 
18. ASC vs. MSC 
In 2001, Gronthos and colleagues showed that ASC express CD105, 
CD106, CD166 and CD44 which are considered as MSC markers. Plus 
the expression of perivascular cell marker, CD146 [323]. In the 
meantime, Zuk stated that ASC and MSC have similar ability to 
differentiate into adipogenic, osteogenic, chondrogenic and 
myogenic cells [312, 321].  
Additionally, similar gene expression table and proliferation rates 
have been documented for MSC and ASC [335, 336]. 
 
19. ASC vs. BM-MSC  
ASC and BM-MSC are both stromal cells with the capacity to adhere 
to plastic. Also, their growth kinetics, cell senescence, gene 
transduction efficiency have been exhibited in a similar pattern 
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[337], as well as their gene transcription and cell surface marker 
expression [324]. Fat tissue, as opposed to bone marrow, is regularly 
removed in cosmetic operations with negligible risk to the patient. 
From this tissue, 200,000 – 290,000 cells/g of tissue [338] or 404,000 
cells/ml of lipoaspirate [314] can be isolated, which this reality 
makes fat tissue a bottomless and available source of stem cells. It is 
difficult to state accurately what volume of tissue will be needed 
until characterized treatment parameters. 
 
20. ASC vs SVF 
The presence of endothelial precursor cells alongside the ASC in SVF 
is the one and only advantage of SVF over ASC. The inconvenience of 
SVF usage is that the quantity of cells that can be applied for cell 
therapy is constrained to what can be removed from the patient. On 
the other hand, purified ASC have a broadened time of cell culture 
which implies that the cells can be cultured up to far more 
prominent numbers than initial isolated cell number [353]. The 
heterogenous mixture of cells in SVF, renders this less suitable for 
e.g. intraocular use: the advantage of cultured cells such as ASC, is 
that these have a significantly lower degree of heterogeneity than 
SVF, albeit not absent.  
 
21. ASC vs. Pericytes 
ASC have been shown to have phenotypic and functional 
resemblance to pericytes [339, 340]. Pericytes and ASC are of 
mesenchymal origin, and harbor a similar potency to differentiate 
into muscle cells, osteoblasts, chondrocytes, and adipocytes [341-
343].  
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Surface markers including NG2, PDGFR α and β, and N-cadherin are 
shared between ASC and pericytes [344]. ASC have a pericytic 
property to self-assemble into vascular network in co-culture with EC 
[345-347]. On monolayers of ASC, EC form branching networks with 
a degree of similarity to the sprouting networks form by EC 
suspensions on matrigel [348]. Injection of ASC-derived pericytes 
after TGF-β1 treatment, could coordinate into abluminal areas 
around retinal capillaries in DR models, which is a significant pericyte 
characteristic [349] and suggesting ASC could serve to substitute 
pericytes [350].  
ASC joined vascular system in murine model of oxygen-induced 
retinopathy (OIR) and maintain their pericytic phenotype for at least 
two months after injection [349]. ASC diminish the capillary loss by 
79% in the Akimba mouse model with DR [351]. ASC promoted re-
endothelialization via Ang-1 secretion in a time-dependent manner 
[352]. The unchanged vessel stabilizing properties of ASC in 
hyperglycemia indicate that ASC are able to maintain fate and 
function in the hostile diabetic condition while retinal pericytes 
cannot [345]. 
 
22. ASC in Cell Therapy 
Initially, the aim of clinical application of ASC was their capacity to 
differentiate into different cell lineages which are important to the 
field of regenerative medicine. This includes tissue engineering of 
bone and cartilage, which is the constructive action of ASC. Injected 
human ASC into immunosuppressed mice differentiated into 
numerous organs, i.e. bone marrow, brain, thymus, heart, liver, and 
lung [354] proposing that ASC can possibly use to repair numerous 
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organs. The systemic distribution of ASC by means of intravenous, 
intraperitoneal, intra-arterial, or intracardial injection depends on 
the native homing of ASC to the damaged site. Expression of 
cytokine and chemokine receptors on ASC cell surface, empower 
them to move to the damaged tissue. MSC culturing brings about 
adjustments of their cell surface receptors expression, i.e. the C-X-C 
chemokine receptor compose 4 (CXCR4), which are fundamental for 
homing after injection [355]. For this purpose, CXCR4 expression can 
be instigated by cytokine cocktail in culture, which has been 
appeared to boost the MSC homing capability [356]. Besides, 
culturing ASC under hypoxia can expand expression of CXCR4 and in 
this way improve the ASC relocation [357]. Accumulation of ASC 
after intravenous injection principally in the lungs and also in the 
liver, heart, and brain has been demonstrated [353]. Extra quantity 
of injected ASC could rapid cell aggregates, which may cause 
pulmonary emboli, infarctions and disturb the bloodstream in the 
patients after cell injection [358].  
In contrast, in the past decade, the instructive action of ASC has been 
appreciated and thoroughly investigated. This constructive action is 
mediated through the secretion of a plethora of biologically active 
molecules that instruct receiving, target cells. As mentioned in 
earlier paragraphs, these paracrine factors may re-educate immune 
cells. ASC have been used widely in cardiac stem cell therapy 
primarily for their instructive capacity [359]. 
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23. ASC Differentiation  
ASC have exhibited a various versatility, including differentiation into 
adipo- [312, 321], osteo- [360, 361], chondro- [362, 363], myo- [364], 
cardiomyo- [365, 366], endothelial [367], hepato- [368], neuro- [369-
373], epithelial [374] and haematopoietic [375] lineages. 
23.1. ASC Differentiation to Contractile smooth muscle 
cells 
ASC differentiation into smooth muscle cells (SMC) may offer 
elective treatment for diseases that include SMC pathology, i.e. 
gastrointestinal disease, urinary incontinence, cardiovascular 
complications, bladder dysfunction, hypertension and asthma [376, 
377].  
The identified markers for contractile SMC incorporate smooth 
muscle α-actin (αSMA), caldesmon, SM22, calponin, smooth 
muscle myosin heavy chain (SM-MHC) and smoothelin. ASC can 
possibly differentiate into functional SMC. Preconditioning of ASC 
with Angiotensin 2 upregulated the expression of smooth muscles 
particular genes and furthermore inspired the TGF-β1 production 
and induced activation by phosphorylation of Smad2 [378]. 
Additionally, precondition the cells with PDGF and TGF-β1, upgrade 
the SMC phenotype in ASC [379]. 
23.2. ASC Differentiation to Osteoblasts 
The osteogenic capability of ASC has been reported in numerous in 
vitro studies [360, 361]. In 2003, a study gave the primary 
confirmation of in vivo bone formation subsequent in vitro 
differentiation of ASC into osteocytes [361]. One year later in 2004, a 
7-year-old young girl with calvarial bone resorption was treated with 
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bone graft from the ilium supplemented with ASC. Figured 
tomography indicated re-ossification of the defect regions [380]. In 
another study ASC formed into mineralised woven bone following a 
month when stacked on a hardening injectable bone substitute 
(HIBS) biomaterial and injected subcutaneously into nude mice [381]. 
Conditioned medium of ASC contained HGF and matrix 
metalloproteinases which invigorated osteoblast proliferation and 
differentiation via an extracellular ERK/JNK signaling kinase and its 
transducer, the Smad transcription factor [382]. 
23.3. ASC Differentiation to Myofibroblasts 
In the presence of TGF-β1, mesenchymal cells as well as ASC [383] 
differentiate into myofibroblasts. These profoundly contractile cells 
are portrayed by increased of the extracellular network (ECM) 
proteins (i.e. collagen type1 and fibronectin), higher expression of 
αSMA and robust stress fibers [384]. It should be noted, that the 
difference between SMC, pericytes, myofibroblasts and even 
cultured ASC/MSC might be more semantic than factual: in culture 
these cell types share several markers that are often considered to 
be specific for each of these cell types. Until extensive ‘omics’ 
comparisons are performed the verdict remains inconclusive. Most 
likely, local tissue microenvironmental conditions dictate the (final) 
fate and function of these mesenchymal like cell types. 
23.4. ASC Differentiation to Cardiomyocytes  
ASC may be an encouraging source for cardiovascular therapeutics 
[365, 366]. Mice ASC could differentiate into cardiomyocytes with 
high effectiveness. These discoveries depended on morphology and 
electrophysical parameters [385]. It should be mentioned that 
differentiation of ASC into cardiomyocytes is rather inefficient, while 
other MSC types such as cardiac precursor/stem cells (CPC/CSC) are 
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by far more efficient to generate large(r) numbes of cardiomyocytes 
that are required to treat the consequences of myocardial infarction. 
23.5. ASC differentiation to Chondrocytes 
Regeneration of damaged cartilage by applying ASC could have huge 
medical and economic advantages. The hyaline cartilage has a low 
inborn regenerative ability and currently there is no regenerative 
treatment accessible for cartilage. In one study, the preconditioning 
of mouse ASC under hypoxia advances the chondrogenic capability 
of the cells that should be considered in further studies [386]. 
 
24. ASC in Vascular Network Formation 
The role of ASC in angiogenesis/vasculogenesis surpasses the 
secretion of VEGF or other pro-angiogenic factors alone, in fact, 
some investigators claim that ASC differentiate into EC [311]. In 
angiogenesis, proliferation and migration of EC from existing 
vasculature generates new microvessels. These microvessels have a 
basic impact in the damaged tissue regeneration [387]. Hypoxia is a 
boost for the onset and progression of angiogenesis  which is 
regulated via hypoxia-inducible factors (HIFs) [388].  
The term of vasculogenesis, on the other hand, alludes to the 
vascular formation by recruitment, aggregation and differentiation 
of endothelial progenitor cells into vascular plexi [387].  
Vessel formation is directed by growth factors signaling, i.e. VEGF, 
VEGF receptor 1 (VEGFR1/FLT1), VEGFR2 (KDR/FLK1), fibroblast 
growth factor (FGF), TGF-β1, angiopoietin-1/2 and Tie-2 [389]. ASC-
derived VEGF, HGF and TGF-β1 have been reported in cultured 
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medium [390]. ASC are claimed to differentiate to both endothelial 
[367, 391, 392] and perivascular cells [101, 393, 394] although 
endothelial differentiation is questioned by several groups including 
by us. ASC can stabilize and support EC that form vascular structures 
by means of direct cell-cell contact guided by ASC-derived paracrine 
cues [348]. Injection of ASC in a hind limb ischemia model showed 
higher capillary density and perfusion in limbs, which this result 
confirms the angiogenic capability of ASC [390, 392].  
Recently, our lab showed that the genetic knockdown of NOTCH2 in 
ASC (SH-NOTCH2) inhibits formation of vascular networks by HUVEC 
both on monolayers of ASC and in organotypical 3-dimentional co-
cultures [395]. 
 
25. ASC in Soft Tissue Implantation and Wound Healing  
ASC in STZ diabetic rats and obese diabetic (db/db) mice could 
augment healing full-thickness skin wounds [396, 397]. Conditioned 
medium from TNF-α-induced ASC accelerated wound repair and 
upregulated angiogenesis in a skin wound model [398]. ASC endorse 
wound healing via both differentiation (construction) and paracrine 
effects (instruction) [399]. Preconditioning of ASC by hypoxia 
enhances their wound-healing potential by stimulating the 
angiogenesis plus migration and deposition of collagen by dermal 
fibroblasts. The augmented wound healing effect of ASC is partly 
mediated via the secretion of VEGF and bFGF [400]. 
 
Introduction and outline 
47 
 
26. ASC in Ischemic Injuries 
Injection of ASC into the myocardium following infarcts in a murine, 
enhanced cardiovascular recovery [401]. Enhanced recovery capacity 
is accredited to the ASCs’ secretion of VEGF, FGF2 and stromal cell 
derived factor 1 alpha (SDF1α) which was followed by recruitment of 
bone marrow-derived endothelial progenitor cells to the ischemic 
damage area [402]. Transplantation of ASC which were 
preconditioned under hypoxia likewise enhances recuperation from 
hindlimb ischemia in murine models [403]. In general, ASC are 
cultured under normoxia (21% oxygen). Despite that, physiologically, 
ASC present at lower oxygen pressures, which is no more than a few 
percent in injured areas, in particular after ischemia [404]. ASC under 
hypoxia maintain their multipotency, proliferate more with less 
apoptosis [405]. Interestingly, ROS generation by hypoxia is high but 
increased the proliferation and viability of ASC [400, 406]. Rehman 
and his colleagues showed higher production of VEGF and HGF under 
hypoxia, that have been appeared to be in charge of the upgraded 
regenerative capability of ASC in ischemia models [407]. 
 
27. ASC in DR 
The way that ASC share phenotypic markers and therapeutic 
properties with perivascular pericytes, makes them an alternative 
choice in the treatment of DR from the viewpoint of vascular 
stabilization and replacement of lost pericytes [408]. ASC particularly 
upregulated retinal EC survival under hyperglycemic conditions. In 
co-cultures with EC, ASC support vascular network formation and 
differentiate into pericytes [347, 348]. The direct cell-cell contact 
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between MSC and EC prompts pericyte phenotype in MSC with high 
expression SMA and CD146 [348, 409].  
One of the difficulties for ASC-therapy in DR is their secretion of 
proangiogenic growth factors i.e. VEGF and HGF [407], which may 
unfavorably stimulate retina for proliferative changes. MSC that are 
preconditioned toward the ‘receiving’ i.e. damaged 
microenvironment, appeared to alter their paracrine factors that 
may tweak between pro-angiogenic to anti-angiogenic state [410-
412].  
Hyperglycemia- induced Oxidative stress induces ASC apoptosis 
[345]. ASC with constitutive expression of antioxidant enzymes 
modulate oxidative stress efficiently [413] and stimulate recovery of 
damaged tissue by secretion of growth factors [414]. Intense 
increase in intracellular ROS activates tyrosine kinases (receptor-type 
or non-receptor-type) in ASC. First of them, PDGFRβ get 
phosphorylated, trailed by the phosphorylation of 
PI3K/Akt/mammalian targets in rapamycin (mTOR) and ERK1/2 
pathway [406]. At that point, activation of these pathways hinders 
the degradation of hypoxia-inducible factor-1 alpha (HIF-1α) via 
propyl-hydroxylation of the von Hippel Lindau tumor suppressor 
protein (pVHL). All these lead to increased levels of cytosolic HIF-1α 
in ASC [400]. The collected HIF-1α translocates to the nucleus. After 
binding to hypoxia-responsive elements (HRE) in the nucleus, it 
regulates the transcription of its target genes. Among these, VEGF 
gene is upregulated bringing about more VEGF secretion [400, 407, 
415]. Injection of ASC in the murine models with T2DM ameliorated 
hyperglycemia in 2 weeks and kept up for about six weeks. In the 
meantime, plasma concentrations of insulin and C-peptide were 
improved [416].  
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ASC can incorporate with retinal vasculature in various murine 
models of retinal vasculopathy, adjusting both pericyte morphology 
and pericyte markers, and protect the retina from diabetic capillary 
damage [349]. Additionally, ASC by suppressing inflammation and 
apoptosis, ameliorate neurodegeneration to improve visual capacity 
in the STZ-rat model [347]. Diabetic ASC are more prone to cellular 
senescence and apoptosis than non-diabetic ASC [417]. 
Hyperglycemia abrogates osteogenic and chondrogenic capability of 
ASC, however improves their adipogenic capacity. ASC under 
hyperglycemia have less proliferation in vitro [417] which is also 
shown in ASC from STZ-diabetic mice [418].  
ASCs’ ability for regeneration and wound healing is diminished under 
diabetic condition because of reduced secretion of HGF, VEGFA, and 
IGF [418]. Diabetic ASC have a higher level of apoptosis than healthy 
ASC [419]. 
 
28. ASC in Inflammatory diseases  
Immunomodulatory and immunosuppressive impact of ASC was 
shown in an in vitro study [318] in 2005; it is demonstrated that ASC 
did not cause alloreactivity and could suppress lymphocyte response 
[420] and virtually block inflammatory cytokines production [421]. 
The immunosuppressive impact of ASC has been reliably seen in all 
following studies after that [268, 422-425]. While it stays disputable 
whether cell to cell contact is required for immunosuppressive 
impact [420, 426-430]. ASC suppress T-cell proliferation via secretion 
of IFN-γ/ IDO and PGE2 [422, 430]. Noteworthy, inhibition of PGE2 
and IDO effectively ended these effects [431]. Expression of Jagged 1 
by ASC adds to the T-cell proliferation suppression by means of its 
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activation of the Notch receptor and resulting hindrance of the NF-
κB pathway [429]. Intravenous injection of human ASC to a mouse 
model of lupus erythematosis enhanced survival rate [432]. 
Comparable results were seen in a murine model of clinical arthritis 
[298, 421]. The co-implantation of ASC enhanced the engraftment of 
pancreatic β-islets in diabetic mice, by upgrading vascularization and 
lessening immune cell infiltration [433, 434]. It has been proposed 
that co-culture of ASC with highly inflammatory chondrocytes, down-
regulate the outflow of inflammatory molecules while no impact was 
shown once chondrocytes had low or moderate levels of 
inflammation [435]. This is additionally confirmed by the study that 
showed the protective ASC was just seen in the osteoarthritis model 
once high synovial inflammation was available [436]. The paracrine 
effect of ASC is the major of their beneficial impacts in cell therapy 
which can be replaced by cell-free conditioned medium to avoid 
following tissue injuries from ASC transplantation [407, 437, 438].  
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29. Conditioned Medium of ASC 
Application of ASC-conditioned medium (ASC-Cme) can be an 
alternative option to transplant of ASC in growth factor-based 
therapies. Cultured ASC, at early passages, secrete HGF, VEGF, TGF-
β1, IGF1, macrophage colony-stimulating factor (CSF1), stromal cell-
derived factor 1 (SDF1/CXCL12) [407], PDGF, super oxide dismutase 
[414], basic fibroblast growth factor (bFGF), TNF-α, IL-6, IL-7, IL-8, IL-
11, adiponectin, angiotensin, cathepsin D, pentraxin, pregnancy zone 
protein and retinol-binding protein [407, 439, 440]. All these factors 
can be collected in ASC-Cme by using standardized and reproducible 
conventions [399]. The secretion of nerve growth factor has been 
shown by ASC as well [441]. Part of the beneficial impacts of ASC in 
promoting angiogenesis and preventing the apoptosis is associated 
with to the secretion of these soluble factors [401].  
The destiny of injected cells and their secretion activity obviously 
depend upon the host microenvironment. Under inflammatory 
conditions, the immunosuppressive ability of ASC is enhanced, while 
their differentiation ability is stable [426, 427]. Secreted growth 
factors such as VEGF, HGF and bFGF by ASC promote angiogenesis, 
EC proliferation, and migration of stromal progenitor cell into the 
developing vessels and promote neovascularization via the 
mobilization of bone marrow-derived endothelial precursors [407, 
442]. Senescence induced by IL-1β, i.e. senescence-related β-
galactosidase activity can be downregulated, at least in part, by ASC-
Cme. Likewise, the morphological changes with increased formation 
of actin stress fibers are modulated by ASC-Cme. Chondrocytes 
under ASC-Cme showed less oxidative stress, less mitogen-activated 
protein kinases and the lower expression of caveolin-1 and p21. The 
Chapter 1 
52 
impacts of ASC-Cme were identified within p53 acetylation which 
depends on increased Sirtuin 1 expression [296, 443].  
Preferentially, ASC-Cme should be serum-free for clinical 
applications. However, serum is required for appropriate cell 
proliferation and impacts ASC expansion ex vivo. In addition, 
prolonged exposure to serum-free conditions causes oxidative stress 
and apoptosis in any cell type including ASC. The proliferation of rat 
BM-MSC in low-serum medium is lower than in high-serum medium. 
Conversely, human ASC under low-serum conditions (LASC) 
demonstrate practically identical growth to human BM-MSC under 
high-serum medium [444, 445]. The suppression of T cell 
proliferation by human LASC has been shown in vitro which is more 
effective than human ASC under high-serum conditions (HASC), 
regardless of the similar capacity of both cell types in differentiating 
into the mesenchymal cell [445].  
Consequently, LASC- immunomodulatory function may have 
incredible potential in cell therapy. Outstandingly, LASC polarized 
macrophages into CD163+ immune-regulatory cells via the 
production of IL-10 more effectively than HASC [446]. Moreover, 
ASC-Cme boosted the activity of ROS scavengers i.e. superoxide 
dismutase and glutathione peroxidase in fibroblasts and 
keratinocytes [414]. All things considered, these outcomes show that 
ASC-Cme display as an antioxidant and anti-apoptotic mediator, 
which assumes a key part in cell protection. 
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30. Challenges of ASC-therapy 
ASC isolated from human lipoaspirates vary in phenotype and purity 
among various investigations. The heterogeneous populations of 
cells after different isolations, making it doubtful if ASC separated 
from other cell types in the population, themselves, are in charge of 
resulted beneficial effects. The pro- angiogenic properties of ASC 
bring up the issue of the connection of these cells with advancing 
tumor formation. Although the administration of MSC into human 
has been stated no tumor formation upon two years follow up [447].  
Up until now, clinical trials around the globe do not show the 
tumorigenicity of MSC-based treatment represent a notable risk. 
Should be noted, couple of conflicting investigations have been 
distributed, with a few reports exhibiting that ASC could advance 
tumor formation [448]. The quickly developing ASC-based therapy 
faces new additional challenges, including how finest to transport 
and stock living cells without harming their therapeutic capacity. 
Transportation and delivery techniques for stem cells are not 
generally concurred on. Presently, stem cell must freeze in a 
procedure known as cryopreservation [449, 450]. Frozen cells are 
costly to transport, as they should be kept frozen. Moreover, they 
are difficult to utilize at their destination as facilities to defrost and 
culture the cells are required. Applying the potential advantages of 
ASC in tissue engineering and cell-based therapies obliges effective 
methodology of maintenance and transportation of ASC with 
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Diabetic retinopathy is the main reason for new instances of visual 
deficiency among grown-ups [27]. During the initial two decades of 
development of DM, about all patients with T1DM and >60% of 
patients with T2DM have DR [27, 28]. The current treatments for DR 
are successful at modulate a significant part of the progression of the 
disease and decrease loss of vision, yet these do not restore lost 
vision and their side effects cannot be ignored [45, 46]. Because 
these therapies are directed for preventing vision loss and DR can be 
asymptomatic, it is necessary to distinguish and treat patients in the 
early phase of the disease, before the onset of PDR. To accomplish 
this objective, cell-based therapies are attractive to both prevent the 
vascular complications and to augment recovery of debilitated 
retina, as shown by recent studies [408].  
Perivascular coordination of ASC-derived pericytes has been shown 
in retinal vasculature. Administration of ASC reduced both vascular 
leakage and apoptosis in retinal vessels [340, 345, 349, 350]. 
Additionally, the immune modulatory effect of ASC could also play a 
role in modulating the DR-induced inflammation [451-453]. ASC 
demonstrate guarantee as potential treatment for DR, albeit that 
basic research is essential to better found clinical trials. The goal of 
this thesis is to achieve the optimal objects before applying the ASC-
based therapy in DR. Although, diabetic retinal cells experience 
hyperglycemic condition and oxidative stress-induced apoptosis 
[168, 175, 176], ASC-derived pericytes onto the diabetic retinal 
vasculature remains unclear. We showed the impact of HG on ASC in 
vitro and established if the HG condition may affect the ASC’s ability 
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to support vascular network formation and their pericytic capacity 
(Chapter 2).  
In the diabetic retina, before histopathology signs can be perceived, 
dysfunctional mitochondria and increments apoptosis are shown 
[185-187]. It is therefore relevant to demonstrate the role of 
mitochondria in the advancement of DR. For this reason, we 
investigated the assessment of energy metabolic changes in 
hyperglycemically challenged ASC in detail. Our techniques gave 
broad data to assess bioenergetic changes in ASC before and after 
culturing under HG condition which may help to evaluate all the 
possible changes of the ASC after injecting to the diabetic 
environment in ASC-based treatment for DR (Chapter 3).  
DR is a chronic inflammation [211]. This inflammation is composed 
by several factors that include release of pro-inflammatory 
cytokines, chemokines, and upregulation of adhesion molecules in 
the retina, serum, and vitreous samples from DR patients [222-224]. 
An immunomodulatory and immunosuppressive impact of ASC was 
shown in recent studies [318], while it remains unclear whether cell 
to cell contact is required for the immunosuppressive impact of ASC 
in diabetes [420, 426-430]. We investigated the double role of ASC in 
promoting the vascular network formation in contact with EC in vivo 
after intravitreal injection of ASC into the ROP mice model and its 
paracrine immunomodulatory effect on retinal endothelial cells 
under HG-induced inflammatory status. MSC ought to be actuated 
by inflammatory mediators (i.e. cytokines) to apply their 
immunomodulatory properties [39]. Along these lines, the 
inflammatory status of the ASC in the time of injection is essential to 
get the best clinical results. We examined the effects of different 
time-points of pre-culturing of ASC under HG condition to obtain the 
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optimal ASC-conditioned medium with the minimum pro-
inflammatory impact and maximum anti-inflammatory and pro-
angiogenic effects on HG-induced EC (Chapter 4).  
Whereas a significant part of the studies centers around how cells 
can be isolated, expanded and transplanted, only minor thought has 
been given to how these cells can be maintained and transported to 
their clinical destination. Hypothermic storing of cells in their own 
particular culture medium proposes a fascinating alternative to skip 
the negative effects of liquid nitrogen cryopreservation or other 
protection techniques. We assessed the efficacy of a new 
pharmacologic compound, SUL-109, that shields ASC during cell 
preservation from hypothermic apoptosis without influencing their 
multi-potency capability. We introduced the new compound which 
would speak to a genuine advance change in how ASC can be 
delivered (Chapter 5).  
Taking everything into account, in our discussion part, the 
consequences of all chapters are discussed and their future 
ramifications are explained (Chapter 6).  
This thesis shows in a comprehensive fashion the restorative 
translational extension of adipose tissue-derived stromal cells-based 
therapy for diabetic retinopathy to state both supporting retinal 
vascular structure and inflammatory modulation. 
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Diabetic retinopathy (DR) is a hyperglycemia (HG)-mediated 
microvascular complication. In DR, the loss of pericytes and 
subsequently endothelial cells leads to pathologic angiogenesis in 
retina. Adipose-derived stromal cells (ASC) are a promising source of 
therapeutic cells to replace lost pericytes in DR. To date, knowledge 
of the influence of HG on the bioenergetics and pericytic function of 
ASC is negligible. Human ASC were cultured in normoglycemia 
medium (5 mM d-glucose) or under HG (30 mM d-glucose) and 
assessed. Our data showed that HG increased the level of apoptosis 
and reactive oxygen species production in ASC, yet their proliferation 
rate was not affected. HG induced alterations in mitochondrial 
function and morphology in ASC. HG also strongly affected the 
bioenergetic status of ASC in which both the maximum oxygen 
consumption rate and extracellular acidification rate were 
decreased. This was corroborated by a reduced uptake of glucose 
under HG. In spite of these observations, in vitro, ASC promoted the 
formation of vascular-like networks of human umbilical vein 
endothelial cells on monolayers of ASC under HG with minimally 
affected. 
 
Key words: Adipose tissue-derived stromal cells, Diabetic 
retinopathy, Hyperglycemia, Oxidative stress. 
 




The International Diabetes Federation estimates that there were 366 
million people living with diabetes in 2011; by 2030 this will have 
increased to 552 million [1]. Diabetes enhances the risk of clinical 
ophthalmologic complications and particular of diabetic retinopathy 
(DR), which is the main cause of blindness in the working-age 
population of developed countries [2]. DR is the result of a 
disordered glucose metabolism and is characterized by the early loss 
of two main cell types of retinal capillaries: the pericyte, which wraps 
capillaries and the endothelial cell [3].  
Pericytes are derived from the vascular smooth muscle lineage and 
exist in contact with endothelial cells. Pericytes provide a nourishing, 
anti-inflammatory and antiangiogenic environment for endothelial 
cells that makes them a potential mediator of the functional blood–
retinal barrier, which is dependent on the interaction of the vascular 
endothelial cells with both glial cells and pericytes [4,5]. The onset of 
DR is caused by intracellular accumulation of reactive oxygen species 
(ROS) that are induced by hyperglycemia (HG). The ROS induces 
apoptosis of pericytes, which exacerbates capillary death. The 
formation of acellular capillaries and pericyte ghosts are typically the 
first abnormalities that are observed clinically in DR [6]. The capillary 
degeneration causes substantial ischemia and local hypoxia, which 
triggers massive neovascularization, typical for later stages of 
retinopathy [7].  
In the absence of pericytes, these new vessels are not quiescent and 
do not mature, while the angiogenesis process continues. The 
resulting capillaries are morphologically and functionally abnormal. 
In particular, their high permeability causes leakage of serum and 
cellular components into the vitreous. If the condition is not 
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diagnosed and treated, the increased pressure can eventually lead to 
blindness [8,9]. Therefore, during DR the retina is in demand of a 
suitable cellular replacement for pericytes. It is well recognized that 
in HG the electron transport chain is overwhelmed with substrate 
and starts to produce oxygen radicals that is, ROS [10]. Exacerbated 
ROS may induce the opening of the permeability transition pore, 
creating swollen mitochondria. These swollen mitochondria may 
present rupture in the mitochondrial outer membrane and leak out 
cytochrome c, calcium ions to mention a few and cause both 
apoptosis and necrosis. Through these effects, oxidative stress 
together with the downregulation of antioxidative enzymes play an 
important role in the pathogenesis of DR [11,12].  
The early stage of retinopathy (non-proliferative retinopathy) 
frequently goes unnoticed as it does not have significant pathological 
signs. However, advanced retinopathy (proliferative retinopathy) is 
in high demand of treatment, due to the existence of leaky, 
nonfunctional, and highly proliferative vessels that require 
normalization of blood glucose levels, laser treatment, vitrectomy, 
and injection of an anti-VEGF (vascular endothelial growth factor) 
medicine combined with anti-inflammatory medicine to name a few. 
All these methods no more than partially prevent or delay loss of 
vision.  
More importantly, replacement pericytes are required to blunt the 
ongoing proliferative angiogenesis while normalizing the capillary 
function. This is not possible to date. Promising results from animal 
models and recent in vitro studies have been published that will 
impact DR via a regenerative medicine-based approach over the 
coming years [13,14]. Adipose tissue-derived stromal cells (ASC) are 
abundant, accessible multipotent mesenchymal stromal cells that 
can be easily isolated from human adipose tissue. ASC have been 
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recently shown to have functional and phenotypic overlap with 
pericytes covering micro-vessels in adipose tissues [15].  
ASC and pericytes share the same surface markers including NG2, 
CD140a, and CD140b (PDGFR α and β). Also, human ASC cooperate 
with endothelial cells to form vascular-like networks in vitro [15,16]. 
It has been shown that in a rodent model for chronic diabetes, ASC 
acquired pericytic features, which rescued proliferative angiogenesis 
in the retina under hyperglycemic conditions [17].  
Importantly, these studies suggested the direct role of ASC in 
providing retinal microvascular support and appear to migrate and 
integrate with the retinal microvasculature [17,18]. ASC features 
may allow a functional replacement, at least short term, pericytes 
loss in DR. While retinal pericytes readily undergo HG and ROS-
driven apoptosis, it is unclear why ASC that engraft diabetic retinal 
vasculature appear refractory to HG. 
In this study, we investigated the influence of HG on the 
mitochondrial function and metabolic activity of ASC and on their 
pericytic function in vitro. This information may help to delineate 




Materials and Methods 
Cell isolation and culture  Human subcutaneous adipose tissue 
samples from healthy human subjects with body mass index <30 
were obtained after liposuction surgery (Bergman Clinics). All donors 
provided informed consent and all procedures were performed in 
accordance to national and institutional guidelines as well as with 
the ethical rules for human experimentation stated in the 
Declaration of Helsinki. 
For ASC isolation, lipoaspirates were enzymatically digested with 
0.1% collagenase A (Roche Diagnostic) in phosphate-buffered saline 
(PBS), containing 1% bovine serum albumin (Sigma-Aldrich) at 37°C 
for 90 mins. Centrifugation (300 g, 4°C, 10 mins) was used to 
separate adipocytes and lipid content from the stromal cell fraction. 
The stromal cell fraction was subjected to Lymphoprep (Axis-Shield 
PoC) density gradient centrifugation. The cells from the interface 
were seeded in culture flasks at 10,000 cells/cm2.  
The culture medium was normoglycemic RPMI-1640 (5 mM D-
glucose, NG-RPMI) (Lonza Biowhittaker Verviers) supplemented with 
10% fetal bovine serum (FBS) (Thermo Scientific), 100 U/mL 
penicillin, 100 μg/mL streptomycin (Gibco, Life Technologies), and 
2 mM L-glutamine (Lonza Biowhittaker Verviers). It was sterilized by 
filtration (0.22 μm). Optimal culture conditions of 37°C, 5% CO2, and 
95% humidity were maintained throughout the culture period.  
ASC in passage 1–3 were harvested with Trypsin-EDTA in 0.9% NaCl 
(Sigma-Aldrich) and routinely checked for both mesenchymal cell 
surface and pericyte markers, including CD31-/ CD44+/ CD45-/ 
CD29+/ CD105+/ CD144-/ NG2+/ PDGFRβ + [19]. The cells were 
passaged at 70%–80% confluence until passage3 (P3) with three 
changes of medium per week. The cells from P3–6 were cultured in 
Hyperglycemia-induced changes in ASC 
105 
 
normoglycemic and hyperglycemic (30 mM d-glucose, HG-RPMI) 
conditions. An osmotic control medium made of 5 mM D-glucose 
plus 25 mM mannitol (NG+Ma-RPMI) of RPMI-1640 was also used. 
Cell culture medium was changed daily during the 7 days of the 
experiment. The pooled ASC from three different donors were used 
for the experiments of this study.  
Human Umbilical vein endothelial cells (HUVEC) were cultured on 
gelatin-coated culture flasks at 10,000 cells/cm2 in endothelial 
culture medium (ECM) consisting of medium NG-RPMI medium 
supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/mL 
streptomycin, 2 mM l-glutamine plus 5 U/mL heparin (Leo Pharma), 
and 50 μg/mL of endothelial cell growth factor [20].  
For the co-cultures of ASC and HUVEC, ASC had to be cultured in 
RPMI-based medium, the influence of DMEM-based and RPMI-based 
medium on the expression of mesenchymal and pericytic markers in 
ASC was assessed (Supplementary Fig. S1, A). The expression of 
PDGFRβ, NG2 were marginally reduced in long-term cultures of ASC 
in ECM and considered of no influence to the experiments. 











SUPPLEMENTARY Figure. S1. ASC were cultured in different medium 
(DMEM, RPMI, and ECM) under normoglycemic condition.  
(A) ASC in passage 1–3 were routinely assessed for pericyte and 
mesenchymal cell surface markers, including CD31-/ CD44+/CD45-
/CD29+/CD90+/CD105+/CD144-/NG2+/PDGFRb+ (*P< 0.01, **P< 0.001, 
***P< 0.0001). Data are plotted as scatter graphs with relative frequencies 
below.  
(B)  The analyses indicate that medium has virtually no influence on these 
markers, with the exception of PDGFRb and NG2 upon culturing in ECM for 
three passages. ASC, adipose tissue-derived stromal cells; ECM, endothelial 
culture medium; NG, normoglycemia.
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Immunofluorescence analysis of cocultured ASC and HUVEC  ASC 
were plated in 24-well cell culture plates (Corning) at 10,000 
cells/cm2 in NG-RPMI medium for 5 days. HUVEC were seeded on top 
of ASC monolayers or as the control on gelatin-coated wells at 
10,000 cells/cm2 in NG-ECM or HG-ECM for 7 more days after which 
vascular networks had formed. Cells were washed with PBS and fixed 
in 2% paraformaldehyde in PBS at RT for 20 min. Cells were 
permeabilized with 0.5% Triton X-100 in PBS (Sigma-Aldrich) for 
15 min. Subsequently, samples were incubated with goat-anti-
human-RGS5 antibody (1:100; Santa Cruz)/rabbit anti-human-SM22α 
antibody (1:100; Abcam) and mouse-anti-human-CD31 antibody 
(1:100; Dako) for 90 min. Samples were washed with PBS and 
incubated with a cyanine3-conjugated-rabbit-antibody to goat-IgG 
for RGS5/cyanine3-conjugated-donkey-antibody to rabbit-IgG for 
SM22a (1:300; Life Technologies) and fluorescein-conjugated-
donkey-antibody to mouse-IgG (for CD31, 1:300; Life Technologies) 
for 45 min. Stained samples were mounted with PBS. Imaging was 
performed with a high-end fully motorized Zeiss AxioObserver Z1 
epifluorescent microscope (TissueGnosticsTissue Faxs). The coculture 
experiment was repeated with HUVEC that were lentivirally tagged 
to express EGFP (green) and ASC lentivirally tagged with dTomato 
(red) to monitor the origin cells irrespective of phenotypes changes 
during coculture. 
 
Apoptosis and proliferation  To estimate the influence of HG on cell 
survival, apoptosis was evaluated by fluorescence-activated cell 
sorting (FACS) analysis using an Apoptotic/Necrotic Cells Detection 
Kit (PromoKine). Briefly, ASC were treated with NG-RPMI, HG-RPMI, 
and NG+Ma-RPMI medium for 7 days and harvested by Trypsin-EDTA 
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in 0.9% NaCl right after treatment. Cells were washed with PBS once 
and resuspended in 500 μL kit binding buffer (100,000 cells/500 μL) 
and stained in the dark with 2.5 μL FITC-AnnexinV (marker for 
apoptosis) and 2.5 μL of Ethidium Homodimer lll (marker for 
necrosis) at RT for 15 min. Samples were analyzed using a FACS 
Calibur flow-cytometer (BD biosciences) within 1 h after staining and 
the results were analyzed with Kaluza 1.2 software. For 
measurement of proliferation, ASC from P3-6 were plated on 24-well 
cell culture plates (Corning) at 10,000 cells/cm2 in NG-RPMI medium 
with 10% FBS for 24 h. The medium was changed for NG-RPMI, HG-
RPMI, or osmotic control, all with 5% FBS for 7 days. Medium was 
changed daily. Cells were fixed and permeabilized as described 
above. Samples were incubated with rabbit-anti-human-ki67 
(Monosan PSX1028) 1:250 in DAPI (5 mg/mL; Sigma-Aldrich) for 
90 min. Samples were washed and subsequently stained by 
incubation with a cyanine3-conjugated-donkey-antibody to rabbit-
IgG (1:100; Life Technologies) for 30 min. Stained samples were 
mounted with PBS. Imaging was performed with a high-end fully 
motorized Zeiss AxioObserver Z1 epifluorescent microscope. 
 
Detection of ROS level  Cellular ROS production was determined 
using the dye 2′,7′-dichlorofluorescein diacetate (DCFH-DA; Sigma-
Aldrich), a cell permeable nonfluorescent probe, which is de-
esterified intracellularly by means of esterases (DCFH) and turns to 
highly fluorescent 2′,7′-dichlorofluorescein (DCF) on oxidation [21]. 
Cells were harvested after 7 days culturing in NG, HG, and NG+Ma-
RPMI medium and suspended in 1 mL of medium followed by 
incubation with 20 μM DCFH-DA in the dark at 37°C for 15 min. 
Samples were analyzed directly without washing using a FACS Calibur 
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flow cytometer (BD Biosciences) within 15 min after the staining and 
the results were analyzed with Kaluza 1.2 software. 
 
Assessment of mitochondrial membrane potential and 
mitochondrial morphology analysis To specify the influence of HG 
on mitochondrial morphology and membrane potential, ASC 
cultured in NG-RPMI or HG-RPMI medium for 7 days were incubated 
at 37°C in a 5% CO2 humidified chamber with 120 nM membrane 
potential–independent dye MitoTracker Green (MTG, Green, Life 
Technologies) and 10 nM tetramethylrhodamine, ethyl ester, 
perchlorate (TMRE, Red-orange; Life Technologies), a membrane 
potential-dependent fluorescent dye for 45 min, washed three times, 
and incubated in medium containing TMRE for 15 min before 
imaging to allow adequate equilibration of the membrane potential-
sensitive TMRE dye within the mitochondria. TMRE was kept in the 
medium while imaging. All experiments were performed in triplicate 
with at least three technical replicates and normalized by the 
number of cells per sample. 
 
Confocal microscopy  Cells were imaged live by confocal microscope 
(Leica TCS SP8 Confocal Microscope) with a 63 × oil immersion 
objective. The cells were kept at 37°C in a 5% CO2 humidified 
microscope stage chamber. MTG was subjected to 490 nm argon 
laser excitation and 516 nm filter emission. TMRE was recorded 
through a band-pass 573–607 nm filter. To observe individual 
mitochondria Z-stack images were acquired in series of six slices per 




Analysis of mitochondrial length and circularity  Mitochondrial 
circularity of ASC was measured as described previously [23]. 
Mitochondrial circularity is a measure of “roundness” of 
mitochondria with 0 referring to a straight line and 1 as a perfect 
circle. Cells containing a majority of long interconnected 
mitochondrial networks were classified as cells with tubular 
mitochondria. Cells with a majority of short mitochondria were 
classified as fragmented and cells with mostly sparse small round 
mitochondria were classified as very fragmented [24]. Morphological 
aspects were measured by ImageJ software for individual 
mitochondria. 
 
Oxygen consumption rate and extracellular acidification rate  The 
oxygen consumption rate (OCR) and extracellular acidification rate 
(ECAR) of ASC grown in NG-RPMI or HG-RPMI medium were 
measured by a bioenergetic assay (XF24; Seahorse Bioscience). ASC 
were plated and grown on V7-PS plate (Seahorse Bioscience, Inc.) in 
NG-RPMI or HG-RPMI medium to reach a confluent monolayer for 7 
days. Assays were initiated by removing growth medium, replacing 
with unbuffered RPMI-1640 medium and incubating at 37°C for 
60 min in a CO2-free incubator to allow temperature equilibrium and 
CO2 degassing from plate. The microplate was then assayed (XF24 
Extracellular Flux Analyzer; Seahorse Bioscience) to measure 
extracellular flux changes of oxygen and pH in the medium 
immediately surrounding the adherent cells. After steady state 
measurement, oxygen consumption and ECARs were obtained. 
Oligomycin (2 μM), which inhibits ATP synthase, and the proton 
ionophore FCCP [carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone; 5 μM], which uncouples mitochondria, were 
injected sequentially through reagent delivery chambers for each 
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well in the microplate, to obtain maximum OCRs. Finally, a mixture 
containing 2 μM rotenone (an inhibitor of mitochondrial complex I) 
and 2 μM antimycin A (an electron transport blocker) was injected to 
confirm that respiration changes were mainly due to mitochondrial 
respiration. The values of oxygen consumption and extracellular 
acidification were normalized to total cellular proteins in each 
sample well. 
 
Assessment of glucose uptake by 2-deoxy D-glucose  To determine 
the influence of HG on glucose uptake in ASC, cells from P3–6 were 
cultured in NG or HG for 7 days. After that cells were washed twice 
with PBS and serum deprived for 4 h, in either NG or HG medium 
supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, 
and 2 mM l-glutamine. Subsequently, the ASC were stimulated with 
100 nM insulin (Novorapid; Novo Nordisk) for 20 min at 37°C or left 
untreated. The medium was removed, cells were washed twice with 
warm PBS, and 1 mL of PBS containing 0.1 μCi 2-deoxy-D-
[14C]glucose (14C-2-DOG) (Perkin Elmer) and unlabeled 2-deoxy-d-
glucose (2DG) (100 μM; Sigma-Aldrich) was added to each well. The 
uptake reaction was carried out at 37°C for 45 min. Glucose 
transport was terminated by washing twice with ice-cold PBS. Cells 
were harvested and lysed in 0.5 mL 0.05M NaOH. Of this, a 400 μL 
aliquot was used for β-scintillation determination by addition of 
scintillation cocktail and subsequent scintillation determination in a 
β-scintillation counter. The remaining 100 μL were used for the 
determination of protein concentration with the Pierce™ BCA 
Protein Assay Kit (Life Technologies). The results were analyzed as 
2DG uptake in pmol/μg of protein. The data are plotted as the fold 
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change in 2DG uptake after culturing in HG compared to culturing in 
NG. 
 
Statistics  All the data are presented as a mean ± SEM and were 
analyzed by GraphPad Prism (GraphPad Software, Inc.). Statistical 
significance was determined using one-way ANOVA and unpaired t-
test analysis. Values of p < 0.05 were considered statistically 
significant. 




HG reduces viability of ASC, but does not influence proliferation 
After 7 days culture in HG medium ∼25% ± 1.1% of the ASC were 
apoptotic and necrotic, while this was reduced in NG 
(16% ± 0.8%, P < 0.0001, Fig. 1A, B). Interestingly, the level of 
proliferation, as determined by the fraction of Ki-67-expressing ASC, 
did not differ between cells cultured in NG medium versus HG 
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Figure. 1. ASC undergo apoptosis after exposure to HG for 7 days.  
Apoptosis and necrosis were quantified by FACS after FITC-Annexin V and 
Ethidium Homodimer lll labeling. 
 (A) Representative FACS data for ASC in NG and HG. The abscissa and 
ordinate represent the fluorescence intensity of Annexin V and Ethidium 
Homodimer lll, respectively.  
(B) Bar graph represents the mean percentage of the total apoptosis and 
necrosis rate – SEM. (n = 5). (***P < 0.0001) 
 (C) Proliferation of ASC is not influenced after exposure to HG for 7 days. 
Immunofluorescent staining of Ki67 (proliferation marker) after 7 days of 
culture in NG or HG medium. Images were analyzed with TissueGnostics 
tissue FAXS software. The bar graph shows the percentage of positive ki67 
cells in HG-medium to the control (NG-medium culturing). The data are 
presented as the mean – SEM. Scale bar = 200 mm. ASC, adipose tissue-
derived stromal cells; FACS, fluorescenceactivated cell sorting; NG, 
normoglycemia; HG, hyperglycemia. 
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HG induces ROS in ASC 
ASC cultured in NG or control medium produced virtually no ROS, as 
determined by FACS analysis of converted DCFH-DA. However, 7 
days culture of ASC in HG medium increased intracellular levels of 
ROS by more than threefold (P < 0.0001, Fig. 2A). In the positive 
control cells which were treated with 1 mM hydrogen peroxide 
(Merk) as a potent ROS inducer, ROS induced well beyond the levels 
induced by HG (Fig. 2B). 
 
Figure. 2. HG induces production of total cellular ROS in ASC. ROS 
production was measured by conversion of DCF in ASC after exposure to 
HG for 7 days.  
(A) The flow cytometric analysis shows a signifi- cantly higher mean 
fluorescence intensity (MFI) in HG compared to NG (***P< 0.0001). The 
graphs show the mean– SEM (n = 8). 
(B) The histograms shows the representative increase of mean intensity 
after exposure to HG or H2O2 control compared to NG. ROS, reactive 
oxygen species. 
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HG alters the mitochondrial membrane potential and changes the 
mitochondrial phenotype of ASC 
The continuous culture of ASC in HG medium decreased their 
mitochondrial membrane potential by ∼31% ± 8% compared to NG 





Figure. 3. HG effected mitochondrial membrane potential of ASC. 
 (A) Mitochondrial membrane potential of ASC grown for 7 days in NG or 
HG medium was detected and measured with mitochondrial membrane 
potential–sensitive TMRE (red) dye using confocal laser scanning 
microscopy. 
 (B) The results were plotted as MFI – SEM (**P< 0.001). 
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This apparent sign of a decreased mitochondrial membrane 
potential was corroborated by disturbances in the mitochondrial 
network of ASC cultured in HG medium for 7 days and assessed 
with MitoTracker dye. This showed a significant decrease of 
23% ± 9.6% compared to the NG control. ASC cultured in NG medium 
had an extensive network of mitochondria throughout the cell 
(P < 0.01, Fig. 4A).  
Another relevant feature to determine mitochondrial dysfunction is 
mitochondrial shape and circularity. We observed a mainly tubular 
mitochondrial morphology in the ASC cultured in NG medium, which 
changed to a fragmented morphology when cultured in HG medium 
for 7 days. The mitochondrial fragmentation increased to virtually 
small fragments in nonphysiologically high (50 mM) glucose 
concentrations (P < 0.0001, Fig. 4B). 






Figure. 4. Mitochondrial morphology of ASC changes after exposure to 
HG. 
 (A) Confocal images of ASC cultured in NG medium stained with 
membrane potential– independent dye MitoTracker Green FM show a 
network of interconnected, long and tubular mitochondria. HG signifi- 
cantly disrupts these mitochondrial networks. (*P < 0.01) 
 (B) HG induces mitochondrial fragmentation in ASC in a dose-dependent 
fashion. Compared to normoglycemic controls, the exposure of ASC to 30 
mM glucose more than doubles the circularity (measure of fragmentation) 
of mitochondria, which increases another twofold when exposed to 50 mM 
glucose. – SEM (***P < 0.0001). 
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HG decreases the maximum OCR and the ECAR in ASC 
ASC cultured in NG or HG conditions were simultaneously measured 
with a bioenergetic assay (XF24; Seahorse Bioscience) to determine 
the rates of cellular oxygen consumption and extracellular 
acidification. Steady state of oxygen consumption and extracellular 
acidification were measured at three time points (Fig. 5).  
Oligomycin (Fig. 5A: injection vertical line A) was injected to inhibit 
ATP synthase, followed by the addition of FCCP (Fig. 5A: injection 
vertical line B) to uncouple mitochondria and obtain values for 
maximum oxygen consumption. Finally, mixture of rotenone and 
antimycin A were injected (Fig. 5A: injection vertical line C) to 
confirm that the respiration changes just could be attributed to 
mitochondrial respiration.  
ASC grown in HG showed a significant decrease (29.54% ± 3%) in 
maximum oxygen consumption compared to ASC grown in NG 
medium (P < 0.0001, Fig. 5B). ECARs were examined simultaneously. 
Changes in the ECAR may indicate changes in the rate of glycolysis in 
these cells. Under HG, ASC showed significantly decreased 
extracellular acidification (Basal: 10%, oligomycin-induced: 34%, and 
FCCP-induced: 44%) as compared with ASC grown in NG medium 
(P < 0.01, Fig. 5C). 
Chapter 2 
124 
HG affects the glucose metabolism of ASC 
Measuring uptake of 2DG is the gold standard to assess glucose 
uptake. ASC cultured in HG showed a 41% ± 0.17% decrease in 
glucose uptake compared to NG medium cultured ASC (P < 0.01, Fig. 
5D), which is in line with the results from the extracellular 
acidification measurements. In mature adipocytes insulin stimulates 
the uptake of glucose into these cells. ASC can be regarded as the 
precursors of adipocytes. Interestingly, in our experiments insulin did 
not affect the glucose uptake into ASC. This shows that under these 
conditions ASC are not sensitive to insulin in terms of increased 
glucose uptake. Yet, GLUT4, the insulin-sensitive glucose transporter, 
was normally expressed (data not shown). 






Figure. 5. HG affects mitochondrial maximum oxygen consumption rate 
(OCR) and extracellular acidification in ASC. 
 (A) Protocol for assessing mitochondrial function in ASC after exposure to 
HG. After measuring the basal respiration rate of cells, compounds 
modulating mitochondrial function are added sequentially. The effect on 
OCR and ECAR are measured after each compound addition. 
(B) The line graph shows the experimental evaluation of steady state and 
maximum OCR for ASC grown in NG or HG 7 days (NG: open circles - B-, HG: 
black squares ---). Dotted lines (A–C) indicate injections of oligomycin, 
FCCP, and rotenone/antimycin A, respectively. The exposure of ASC to HG 
for 7 days results in reduced maximum OCRs compared to normoglycemic 
controls. (***P < 0.0001) 
 (C) HG reduces the extracellular acidification rate of ASC in basal state and 
also after inhibiting ATP synthase by oligomycin (after dotted line A) and 
injection of FCCP, which uncouples mitochondria (after dotted lineB). (*P< 
0.01, ***P< 0.0001)  
(D) HG significantly decreases the uptake of labeled 2-deoxyglucose by ASC. 
Figure shows the rate of glucose uptake, measured as pmol per mg protein 
and presented as the fold change compared to the control– SEM. (n = 9). In 
all cases the scored data were normalized for protein content (*P< 0.01). 
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The stimulation by ASC of vascular networks of HUVEC in vitro is 
affected by HG 
In NG medium, preformed monolayers of ASC promoted the 
formation of vascular network-like structures by seeded HUVEC 
during 7 days coculture (Fig. 6A). These networks were absent in ASC 
or HUVEC controls (data not shown). The vascular-like networks 
comprise of interconnected multicellular tubes of endothelial cells 
with a lumen ranging from capillary size to multicellular structures to 
which ASC attach in a pericytic fashion as shown by their pericytic 
position and expression of SM22α (Fig. 6B, Supplementary Video S1). 
This is corroborated by the absence of SM22α expression by the ASC 
that are not involved in vascular stabilization that is, which remained 
bound to the tissue culture plate itself (Fig. 6B). In HG medium, the 
ASC still supported the formation of vascular networks by HUVEC, 
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Figure. 6. (A) HUVEC (CD31, green) seeded on top of a monolayer of ASC 
(RGS5, red) for 7 days, results in the formation of vascular networklike 
structures, which does not occur in monolayers of HUVEC and ASC 
separately.  
(B) High resolution (63 x) imaging using confocal laser scanning microscopy 
of interactions of ASC with vascular-like networks of HUVEC (green CD31). 
These vascular-like networks comprise of interconnected multicellular 
tubes of endothelial cells with a lumen ranging from capillary size to 
multicellular structures to which ASC attach in a pericytic fashion as shown 
by their pericytic position and expression of SM22a (red). Nuclei—blue 
(DAPI) 
(C) HG decreases the number of branches in vascular networks on the 
monolayer of ASC. The network formation was analyzed with the ImageJ 
angiogenesis analyzer for each well (growth area 1.9 cm2) and the number 
of branches were compared with the control condition (NG) (***P 




DR is characterized by progressive alterations in the retinal 
microvasculature, increasing vascular permeability caused by 
apoptosis in endothelial cells, and pericyte loss that leads to 
abnormal neovascularization in the late stage of the disease [25, 26]. 
Consequently, pericyte replacement would be an important step in 
the treatment or reversal of DR. Although, ASC are pericyte-like cells 
and they would be promising to stabilize the vessels in DR, more 
studies are necessary to show the mechanism of ASC in interaction 
with endothelial cells in DR in vivo. In this study we showed the 
influence of HG on these cells in vitro individually. HG has a 
remarkable influence on retinal pericyte and retinal endothelial cells 
including bioenergetics and metabolic dysfunction, reduced 
mitochondrial function, and induced mitochondrial fragmentation 
[22,27]. The detrimental effects of HG on mitochondrial function and 
cellular metabolism could play a role in the apoptosis associated with 
the retinal pericytes and endothelial cells in DR [28].  
We showed ASC had increased intracellular ROS after a long-term (7 
days) exposure to HG. Chronic HG caused mitochondrial dysfunction 
in ASC, which was observed both as a decreased membrane 
potential in HG and as structural changes as well. The increased ROS 
production correlated with increased apoptosis and necrosis of ASC. 
Interestingly, the proliferation capacity of ASC after exposure to HG 
for 7 days was not affected. This indicates that, with respect to 
function, ASC are largely refractory to the mitochondrial dysfunction 
that is induced by HG in vitro. It is well known that HG-induced 
overproduction of ROS can disrupt the mitochondrial membrane 
potential and damage appropriate functioning of the mitochondria 
[29].  
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This deviation in mitochondrial function is an early sign of apoptosis, 
which was confirmed by the apoptosis increased in treated cells 
[30,31]. We showed that ASC, similar to most mammalian cell types 
in NG, form long and tubular networks of mitochondria. These 
networks are critical for a normal function of the mitochondria by 
regulation of fusion and fission events that involve the formation or 
breaking of the mitochondria network, respectively [32]. A decrease 
in the rate of fusion and a simultaneous increase in the rate of fission 
cause fragmentation of the mitochondrial network, which results in 
shorter and rounder mitochondria [33].  
Our results suggest that HG-induced mitochondrial fragmentation 
maybe involved in the increased ROS production in ASC. It remains 
unclear, however, why the proliferation rate of ASC was unaffected 
by ROS production under HG. While mitochondria are functional, 
they support cell proliferation. The fact that mitochondria under HG 
display similar basal respiration as NG, means that HG cells can deal 
with the stress condition. However, they are still suffering from HG 
according to the statement that maximal respiration is decreased 
and losing their capacity to make ATP.  
Our results indicate that HG caused a decrease of the maximal OCR 
and the rate of extracellular acidification. The basal level of 
extracellular acidification in ASC decreased during HG exposure, and 
also after incubation with ATP synthase inhibitor (Oligomycin) and 
mitochondria uncoupler (FCCP). Corroborating the data obtained 
from the flux analyses, HG caused a significant decline in glucose 
uptake in ASC. Interestingly, this diminished rate of glycolysis was 
unresponsive to insulin stimulation. Our results indicate that ASC 
cultured in HG compensate the hyperglycemic environment by 
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changing the metabolic capacity, as displayed by decreased oxygen 
consumption and glycolysis. 
In this study the question was addressed how the chronic diabetic 
microenvironment affects the ASC's therapeutic potential. This was 
investigated through continuous exposure of HG on ASC and their 
capacity to support the formation of vascular networks by HUVEC. 
Interestingly, the networks were still formed, although with a 
reduced number of branches. The ROS-induced mitochondrial 
dysfunction and apoptosis, only partly affected the pericytic function 
of ASC, because network formation by endothelial cells was only 
marginally affected.  
Our in vitro results corroborate published data that ASC could 
functionally engraft in the retinal vasculature of hyperglycemic mice 
[17,18], while providing part of the protective measurements taken 
by HG-exposed ASC. Taken together, our results suggest ASC are 
largely resistant to long-term exposure to HG, which would explain 
why ASC can acquire a pericytic function in the diabetic retinal 
vasculature in mouse models for DR.  
Our current research focuses on the paracrine and juxtacrine 
interactions between pericytic ASC and retinal microvascular 
endothelial cells under HG to understand how ASC protect 
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Adipose tissue-derived stromal cells (ASC) are promising candidates 
for therapeutic applications in cardiovascular regenerative medicine. 
By definition, the phenotype ASCs e.g. the ubiquitous secretion of 
growth factors, cytokines and extracellular matrix components is not 
met in vivo, which renders ASC a culture ‘artefact’. The medium 
constituents therefore impact the efficacy of ASC. Little attention has 
been paid to the energy source in medium i.e. glucose, which feeds 
the cell’s power plants: mitochondria. The role of mitochondria in 
stromal cell biology goes beyond their function in ATP synthesis, 
because it includes cell signaling, reactive oxygen species (ROS) 
production, regulation of apoptosis and aging. Appropriate 
application of ASC for stromal cells therapy of cardiovascular disease 
warrants knowledge of their mitochondrial phenotype and function. 
We discuss several methodologies for assessing ASC mitochondrial 
function and structural changes under environmental cues in 
particular  increased ROS caused by hyperglycemia.  
 
Keywords: ASC, Mitochondria,  Hyperglycemia,  ROS, Energy 
Metabolism. 




Adipose tissue-derived stromal cells (ASC) are a promising source of 
white adipose tissue stromal cells for use in cardiovascular 
regenerative medicine; for their differentiation potential, their ease 
of isolation and their secretion of therapeutically relevant trophic 
factors [1,2]. The therapeutic potential of ASC has been assessed in 
various animal models with specific disorders such as Parkinson’s 
disease [3] and Alzheimer’s disease [4,5], bone and cartilage defects 
[6,7], skin wound healing [8], myocardial infarction [9,10] and 
diabetic retinopathy [11,12]. 
There is new evidence that, in addition to growth factors and 
extracellular matrix cues, the (energy) metabolism of stromal cell 
directs self-renewal and differentiation [13-15].   
Recent studies have revealed limitations in the therapeutic efficacy 
of ASC derived from patients that were compromised by diabetes or 
aging or obesity. It has been demonstrated that ASC from these 
patients have impaired differentiation and migration [16-19]. 
Recently, we also showed in vitro, that ASC respond to chronic 
hyperglycemic exposure by increased apoptosis caused by amplified 
ROS. In addition, hyperglycemically cultured ASC showed an altered 
mitochondrial membrane potential and changes in mitochondrial 
network morphology. Interestingly, we found an altered glycolysis 
and glucose uptake potential in ASC upon culture under 
hyperglycemic conditions (30mM D-glucose) compared to 
normaglycemically (5mM D-glucose) cultured ASC.  
These data confirm the well-established fact that mitochondrial 
disorders have a key role in apoptosis [20] and it contributes to a 
wide number of diseases, including mitochondrial myopathies [21], 
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mitochondrial neuropathies [22] and diabetes [23]. Mitochondria are 
a main source of reactive oxygen species (ROS) in the cell [24]. In 
healthy cells, the inner membrane of mitochondria is impermeable 
to ions [25] which allows the electrons transport chain (ETC) to build 
up the proton gradient required to generate energy. The 
mitochondrial membrane potential (ΔΨm) results from the 
difference in electrical potential generated by the electrochemical 
gradient across the inner membrane [26].  
Mitochondria are the source for ROS, but also the major target of 
their damaging effects, demonstrating the trigger for several 
mitochondrial dysfunctions. Chronic increases in ROS production 
cause the accumulation of ROS-associated damage in DNA, proteins, 
and lipids, and is headed by severe perturbations in mitochondrial 
function detected as a decrease in ΔΨm. This reduction in ΔΨm is 
accompanied by the production of ROS contributing to cell apoptosis 
[27].  Alterations of the glucose metabolism may cause 
mitochondrial dysfunction, i.e. affect the energy metabolism, and 
may be responsible for further cellular damage and disease 
pathogenesis. The failure to manage cellular energy pathways either 
the aerobic respiration or glycolysis via mitochondria may result in 
serious complications in diseases such as diabetes [28]. Detecting 
mitochondrial dysfunction in therapeutic used ASC is a prerequisite 
in the development of novel stromal cell therapies for diseases such 
as diabetes. 




2.1. Isolation of ASC 
1. Human subcutaneous fat tissue or liposuction-derived fat 
2. Phosphate-buffered saline (PBS) 
3. PBS/1% Bovine serum albumin (BSA) 
4. 0.1% Collagenase dissolved in PBS/1%BSA, freshly prepared 
prior to use (Dissociation medium) 
5. Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 
100U/ml Penicillin, 100g/ml Streptomycin, 2mM L-
glutamine and 1 (gr/L) D-glucose (control medium). Store at 
4°C. 
6. 50-ml Centrifuge tube 
7. 40-μm Nylon mesh 
8. Lymphoprep 
9. Lysis buffer 




2.2. ASC Culture 
1. DMEM supplemented with 10% fetal bovine serum (FBS) and 
100U/ml Penicillin, 100g/ml Streptomycin, 2mM L-
glutamine and 1 (gr/L) D-glucose (control medium) or 4.5 
(gr/L) D-glucose (hyperglycemic medium). Store at 4°C. 
2. Trypsin (0.25%) and ethylenediaminetetraacetic acid (EDTA, 1 
mM) 
 
2.3. Apoptosis detection of ASC (using FACS Calibur flow-
cytometer) 
 
1. Annexin V- Ethidium Homodimer lll (EthD-III): 
Apoptotic/Necrotic Cells Detection Kit (#PK-CA707-30018-
Promokine) 
2. Trypsin (0.25%) and ethylenediaminetetraacetic acid (EDTA, 1 
mM). 
3. FACS tubes 
 
2.4. Intracellular ROS and mitochondrial ROS measurement 
in ASC (using FACS Calibur flow-cytometer) 
 
1. 2′,7′-Dichlorofluorescin diacetate: H2DCFDA (#D399-Thermo 
Fisher) 
2. MitoSOX™ Red: Mitochondrial superoxide indicator  
(#M36008-Thermo Fisher)  
3. Trypsin (0.25%) and ethylenediaminetetraacetic acid (EDTA, 1 
mM). 
4. Control medium/PBS 
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2.5. Monitoring mitochondrial health 
2.5.1. Assessment of mitochondrial membrane potential  
 
1. MitoProb TM JC1 ( 5’,6,6’-tetrachloro-
1,1’,3,3’tetraethylbenzimidazolylcarbocyanine iodide 
(#M34152-Thermo Fisher) 
2. CCCP (carbonyl cyanide 3-chlorophenylhydrazone) 
3. Trypsin (0.25%) and ethylenediaminetetraacetic acid 
(EDTA, 1 mM). 
4. Control medium/PBS 
 
2.5.2. Mitochondrial Morphology Analysis 
 
1. Mito-Tracker Green [MTG] (#M7514-Thermo Fisher) 
2. Trypsin (0.25%) and ethylenediaminetetraacetic acid (EDTA, 1 
mM). 
3. Control medium/PBS  
  
2.6. ASC bioenergetics profiling  
1. V7-PS XF24 cell culture microplates (#11915-
Seahorse Bioscience), XF24 extracellular flux assay kits 
(#Q09015-Seahorse Bioscience) 
2. DMEM-XF containing, 1 mM glutamine, 1% FBS, 1 (gr/L) D-
glucose (control medium) or 4.5 (gr/L) D-glucose 
(hyperglycemic medium) and pyruvate-free (Unbuffered 
medium)  
3. Oligomycin (#103015-Seahorse Bioscience)  




5. Rotenone and Antimycin A (#103015-Seahorse Bioscience) 
6. 2-deoxy-D-glucose (#D8375-Sigma Aldrich) 
7. Pierce™ BCA Protein Assay Kit (#23225-Thermo Fisher) 
 
 
2.7.  Assessment of Glucose uptake 
1. 2-deoxy D-glucose (#D8375-Sigma Aldrich) 
2. PBS  
3. DMEM supplemented with 10% fetal bovine serum (FBS) and 
100U/ml Penicillin, 100g/ml Streptomycin, 2mM L-
glutamine and 1 (gr/L) D-glucose (control medium) or 4.5 
(gr/L) D-glucose (hyperglycemic medium). Store at 4°C. 
(serum-free medium) 
4. Insulin  
5. 2-deoxy-D-[14C]glucose (14C- 2-DOG) (#NEC495-Perkin Elmer)  
6. NaOH 
7. β-scintillation cocktail and β-scintillation counter 
8. Pierce™ BCA Protein Assay Kit (#23225-Thermo Fisher) 




3.1. Isolation of ASC 
1. Mince the fat tissue with fine scissors in culture dishes, and 
transfer the material into a 50ml centrifuge tube. 
Alternatively, lipoaspirated fat can be transferred to 
centrifuge tubes directly. 
2. Wash the fat 3 times with PBS, centrifuge at 300xg for 3 min 
each time. 
3. Add an equal volume of dissociation medium with the fat, stir 
for 90 min in 37°C water bath. 
4. Filter the digested fat through 40-μm Nylon mesh; collect the 
flow-through in 50 ml tubes. 
5. Centrifuge the cell suspension at 600×g for 10 min to obtain a 
high-density ASC pellet. 
6. Aspirate the supernatant, being careful not to disturb the cell 
pellets. 
7. Resuspend the cell pellets in 30 ml PBS/1%BSA and add the 
cell-suspension gently on top of 15 ml Lymphoprep.   
8. Centrifuge at 4°C, 1,000×g for 20 min.  
9. Carefully aspirate the cells from the interphase. 
10. Resuspend cells in lysis buffer and place on ice for 5 min, 
centrifuge at 600×g for 10 min. 
11. Count the cells using Trypan blue and seed at a concentration 
of 1.25 × 105 cells/cm2 in culture flasks. 
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3.2.  ASC Culture 
1. Maintain the primary ASC in control medium at 37°C in 
5% carbon dioxide. Change the culture medium every 
3 days. 
2. Once adherent cells become confluent, aspirate the 
culture medium and wash the cells with 5 ml of PBS. 
Add 1-3 ml of trypsin–EDTA at 37°C for 5 min to detach 
the cells.  
3. Resuspend the ASC with an equal volume of control 
medium. 
4. Centrifuge the cell suspension at 300×g for 10 min at 
4°C and split the cells 1:3 in control medium. 
5. Use the cells from passage 2-7 for the experiments 
(e.g. to expose the cells to an apoptotic condition such 
as hyperglycemia) 
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3.3. Apoptosis detection of ASC (using FACS Calibur flow 
cytometer) 
 
1. Harvest ASC from control/ treated group:  aspirate the 
culture medium and wash the cells with 5 ml of PBS. 
Add 1-3 ml of trypsin–EDTA at 37°C for 5 min to detach 
the cells. 
2. Wash the cells, centrifuge at 300×g for 10 min at 4°C 
and resuspend the cells in 500μl binding buffer 
(100,000 cells/500μl) in FACS tubes. 
3. Stain the cells with 2.5μl FITC-AnnexinV (marker for 
apoptosis) and 2.5μl of Ethidium Homodimer lll 
(marker for necrosis) in the dark at room temperature 
for 15min 
4. Analyze the samples (FITC-AnnexinV -Ex/Em= 
~492/514 nm and EthD-III-Ex/Em= ~528/617 nm) using 





3.4.  Intracellular ROS and mitochondrial ROS measurement 
in ASC (using FACS Calibur flow-cytometer) 
 
1. Harvest ASC from control/ treated groups:  aspirate the 
culture medium and wash the cells with 5 ml of PBS. Add 1-3 
ml of trypsin–EDTA at 37°C for 5 min to detach the cells. 
2. Wash the cells, centrifuge at 300×g for 10 min at 4°C and 
resuspend the cells in FACS tubes with 1ml of warm control 
medium followed by incubation with 20μM H2DCFDA or 5 μM 
MitoSOX™ Red in the dark at 37 °C for 15min.  
3. Analyze the samples (DCF: Ex/Em= ~492/527 nm and oxidized 
MitoSOX: Ex/Em= ~510/580 nm) directly without washing, 
using a FACS Calibur flow-cytometer within 30 min after the 
staining. 
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3.5. Monitoring mitochondrial health 
3.5.1.  Assessment of mitochondrial membrane potential  
 
1. Harvest ASC from control/ treated groups:  aspirate 
the culture medium and wash the cells with 5 ml of 
PBS. Add 1-3 ml of trypsin–EDTA at 37°C for 5 min to 
detach the cells. 
2. Wash the cells, centrifuge at 300×g for 10 min at 4°C 
and resuspend the cells in 1 mL warm control medium 
at 1 × 106 cells/mL, followed by adding 2 μM 
MitoProbe JC-1 and 50 μM CCCP as control. 
3. Incubate the samples at 37°C for 15 minutes.  
4. Determine the mitochondrial accumulation of the 
probe by fluorescence emission shift from green 
(~529 nm) to red (~590 nm) by FACS Calibur flow-




3.5.2. Mitochondrial Morphology Analysis 
 
1. Once ASC cultures from control/ treated group 
become confluent, aspirate the culture medium and 
wash the cells with PBS twice.  
2. Incubate the ASC at 37°C in a 5% CO2 humidified 
chamber with 120 nM membrane potential–
independent dye: Mito- Tracker Green [MTG] in 
culture medium for 45 min. 
3. Wash the cells three times with PBS and refresh the 
medium. 
4. Keep the cells at 37°C in a 5% CO2 humidified 
microscope stage chamber and image the cells live by 
confocal microscope with a 60x oil immersion 
objective (MTG: Ex/Em= ~488/550 nm) 
5. Acquire in series of 6 slices per cell ranging in 
thickness from 0.5 to 0.8 µm per slice to visualize 
individual mitochondria as well as their inter-
connective network or disturbances. 
6. Analyze the mitochondrial length and circularity of 
ASC with ImageJ software.  
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3.6.  ASC bioenergetics profiling 
  
1. Plate the ASC on V7-PS microplate under control or 
treatment condition to reach a confluent monolayer. 
2. Wash the cells three times with PBS. 
3. Replace the unbuffered medium and incubate cell at 37°C 
in a CO2-free incubator for 60min.  
4. For oxygen consumption rate (OCR): pipet 2μM 
oligomycin in port A, 5μM FCCP in port B and a mixture 
containing 2μM rotenone and 2 μM antimycin A in port C.  
For extracellular acidification rate (ECAR): pipet the 
saturating concentration of glucose (10 mM) in port A, 
2μM oligomycin in port B and 100μM 2-deoxy-D-glucose 
in port C.  
5. Place the microplate in XF24 Extracellular Flux Analyzer; 
Seahorse Bioscience to measure extracellular flux changes 
(Follow the protocol in Fig. 2C) 
6. Normalize the results from the measurement to total 




3.7. Assessment of Glucose uptake 
  
1. Once ASC cultures from control/ treated group 
reach confluency, aspirate the culture medium 
and wash the cells twice with PBS.  
2. Incubate the cells in serum-free medium at 37°C 
for 4 hours. 
3. Stimulate the ASC with 100nM insulin for 20 min 
at 37°C or leave untreated. 
4. Remove the medium; wash the cells twice with 
warm PBS. 
5. Add 1ml of PBS containing 0.1μCi 2-deoxy-D-
[14C]glucose (14C-2-DOG) and unlabeled 100μM 2-
deoxy-D-glucose to each well.  
6. Incubate the cells at 37°C for 45min.  
7. Terminate the glucose transport by washing twice 
with ice-cold PBS.  
8. Lyse the cells in 500μl 0.05M NaOH.  
9. Use 400μl of the aliquot for β-scintillation 
determination.  
10. Use the remained 100μl for the determination of 
protein concentration with the Pierce™ BCA 
Protein Assay Kit. 
 
 





 MitoSOX is considered a superoxide-specific probe to 
visualize superoxide ions inside mitochondria [29]. The 
MitoSox specify for hydrogen peroxide or reactive nitrogen 
species is quite low [30]. 
  
 DCF formation is reflected to H2O2 production but it cannot 
be used to measure H2O2 production exclusively inside 
mitochondria. For imaging mitochondrial H2O2 in living cells 
we recommend peroxy-yellow-1 (MitoPY1), a new type of 
fluorophore [31], although advanced studies have to be 
performed to stablish its efficacy. 
 
 Mitochondrial circularity is a measure of the "roundness" of 
mitochondria with 0 referring to a straight line and 1 as a 
perfect circle. Cells containing a majority of long 
interconnected mitochondrial networks were classified as 
cells with tubular mitochondria. Cells with a majority of short 
mitochondria were classified as fragmented and cells with 
mostly sparse small round mitochondria were classified as 
very fragmented [32]. 
 
  As an example we showed a mainly long and tubular 
mitochondrial network morphology in the healthy ASC 
cultured in 5mM D-glucose  medium, which changed to a very 
fragmented morphology when cultured in medium with a 
non-physiologically high (50mM) concentration of D-glucose 




Figure. 1. Confocal analysis of ASC using staining with Mitotracker Green 
FM. Long and tubular mitochondrial network morphology in healthy ASC 
cultured in 5mM D-glucose medium (A). Very fragmented mitochondrial 
morphology of ASC after culturing in non-physiologically high (50mM) D-
glucose concentration medium (B). Blue pseudocolor = DAPI, nucleus 
staining.  
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The tubular mitochondria networks are desired for a normal 
function of the mitochondria by regulation of fusion and 
fission events that involve the formation or breaking of the 
mitochondria network, respectively. A decrease in the rate of 
fusion and a simultaneous increase in the rate of fission cause 
fragmentation of the mitochondrial network which results in 
shorter and rounder mitochondria [33, 34].  
 
 OCR measurement steps:  
1. Measuring the basal OCR. 
2.  Inhibitory analysis using injections of oligomycin (Olig) at 
2 μM which inhibits ATP synthase [ATP-linked respiration 
=OCRpre-Olig − OCRpost-Olig], [proton leak =OCRpost-Olig − OCRpost-
AntA/R].   
3. Applying proton ionophore FCCP at 5 μM, which uncouples 
mitochondria to obtain the maximum oxygen consumption 
rates [maximal respiration =OCRpost-FCCP − OCRpost-AntA/R], 
[respiratory capacity =OCRpost-FCCP − OCRpre-Olig]. 
4. Adding a mixture of an electron transport blocker, 
antimycin A (AntA) at 2 μM and rotenone at 2 μM as an 
inhibitor of mitochondrial complex to confirm that respiration 




 ECAR measurement steps: 
1. Measuring the basal ECAR in a medium without 
glucose or pyruvate. 
2. Measuring glycolysis rate of cells in saturating 
concentration of glucose [basic glycolysis =ECARpre-Olig]. 
3. Inhibitory analysis using injections of oligomycin (Olig) 
at 2 μM which inhibits ATP synthase and shifts the 
energy production pathway to glycolysis to reach to 
the cellular maximum glycolytic capacity [glycolytic 
capacity =ECARpost-Olig], [glycolytic reserve =ECARpost-
Olig − ECARpre-Olig]. 
4. Inhibiting the glycolysis by using 100μM 2-deoxy-
glucose, a glucose analog. 
After normalization and analyzing the data, the mentioned 
mitochondrial respiration and glycolytic indexes can be 
calculated (Fig. 2A, B).  







Figure. 2. Mitochondrial respiration graph of ASC : Basal respiration, ATP 
production and proton leak after injecting oligomycin, maximal respiration 
after exposure the ASC to FCCP and spare respiratory capacity of the cells 
were measured by using a Seahorse XF-analyzer and plotted (A). The 
glycolytic function of ASC: glycolysis, glycolytic capacity after injecting 
oligomycin and glycolytic reserve are shown (B). Protocol commands for 
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The immunomodulatory capacity of adipose tissue-derived stromal 
cells (ASCs) is relevant for next-generation cell therapies that aim to 
reverse tissue dysfunction such as that caused by diabetes. Pericyte 
dropout from retinal capillaries underlies diabetic retinopathy and 
the subsequent aberrant angiogenesis.  
We investigated the pericytic function of ASCs after intravitreal 
injection of ASCs in mice with retinopathy of prematurity (ROP) as a 
model for clinical diabetic retinopathy. In addition, ASCs influence 
their environment by paracrine signalling. For this, we assessed the 
immunomodulatory capacity of conditioned medium from cultured 
ASCs (ASC-Cme) on high glucose (HG)-stimulated bovine retinal 
endothelial cells (BRECs).  
ASCs augmented and stabilised retinal angiogenesis and co-localised 
with capillaries at a pericyte-specific position. This indicates that 
cultured ASCs exert juxtacrine signalling in retinal microvessels. ASC-
Cme alleviated HG-induced oxidative stress and its subsequent 
upregulation of downstream targets in an NF-κB dependent fashion 
in cultured BRECs. Functionally, monocyte adhesion to the 
monolayers of activated BRECs was also decreased by treatment 
with ASC-Cme and correlated with a decline in expression of 
adhesion-related genes such as SELE, ICAM1 and VCAM1.   
The ability of ASC-Cme to immunomodulate HG-challenged BRECs is 
related to the length of time for which ASCs were preconditioned in HG 
medium. Conditioned medium from ASCs that had been chronically 
exposed to HG medium was able to normalise the HG-challenged BRECs to 
NG levels. In contrast, conditioned medium from ASCs that had been 
exposed to HG medium for a shorter time did not have this effect.  
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Our results show that the manner of HG preconditioning of ASCs 
dictates their immunoregulatory properties and thus the potential 
outcome of treatment of diabetic retinopathy. 
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Adipose tissue-derived stromal cells; Diabetic retinopathy; High 




Diabetic retinopathy is the most common microvascular 
complication of diabetes and remains a leading cause of blindness 
worldwide [1]. The prevalence of diabetic retinopathy increases with 
diabetes duration and develops from non-proliferative diabetic 
retinopathy to proliferative diabetic retinopathy (PDR) and macular 
oedema [2]. Hyperglycaemia in the retina activates four main 
biochemical pathway-related changes: (1) polyol pathway flux; (2) 
accumulation of advanced glycation end-products (AGEs); (3) 
activation of protein kinase C (PKC); (4) activation of hexosamine 
pathway flux [3]. Together, these molecular changes induce 
formation of reactive oxygen species (ROS), which induces impaired 
retinal blood flow and increased vascular permeability [4].  
Retinas or vitreous from diabetic individuals with PDR contain 
increased levels of proinflammatory mediators including TNF-α, IL-1β 
[5], IL-6 [6], IL-8 [7] and chemokine (C-C motif) ligand 2 (CCL2) [8, 9]. 
NF-κB is the main transcription factor that regulates expression of 
proinflammatory genes. Activation and nuclear translocation of NF-
κB promotes forward feedback that augments the proinflammatory 
state of activated cells [10]. Diabetes is related to the upregulation of 
cyclooxygenase-2 (COX2) encoded by the prostaglandin-
endoperoxide synthase 2 gene (PTGS2), both in macro- and 
microvessels [11]. In retinas of diabetic animals, increased COX2 is 
followed by increased production of prostaglandin E2 (PGE2) [12].  
At the onset of diabetic retinopathy, pericyte dropout and the 
subsequent loss of retinal endothelial cells through apoptosis causes 
vasoregression. This is the driving force for the pathological 
angiogenesis of PDR [13].  
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In the normal retina, pericytes protect and regulate endothelial cell 
survival and proliferation, vessel integrity and the susceptibility of 
vascular cells to environmental stimuli [14]. Cell therapy with 
adipose tissue-derived stromal cells (ASCs) were promising in 
diabetic animal models. Adipose tissue is easy to acquire and is rich 
in ASCs. These ASCs are the endogenous mesenchymal stem cells in 
fat and they harbour a multipotent capacity to differentiate, for 
example, into adipocytes, chondrocytes and osteoblasts [15].  
Recent studies suggested a direct role for ASCs in retinal 
microvascular support [16]. In rodent models of diabetic retinopathy, 
ASCs acquired pericytic features, which dampened proliferative 
angiogenesis [17, 18]. Recently, we showed that the pericytic nature 
of ASCs depends on neurogenic locus notch homolog protein 2  
(NOTCH2)-based juxtacrine interaction between ASCs and 
endothelial cells [18]. Moreover, ASCs may home in on sites of 
inflammation [19]. The prime immunosuppressive factors produced 
by mesenchymal stem cells and ASCs include indoleamine 2,3-
dioxygenase [20], PGE2 [21], nitric oxide (NO) [22], IL-10 [23] and 
antioxidant enzymes such as haem oxygenase-1 [24].  
Individually or in combination, these factors also reduce oxidative 
stress in target cells [25, 26]. We hypothesised that ASCs 
preconditioned in high glucose (HG) can rescue a dysfunctional 
retinal endothelium through suppression of the inflammation that 
was caused by glucose-induced oxidative stress.  
The aim of this study was to investigate the immunomodulatory 
paracrine function of ASCs in decreasing the production of 
endothelial ROS and in the normalisation of dysfunctional 




Materials and Methods 
Cell isolation and culture Human subcutaneous adipose tissue 
samples from healthy individuals (white females aged 25 to <75 
years and BMI < 30 kg/m2) were obtained after liposuction surgery 
(Bergman Clinics, Zwolle, the Netherlands). Anonymously donated 
samples were obtained with informed consent as approved by the 
ethical board of the University Medical Center Groningen, following 
the guidelines for ‘waste materials’. Lipoaspirates were 
enzymatically digested to obtain the ASCs, as described in our 
previous study [27]. The pooled ASCs from passages 3 to 6 were used 
for experiments. The ASCs were cultured in DMEM (Lonza, Basel, 
Switzerland) either with normal glucose (NG; 5 mmol/l D-glucose) or 
HG (30 mmol/l D-glucose) at normoxia (21% O2). Continuous HG 
maintenance of ASCs (more than three passages; ≥ 21 days) was 
considered to be chronic HG, while short-term exposure to HG (7 
days) was considered to be acute HG. Conditioned medium from 
ASCs (ASC-Cme) was collected from confluent monolayers after 
culturing for more than three passages in HG-DMEM. The 
percentage of FBS was reduced from 10% to 2% (vol./vol.) for 24 h 
prior to collection [28].  
For the co-culture of ASCs and HUVECs, single-cell suspensions of 
HUVECs were seeded on top of confluent ASCs monolayers or, as a 
control, on gelatin-coated wells at 10,000 cells/cm2 and vascular 
networks were allowed to form for at least 7 days [29]. Bovine 
retinal endothelial cells (BRECs) were isolated from freshly-
enucleated cow eyes obtained from the slaughterhouse as described 
previously [30]. First-passage BRECs were used in all experiments. A 
purity of >99% was routinely achieved in BREC culture, which was 
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checked microscopically, and by immunofluorescence staining of von 
Willebrand factor (not shown). Confluent monolayers of BRECs were 
incubated in three different groups (NG-DMEM, HG-DMEM and ASC-
Cme) for 7 days to study the effects of each set of conditions. 
 
Ultrastructural analyses Co-cultures were fixed in 2% (wt/vol.) 
glutaraldehyde (Polysciences, Eppelheim, Germany) for 24 h. 
Samples were post-fixed using osmium tetroxide (Sigma-Aldrich, St. 
Louis, MO, USA) / potassium ferrocyanide (Sigma-Aldrich) for 30 min. 
Next, samples were embedded in Epon 812 (SERVA, Heidelberg, 
Germany) and polymerised at 37°C for 16 h followed by 56°C for 24 
h. Thick sections (0.5 μm) were stained with toluidine blue (Sigma-
Aldrich). Ultrathin sections (60 nm) were stained with uranyl-acetate 
(Sigma-Aldrich) in methanol and lead citrate (Sigma-Aldrich). Imaging 
was performed using a CM100 Biotwin transmission electron 
microscope (FEI, Eindhoven, the Netherlands). 
 
Animals and the retinopathy of prematurity model All animal 
experiments in this study adhered to the association for research in 
vision and ophthalmology (ARVO) Statement for the use of animals 
in ophthalmic and vision research. Male C57BL/6J mice (Charles 
River, Frankfurt, Germany) were housed with free access to standard 
chow and water under a 12 h light-dark rhythm. To study the effect 
of ASCs on hypoxia-driven angiogenesis, newborn mice were 
subjected to the model of retinopathy of prematurity (ROP) [31]. 
Mice at postnatal (P) day 7 (P7) were exposed to an atmosphere of 
75% oxygen with their nursing mother for 5 days and then returned 
to room air at P12. Directly after their return to room air, randomly 
selected mice were intravitreally injected under anaesthesia with 
either 1 μl of PBS containing approximately 10,000 ASCs (passage 1) 
or 1 μl of PBS as a control. Eyes were enucleated under deep 
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anaesthesia at P13 for immunofluorescence analysis; at P13 and P19 
for quantitative real-time PCR (qPCR) analysis; and at P17 for 
quantification of neovascularisation. After collection, eyes were 
immediately fixed in buffered formalin or stored at −80°C for the 
following analysis.  
 
Quantification of hypoxia-driven neovascularisation 
Neovascularisation in retinas was assessed in paraffin sections of P17 
animals injected at P12 with ASCs or a control. To this end, sections 
(6 μm) were stained with periodic acid–Schiff’s reagent (Sigma-
Aldrich). Nuclei of neovessels at the vitreous side of the inner 
limiting membrane of the retinas were counted as described 
previously [32].  
 
Assessment of ASCs in vivo Whole-mount retinas from P13 animals 
were permeabilised with 0.5% (wt/vol.) Triton-X100 at room 
temperature for 1 h. Overnight staining was with FITC/TRITC-labelled 
isolectin-B4 (1:50; Sigma-Aldrich) at 4°C. After PBS washes, retinas 
were flat-mounted in glycerol and micrographs were obtained with a 
fluorescence microscope (Lectin-FITC/ASC-Dil red staining; Leica 
BMR, Bensheim, Germany) or a confocal microscope (Lectin-
TRITC/ASC-EGFP staining; Leica TCS SP2 confocal microscope, Leica, 
Wetzlar,  Germany). ASCs presence was revealed through their 
preinjection label, which was either CM-DiI-red (ThermoFisher, 
Waltham, MA, USA) or enhanced green fluorescent protein (EGFP) 
lentiviral tag. 
 
Gene expression analysis Total RNA was extracted from ASCs and 
BRECs in TRIzol reagent (Life Technologies, Carlsbad, CA, USA) 
following the manufacturer’s protocol. Retinas were isolated from 
frozen eyes of ROP and control mice at P13 (n=5) and ROP mice at 
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P19 in the presence of ASC injection or PBS (n=5). Afterwards, 1 μg of 
total RNA from each sample was reverse transcribed using the First 
Strand cDNA Synthesis Kit (Fermentas, Vilnius, Lithuania) according to 
the manufacturer’s instructions. The cDNA equivalent of 10 ng RNA 
was used for amplification in 384-well plates in a TaqMan ABI 
7900HT thermal cycler (Applied Biosystems, Foster City, CA, USA) in a 
final reaction volume of 10 μl containing 5 μl SYBR Green Universal 
PCR Master Mix (BioRad, Hercules, CA, USA) and 6 μmol/l primer mix 
(forward and reverse). The cycle threshold (Ct) values were 
normalised to GAPDH/ACTB as a reference gene using the ΔΔCt 
method [33]. 
 
Assessment of cell viability Viability was assessed using the 
Apoptosis & Necrosis Kit (Promokine, Heidelberg, Germany) as 
recommended in the manufacturer's instructions. In short, BRECs 
were incubated with 5 μl fluorescein-conjugated annexin V (a marker 
of apoptosis) and 5 μl ethidium homodimer III (at a concentration of 
2×106 cells/ml) at room temperature for 15 min. Fluorescence was 
recorded on a BD FACSCalibur (BD Biosciences, Franklin Lakes, NJ, 
USA) within 1 h of staining. 
 
Quantification of ROS  Cellular ROS production was determined 
using the dye 2′,7′-dichlorofluorescin diacetate (DCFH-DA, Sigma-
Aldrich). Two-electron oxidation of DCFH-DA results in the formation of a 
fluorescent product, dichlorofluorescein (DCF) [34]. Experimental cells 
were suspended in 20 μmol/l DCFH-DA in the dark at 37°C for 15 
min. The general ROS scavenger N-acetyl-L-cysteine (NAC, 10 mmol/l, 
Sigma-Aldrich) and H2O2 (3 μmol/l, Merck Millipore, Darmstadt, 
Germany) were used as negative and positive controls, respectively. 





Screening for immune stimulation The supernatant of HG-
stimulated BRECs cultured with or without ASC-Cme and the control 
group (BRECs in NG) were collected after 7 days. To assess the 
immunogenicity of these samples, THP1-XBlue-MD2-CD14 cells 
(InvivoGen, Toulouse, France) were used as described previously 
[35]. THP1-XBlue-MD2-CD14 cells were plated, then each well was 
stimulated with samples of supernatants and cultured overnight at 
37°C in 5% CO2. Lipopolysaccharide (LPS,10 μg/ml, Sigma-Aldrich) 
was used as a positive control. Production of SEAP in the 
supernatant was quantified using QUANTI-Blue (InvivoGen). An 
aliquot of QUANTI-Blue (200 μl) was dispensed into a new flat-
bottomed 96-well plate with 20 μl of supernatant from the 
stimulated cell-lines for 45 min at 37°C. SEAP activity, representing 
activation of NF-κB, was then measured at a wavelength of 650 nm 
on a VersaMax microplate reader (Molecular Devices, Biberach an 
der Riss, Germany) [35].  
 
ELISA Culture medium was collected from different experimental 
conditions. The concentrations of PGE2 and CCL2 in the medium 
were quantified, respectively, with the Prostaglandin E2 Human 
ELISA Kit (ThermoFisher) and the Human CCL2/MCP-1 DuoSet ELISA 
(R&D Systems, Minneapolis, MN, USA) according to the 
manufacturer’s protocol. LPS (200 ng/ml) and TNF-α (50 ng/ml, 
Sigma-Aldrich) were used as positive controls. The COX2 inhibitor 
celecoxib (10 mmol/l , Sigma-Aldrich) was used to inhibit PGE2 
production. Results were normalised to the number of cells in each 
experimental condition and presented in pg/ml as fold change 
relative to their respective experimental controls. 
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Monocyte adhesion assay One of the cardinal steps of inflammation 
is the infiltration of immune cells such as monocytes across the 
endothelial cell layer [36]. THP-1 monocytes were stained using the 
Vybrant CFDA SE Cell Tracer Kit (ThermoFisher) according to the 
manufacturer's instructions. Treated groups of BRECs (under HG with 
or without ASC-Cme), a positive-control group (pre-incubated with 
medium containing TNF-α [10 ng/ml] for 8 h) and a control group 
(NG) were plated at a density of 5×103 cells/cm2 in standard 96-well 
culture plates and allowed to adhere at 37°C for 4 h. Labelled THP-1 
cells (2×105 cells/ml) were added to each well. After incubation for 1 
h, wells were washed to remove non-adhered cells. Fluorescence of 
adherent cells was recorded on a Varioskan spectrofluorometer 
(Thermo Scientific, Waltham, MA, USA) at excitation/emission =  
492/520 nm [37]. 
 
Scratch wound healing assay BRECs in three different groups (NG, 
HG and ASC-Cme) were cultured until they reached confluency. The 
straight, width-limited scratch was made in all the wells, simulating a 
wound. The recovery of both wound edges was recorded 
simultaneously using the Solamere Nipkow confocal live cell imaging 
microscope (Solamere Technology Group, Salt Lake City, UT, USA) for 
30 h. The percentage of covered area between the edges was 
analysed by imageJ 1.8.0-172 software (imagej.nih.gov/ij/download/). 
Statistical analysis Data are expressed as average ± SEM and relative 
to vehicle controls of at least three independent experiments in 
triplicate. Statistical evaluation was performed using unpaired t tests 
and ANOVA followed by Bonferroni post hoc analysis. p values <0.05 





Ultrastructure of ASC-induced vascular networks  
 
The 0.5 μm cross-sections showed that interconnected laminar 
structures had been formed by co-cultures of endothelial cells on 
ASC monolayers at day 5 and subsequent days (Fig. 1a). 
 Transmission electron micrographs of longitudinal sections showed 
the build-up of 3D structures that comprised endothelial-cell-derived 
(Fig. 1c) vessel-like structures with a lumen (Fig. 1a–c), surrounded 
and tightly aligned by ASCs (Fig. 1c). At high magnification, these 
vessel-like structures appeared as intermittent structures between 
the ASCs (Fig. 1d).  
The vascular networks formed were reminiscent of genuine vessels 
with respect to the slanted intercellular junctions between 
endothelial cells (Fig. 1e,h,i). Peg-and-socket processes [38, 39] that 
extended from ASC-derived pericytes to endothelial cells had also 
formed (Fig. 1f,g), as well as an extracellular matrix-based membrane 
between pericytes and endothelial cells (Fig. 1f,i).  
ASC-derived pericytes, i.e. those cells in close contact with 
endothelial cells, had lost their typically abundant vesicular contents 
compared with more distal ASCs (Fig. 1d).  
These ultrastructural results indicate that ASCs promoted formation 
of vascular networks by endothelial cells and that ASCs had acquired 
a functional pericytic phenotype in vitro (Fig. 1g).  





 Fig. 1 Ultrastructure of ASC-induced vascular network. HUVECs 
were seeded on confluent monolayers of ASCs. After 5 days, 0.5 µm 
sections were stained with toluidine blue and analysed by light microscopy, 
and 60 nm sections of glutaraldehyde-fixed and plastic-embedded co-
cultures were analysed by transmission electron microscopy.  
(a–c) Representative light micrographs: (a) Planar, parallel section (i.e. the 
top view of the culture) showing the formation of a vascular network 
(arrows, endothelial cells) demarcated by the dotted lines. Lumens (L) have 
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formed, which are aligned by ASCs (black arrowheads) in close contact. (b) 
Cross section of the lumen-containing 3D vascular structures in between 
(interrupted) layers of ASCs. (c) Enlargement of a vascular structure with 
several aligned ASCs (arrows, endothelial cells; black arrowheads, ASCs).  
(d–i) Transmission electron micrographs of the vascular structures: (d) a 
vascular structure consisting of endothelial cells (arrows) and lumen is 
depicted by the dotted lines with surrounding ASCs (black arrowheads).  
(e) Specific cell–cell connections with tight junctions between endothelial 
cells (white arrowheads), with lumen  formation on top of the ASCs.  
(f) ASCs deposited extracellular matrix (black asterisks), which forms a 
basement membrane-like structure between the endothelial cells and the 
ASCs.  
(f, g) Peg-and-socket connections are shown by the lightning symbols, and 
the inset in (g) shows intracellular filaments (white asterisks), indicative of 
contractility, similar to smooth muscle cells, i.e. hinting at the maturation 
of ASCs to pericytes.  
(h, i) Details of the endothelial cell–cell connections and basal membrane 
formation around the endothelial cells, i.e. the vascular structure with 
connected ASCs. Scale bar, 5 µm.  
Lumen (L); endothelial cells (arrows); ASCs (black arrowheads); endothelial 
cell–cell connections (white arrowheads); extracellular matrix formation 
(black asterisks); intracellular filaments representative for smooth muscle 
cell phenotype (white asterisks); peg-and-socket connections of ASCs with 
endothelial cells (lightning symbols) 
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ASCs stabilise hypoxia-driven angiogenesis but also engraft at 
pericytic sites in the animal model of ROP  
 
ASCs were injected intravitreally at P12 in the eyes of ROP-model 
mice (Fig. 2a). At P13, injected ASCs were present in angiogenic 
sprouts and had attached to endothelial cells of maturating 
capillaries at a pericyte-like position (arrows, Fig. 2b,c). Further 
analyses showed that dye-labelled-ASCs (green, Fig. 2d–f) had 
aligned and attached to maturing intraretinal capillaries (red, Fig. 
2d–f) at pericyte-specific perivascular positions and in contact with 
the endothelium. 
Quantification of hypoxia-induced retinal neovascularisation at P17 
showed that injection of ASCs in the animal models of ROP increased 










Fig. 2 ASCs enhance hypoxia-driven angiogenesis in the ROP mouse 
model.  
(a) Scheme of the ROP model. Mouse pups were exposed to hyperoxia 
(75% O2) from P7 to P12 and subsequently transferred to room air (21% 
O2). This causes hypoxia at room air that results in extensive retinal 
neovascularisation at P17. ASCs were injected into the vitreous at P12 to 
evaluate their influence on hypoxia-driven neovascularisation.  
 
(b, c) Representative micrographs of CM-DiI-labelled ASCs (red, white 
arrows) co-localising with the endothelial layer (lectin, green); 
magnification ×20. 
 
 (d–f) Micrographs of EGFP-tagged ASCs (green) co-localising with the 
endothelial layer (lectin, red) in the pericytic position. The scale bars in (d–
f) are 100 µm, 25 µm and 15 µm, respectively.  
 
(g, h) Histological analysis of the effects of ASC injection on hypoxia-
induced retinal neovascularisation; magnification ×20. Neovascularisation 
was assessed histologically by counting the endothelial cell nuclei anterior 
to the inner limiting membrane. (g) Histological features of retinal 
neovascularisation in the control group. (h) Histological features of retinal 
neovascularisation in ASC-injected mice. Intravitreal injection of ASCs in the 
ROP mouse model increased the number of neovascular tufts extending 
into the vitreous (black arrows). 
 
 (i) Hypoxia-driven neovascularisation in the retinas was enhanced by 54% 
in animals injected with ASCs (PBS vs ASC, 8.3±0.62 vs 12.8±0.96). The 
graph shows the mean number of neovascularisation nuclei per section per 
animal, ***p<0.001. GCL, ganglion cell layer;  ILM, inner limiting 
membrane; INL, inner nuclear layer; neovascul., neovascularised; ONL, 
outer nuclear layer 
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ASCs modulate the inflamed ROP microenvironment  
 
ROP and control retinas (P13) were assessed by qPCR. At P13, i.e. 24 
h after returning the animals from hyperoxia to ambient oxygen, 
Angpt1 (encoding angiopoietin [ANGPT] 1) expression had slightly 
decreased in ROP retinas, while Angpt2 had slightly increased 
(although neither significantly) compared with the non-ROP controls 
(Fig. 3a). This was accompanied by increased expression of 
angiogenesis-related genes i.e. Vegfa (encoding vascular endothelial 
growth factor [VEGF] A; 2.0-fold change), Fgf2 (3.2-fold change), and 
Col4a1 (1.4-fold change) (Fig. 3a). The analysis showed increased 
expression of proinflammatory genes i.e. Il1b (2.0-fold change) and 
Ccl2 (2.1-fold change) compared with P13 controls. Cxcl15 (mouse 
orthologue of human CXCL8) and Tnf changed non-significantly 
(Fig. 3a). Comparison of ROP retinas with and without ASC 
intervention showed that injection of ASCs at P12 caused a 1.5-fold 
increase of Angpt1 and a 0.6-fold decrease of Angpt2, suggesting 
induction of vascular quiescence. Injection of ASCs into the ROP eyes 
caused increased expression of inflammatory genes such as Tnf, 
Cxcl15 and Ccl2 by 2.2-, 1.8- and 2.5-fold, respectively. A slight 
decrease was observed in the expression of proangiogenic Vegfa and 
a 1.3-fold increase of Fgf2 was observed in ROP at P19 with ASCs, 
compared with the control ROP at P19 without ASCs (Fig. 3b). No 
differences in the expression of Pdgfb, Col4a1 and Il1b were 
detected. 




Fig. 3 ASCs modulate the ROP micro-environment. Gene expression 
analyses normalised to Gapdh of (a) dissected ROP retinas at P13 (grey 
bars) compared with the control retinas at P13 (white bars). The expression 
levels of  Vegfa, Fgf2, and Col4a1 were increased. In addition, an 
inflammatory response was induced, as measured by increased expression 
of Il1b and Ccl2. (b) To assess the ASC-guided changes to the ROP micro-
environment at P19, ROP retinas of eyes with ASC injection (grey bars) and 
controls (white bars) showed increased expression of Angpt1 and Fgf2, and 
decreased expression of Angpt2. The expression of Vegfa, Pdgfb and 
Col4a1 was similar to controls. The inflammatory response was modulated 
by normalised Il1b expression, while the expression of Tnf, Cxcl15 and Ccl2 
was increased. *p<0.05, **p<0.01 vs control retinas. Graphs represent 




Chronic or acute exposure to HG influences ASC gene expression  
The expression of 36 relevant genes was measured in ASCs after 
acute exposure to HG (i.e. maintained in NG medium, followed by 7 
days in HG medium) or chronic exposure to HG (i.e. always 
maintained in HG medium and for more than 21 days). Data are 
presented as the fold change compared with (chronic) maintenance 
in NG medium (Fig. 4a,b). The acute exposure of ASCs to HG 
upregulated the proinflammatory genes TNF (1.8-fold change), IL1A 
(6.0-fold change), IL6 (4.5-fold change), CCL2 (4.3-fold change) and 
CXCL8 (6.0-fold change); as well as the proangiogenic genes VEGFA 
(4.8-fold change), ANGPT2 (1.8-fold change) and MMP1 (4.2-fold 
change). Expression of the angiopoietin receptors TIE1 and TEK (also 
known as TIE2) was downregulated (0.52-fold and 0.47-fold change, 
respectively). The glucose transporter SLC2A1 (encoding GLUT1) was 
upregulated 2.5-fold.  
Interestingly, acute HG exposure induced a 4.9-fold change in the 
mesenchymal pericyte marker RGS5, while expression of other 
mesenchymal markers such as ACTA1, TAGLN and PDGFRB changed 
only marginally. Endothelial marker PECAM1 was also upregulated 
(1.3-fold change). The expression of two immunoregulatory genes, 
PTGS2 (encoding COX2) and IDO1, were upregulated (3.4-fold and 
3.6-fold change, respectively).  
The expression of all genes in ASCs was similar upon culture under 
chronic HG and chronic NG conditions, which indicated that ASCs 
adapt to different glucose concentrations in the culture medium 
during log-term culture. The inflammatory response after acute 
exposure to HG resulted in an increased release of PGE2 (11.0-fold 
change) and CCL2 (1.6-fold change) by ASCs, compared with chronic 
exposure to HG (Fig. 4c,d). Interestingly, chronic exposure to HG 
medium slightly decreased PGE2 secretion (0.3-fold change) and 
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secretion of CCL2 (0.8-fold change) compared with controls 
maintained in NG. LPS and TNF-α both induced the secretion of PGE2 
and CCL2, while celecoxib inhibited the production of PGE2 
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Fig. 4 Anti-inflammatory and anti-apoptotic effects of ASCs depend on 
chronic HG preconditioning.  
(a, b) Expression of 36 genes, normalised to ACTB, in ASCs after acute 
exposure to HG (7 days) or chronic HG (more than 21 days maintenance in 
HG) compared with NG-exposed controls. Grey bars, acute HG exposure; 
white bars, chronic HG exposure. Graphs represent data ± SEM from n=4 
independent experiments. *p<0.05, **p<0.01, ***p<0.001 vs NG-exposed 
control. (c, d) The inflammatory response in HG conditions was induced in 
ASCs and measured by ELISA to detect PGE2 and CCL2 in ASC-Cme. LPS and 
TNF-α were used as positive-stimulated controls. Celecoxib (10 mmol/l) 
was used as an inhibitor of COX2 in acute-HG-treated ASCs. Graphs show 
mean ±  SEM from n=5 independent experiments. *p<0.05, **p<0.01, 
***p<0.001 vs NG control; ††p<0.01, †††p<0.001 vs chronic HG. Genes 
encode the following proteins: TNF, tumor necrosis factor; IL1B, IL-1β; IL1A, 
IL-1α; IL6, IL-6; CXCL8, C-X-C motif chemokine ligand 8 (also known as IL-8); 
CCL2, chemokine (C-C motif) ligand 2; PTGS2, prostaglandin-endoperoxide 
synthase 2; CXCL12, C-X-C motif chemokine 12; NFKB1, NF-κB subunit 1; 
MMP1, matrix metallopeptidase 1; ICAM1, intercellular adhesion molecule 
1; IDO1, indoleamine 2,3-dioxygenase 1; IL1R1, IL-1 receptor type 1; IL1RN, 
IL-1 receptor antagonist; IL10RA, IL-10 receptor subunit α; IL10RB, IL-10 
receptor subunit β; SLC2A1, solute carrier family 2 member 1 (also known 
as GLUT1); SLC2A4, solute carrier family 2 member 4 (also known as 
GLUT4); VEGFA, vascular endothelial growth factor A; KDR, kinase insert 
domain receptor/VEGF receptor 2; TGFB1, TGF-β1; FGF2, fibroblast growth 
factor 2; IGF, IGF; ANGPT1, angiopoietin 1; ANGPT2, angiopoietin 2; TIE1, 
tyrosine kinase with immunoglobulin like and EGF like domains 1; TEK, TEK 
receptor tyrosine kinase (also known as Tie2); PDGFRB, platelet derived 
growth factor receptor β; RGS5, regulator of G-protein signaling 5; TAGLN, 
transgelin; ACTA1, actin α1; PECAM1, platelet/endothelial cell adhesion 
molecule 1 (skeletal muscle); CNN1, calponin 1; MCAM, melanoma cell 
adhesion molecule (also known as CD146); DES, desmin; THY1, Thy-1 cell 
surface antigen (also known as CD90) 
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The antioxidant role of ASC-Cme abrogates NF-κB activation and 
promotes cell viability of BRECs  
Culture of BRECs under HG conditions for 7 days induced cell death 
(viability ∼88% vs 94.6% for HG vs NG, Fig. 5a). Apoptosis was 
increased (annexin V-positive cells ∼11.2% vs 4.6% for HG vs NG, Fig. 
5b), while necrosis had also increased (ethidium homodimer lll-
positive cells ∼0.73% vs 0.45% for HG vs NG, Fig. 5c). Simultaneous 
treatment of HG-stimulated BRECs with ASC-Cme (i.e. conditioned 
medium from ASCs chronically cultured in HG medium) normalised 
viability (∼93.9% vs 88% for ASC-Cme vs HG, Fig. 5a) and suppressed 
apoptosis (∼4.8% vs 11.2% for ASC-Cme vs HG, Fig. 5b) and necrosis 
(∼0.25% vs 0.73% for ASC-Cme vs HG, Fig. 5c) of the BRECs.  
Exposure of BRECs to HG increased intracellular ROS production (4.6-
fold change compared with NG controls, Fig. 5e), while ASC-Cme 
abrogated this (0.4-fold change, Fig. 5e). This was comparable to the 
NAC effect on HG induced BRECs (0.25-fold change, Fig. 5e).  
The monocytic NF-κB reporter (SEAP) cell line THP1-XBlue-MD2-
CD14 was used to assess the proinflammatory capacity of 
conditioned medium obtained from BRECs that were co-treated with 
HG and ASC-Cme. The strongest activation of NF-κB occurred after 
stimulation with LPS (29.0-fold change, Fig. 5f), while neither NG nor 
HG medium (DMEM) had any influence. Compared with NG controls, 
the activation of monocyte-expressed NF-κB increased (1.4-fold 
change) upon exposure to conditioned medium from HG-stimulated 
BRECs. In contrast, NF-κB activation was normalised to NG control 
levels (0.6-fold change) by conditioned medium from BRECs that 
were HG induced and simultaneously treated with ASC-Cme.  






Fig. 5 The antioxidant role of ASC-Cme, combined with declining NF-κB 
activation, promotes cell viability of HG-challenged BRECs.  
(a) ASC-Cme promotes BREC viability following HG-induced apoptosis 
(viability ∼88% vs 94.6%, HG vs NG; 88% vs 93.9%, HG vs Cme). 
 (b) HG-induced apoptosis was normalised by ASC-Cme (annexin V-positive 
cells ∼11.2% vs 4.6%, HG vs NG; 11.2% vs 4.8% for HG vs Cme). 
 (c) Necrosis (ethidium [ET] homodimer lll-positive cells ∼0.73% vs 0.45%, 
HG vs NG; 0.73% vs 0.25% for HG vs Cme). (a–c) LPS was used as a 
positive control. 
 (d) The histogram shows the representative increase of fluorescence 
intensity (by DCF) after exposure to HG or H2O2 control compared with NG 
or ASC-Cme and NAC treatment.  
(e) HG induces ROS in BRECs. Total cellular ROS production was measured 
by DCF. ASC-Cme suppressed ROS production in the presence of HG, 
compared with HG alone. The ROS inhibitor NAC and H2O2 were used as 
negative and positive controls, respectively. 
 (f) NF-κB activation by conditioned BREC medium in THP1-XBlue-MD2-
CD14 cells, and  mediated by ASC-Cme. NF-κB activation was significantly 
higher in cells treated with BREC conditioned medium under HG conditions 
(BREC under HG), compared with unstimulated control. This response was 
almost absent when cells were treated with ASC-Cme alongside BREC 
conditioned medium under HG conditions (BREC under Cme). LPS was used 
as a positive control for THP1-XBlue-MD2-CD14 cells and induced NF-κB 
activation. RPMI-1640 medium, NG-DMEM and HG-DMEM were used as 
controls, which had no effect on activation of THP1-XBlue-MD2-CD14 cells. 
Absorbance values were plotted to express NF-κB activation with arbitrary 
units. *p<0.05, **p<0.01, ***p<0.001 vs NG control; †p<0.05, ††p<0.01, 
†††p<0.001 vs HG. Values are mean ± SEM (n=4 in a–c, f and n=5 in e). 
Cme, ASC-Cme 
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ASC-Cme downregulates principal inflammatory factors in HG-
challenged BRECs  
HG stimulation of BRECs for 7 days upregulated the gene expression 
of the relevant proinflammatory genes TNF, IL1B, IL1A, IL6, CXCL8 
and CCL2, as well as leucocyte adhesion-related genes SELE, ICAM1 
and VCAM1. In addition, the proangiogenic genes ANGPT1, ANGPT2, 
VEGFA, VEGFB and PDGFB, and the endothelial NO synthases, NOS2 
and NOS3, were upregulated, as well as PTGS2. The upregulation of 
these genes was normalised to NG control level in ASC-Cme-treated 
HG-challenged BRECs. Only KLF4 did not change after HG challenge 
of BRECs. Interestingly, expression of both KLF4 and NOS2 were 
upregulated in ASC-Cme-treated HG-challenged BRECs. The 
expression of ANGPT1, a vessel quiescence-associated factor, 
remained increased upon ASC-Cme treatment of HG-challenged 
BRECs (Fig. 6a–r).  
As expected, the proinflammatory condition of HG-challenged BRECs 
(Fig. 6a–r) also increased their adhesiveness to THP-1 monocytes 
(2.4-fold change, Fig. 7a), while treatment with ASC-Cme normalised 
monocytic adhesion to NG levels (0.6-fold change). Treatment of 
BRECs with TNF- promoted the strongest adhesion of monocytes 
(4.5-fold change, Fig. 7a). 
Wound closure of BRECs cultured in NG medium, after HG challenge 
or treatment with ASC-Cme during HG challenge, was similar over a 
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Fig. 6 ASC-Cme downmodulates the main inflammatory genes in HG-
challenged BRECs, compared with NG-treated controls. (a–r) HG 
upregulated the expression of the main genes related to inflammation. This 
upregulation of TNF, IL1B, IL1A, IL6, CXCL8, VCAM1, SELE, ICAM1, VEGFA, 
VEGFB, PDGFB, CCL2, PTGS2, and NOS3 is significantly modulated by ASC-
Cme. ASC-Cme upregulated the gene expression of ANGPT1, KL4 and NOS2. 
Values are mean ± SEM (n=6). *p<0.05, **p<0.01, ***p<0.001 vs NG 





Fig. 7 (a) THP-1 cell adhesion to BRECs exposed to HG, with and without 
ASC-Cme. The intensity of fluorescence of adherent THP-1 cells (mean ± 
SEM, n=3, fold change of NG-treated control) in resting or activated BRECs 
was measured. A significant decrease in adhered THP-1 cells occurred after 
treatment of HG-challenged BRECs with ASC-Cme, compared with HG 
treatment alone.   
(b) Scratch wound healing assay to study interaction in the BREC 
monolayer under NG, HG and ASC-Cme conditions. The percentage of 
covered area between the edges was analysed. The percentage signifies 
the remaining gap size 30 h after making the scratches, compared with the 
initial gap size. The gap width decreased in a similar pattern in all three 
groups (NG, closed circles; HG, open circles; ASC-Cme, open diamond) and 
was not significantly delayed in HG conditions. Values are mean ± SEM. 
**p<0.01, ***p<0.001 vs NG control; †p<0.05 vs HG 




The main results of our studies are that human ASCs stimulate retinal 
angiogenesis in ROP mice via acquisition of a pericytic position and 
function. This was confirmed by ultrastructural analyses showing 
that in vitro ASCs promote vascular network formation of endothelial 
cells and stabilise these networks via a pericytic function. 
Extracellular matrix was deposited between ASC-derived pericytes 
and endothelial cells in vitro, while typical peg-and-socket 
connections were also formed [38, 39]. Acute exposure of ASCs to 
HG caused a proinflammatory and proangiogenic activation 
compared with ASCs that were propagated chronically in HG. In fact, 
conditioned medium from ASCs that had been chronically exposed to 
HG reduced ROS and proinflammatory activation of BRECs 
challenged with HG. Activated genes were reduced to normal 
expression levels, while endothelial protective genes such as KLF4 
were upregulated. The immunomodulatory properties of ASCs [40-
42] may vary upon passaging in culture [41]. Early passages of ASCs 
express markers, e.g. ligands that stimulate cells of the adaptive 
immune system such as MHCII, CD80 and CD86, which are lost upon 
passaging  [41, 43]. Our results show that ASC injection into ROP 
mice, a model of pathological angiogenesis in PDR [44], led to an 
increased expression of inflammatory genes such as Tnf, Cxcl15 and 
Ccl2, which might relate to the early passaging of ASCs. The balance 
of ANGPT1 and ANGPT2 and the expression of VEGFA are among the 
most important regulators of vascular development, maturation and 
maintenance [45]. Reduced expression of pericyte-derived ANGPT1, 
and concomitant upregulation of its antagonist ANGPT2 and 
increased VEGFA levels induce pericyte dropout, vessel 
destabilisation and sprouting angiogenesis [46]. In ROP retinas of 
ASC-treated mice, expression of Angpt1 and Fgf2 were increased, 
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while levels of Angpt2 and Vegfa were reduced. Injected ASCs 
adhered to neovessels at a pericytic position. This corroborates the 
role of NOTCH2 in the juxtracrine function of ASCs [18]. Earlier work 
from our group showed that under acute HG culturing, ASCs largely 
maintain their pericytic role as an endothelial supporting cell, despite 
an upregulated ROS production accompanied by increased apoptosis 
in ASCs [29].  
In general, most papers use DMEM as constitutive culture medium 
to propagate ASCs. This medium contains 25 mmol/l D-glucose, 
which is, in fact, similar to hyperglycaemic conditions in vivo.  A main 
finding of our study was that chronic exposure of ASCs to HG 
medium normalised gene expression to levels seen under NG 
conditions. Interestingly, in comparison to chronic propagation in 
HG, ASCs that were shifted from NG-DMEM to HG-DMEM for 7 days 
had upregulated gene expression of proinflammatory cytokines and 
chemokines, but also of proangiogenic factors. Moreover, secretion 
of PGE2 and CCL2 were also strongly increased. COX2 is responsible 
for the diabetes-induced retinal PGE2 production, and inhibition of 
COX2 inhibited the diabetes-induced upregulation of retinal VEGF, 
which links COX2 expression to angiogenesis in diabetic retinopathy 
[12, 47, 48]. PGE2 activates the extracellular signal-regulated kinases 1 
and 2 (ERK1/2) and thus promotes angiogenesis through endothelial 
upregulation of the secretion of e.g. VEGF, chemokines and 
activation of cell cycle genes [49, 50]. Thus, the acute HG exposure of 
ASCs likely renders these cells in a proangiogenic state. Their 
upregulated expression of proinflammatory genes likely also 
activates endothelial cells. Yet the exposure of retinal endothelial 
cells to HG alone activated NF-κB and increased expression of 
downstream IL1B, VEGFA, TNF and ICAM1 to name a few of the 
upregulated main proinflammatory genes. ASC-Cme suppressed 
these proinflammatory genes such as PTGS2 in BRECs plus VEGFA as 
The dual role of ASC in DR 
197 
 
a proangiogenic gene. Acute HG exposure of ASCs would induce 
endothelial dysfunction rather than counteract it. However, the 
continuous propagation of ASCs in HG medium not only suppresses 
their proinflammatory status, but also augments their capacity to 
normalise endothelial cell function. This was corroborated in HG-
activated BRECs by the suppression, by ASC-Cme, of ROS production, 
the reduction of monocyte adhesion and improved cell survival (Fig. 
8). Part of the immunosuppression resides in the suppression of 
endothelial ROS production by ASC-secreted factors, because ROS 
functions, via activation of TAK1, as an activator of NF-κB. Taken 
together, our results show that HG preconditioning of ASCs 
potentially improves their therapeutic efficacy as compared with 
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Encouraging advances in cell therapy research with adipose derived 
stromal cells (ASC) require an effective short-term preservation 
method that provides time for quality control and transport of cells 
from their manufacturing facility to their clinical destination.  
Hypothermic storage of cells in their specific growth media offers an 
alternative and simple preservation method to liquid nitrogen 
cryopreservation or commercial preservation fluids for short-term 
storage and transport. However, accumulation of cell damage during 
hypothermia may result in cell injury and death upon rewarming 
through the production of excess reactive oxygen species (ROS). 
Here, the ability of the cell culture medium additive SUL-109, a 
modified 6-chromanol, to protect ASC from hypothermia and 
rewarming damage is examined. SUL-109 conveys protective effects 
against cold-induced damage in ASC as is observed by preservation 
of cell viability, adhesion properties and growth potential. SUL-109 
does not reduce the multilineage differentiation capacity of ASC. 
SUL-109 conveys its protection against hypothermic damage by the 
preservation of the mitochondrial membrane potential through the 
activation of mitochondrial membrane complexes I and IV, and 
increases maximal oxygen consumption in FCCP uncoupled 
mitochondria. Consequently, SUL-109 alleviates mitochondrial ROS 
production and preserves ATP production. In summary, here we 
describe the generation of a single molecule cell preservation agent 
that protects ASC from hypothermic damage associated with short-
term cell preservation that does not affect the differentiation 
capacity of ASC. 
Keywords: Adipose tissue-derived stromal cells (ASC), hypothermia, 
cold storage, mitochondrial damage, chromanol 




Adipose derived Stromal Cells (ASC) hold great promise in 
regenerative medicine. ASC are multipotent mesenchymal-like stem 
cells that reside in the perivascular niche as pericytes or 
periadventitial cells [1] in white adipose tissue throughout the body 
[2-4]. ASC secrete a plethora of trophic factors [5] that suppress 
inflammation and apoptosis, yet promote angiogenesis and mitosis 
of parenchymal cells [6]. Moreover, ASC have the ability to 
differentiate into several cell types, including adipocytes, 
chondrocytes, osteoblasts and muscle cells under lineage-specific 
culture conditions [2-4]. 
Encouraging advances in cell therapy research using ASC or ASC-
derived tissue engineered constructs demonstrated their ability in 
the regeneration of bone and cartilage defects [7,8], ischemic limb 
disease [9], skin wound healing [5], and myocardial infarction [10]. 
However, the clinical application of ASC requires an effective short-
term preservation method, thus providing time for quality control 
and transport of cells from their manufacturing facility to their 
clinical destination. 
Hypothermic storage of cells in their normal culture media offers an 
accessible, logistically easy and cost-effective alternative to 
cryopreservation, vitrification and protocols using preservation fluids 
(e.g. ViaSpan or HypoThermosol) for short-term storage and 
transport [11]. In contrast to cryopreservation, which is a 
complicated cell type-specific process hampered by cell loss and 
mutagenesis [12,13], hypothermic storage should be a simplified 
process that voids these complications at low costs. Hypothermia 
slows metabolic activity and cell cycle progression, thereby 
maintaining the ASC in their current state. However, hypothermia 
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may produce significant cell injury and death, particularly upon 
rewarming when excess reactive oxygen species (ROS) are produced 
[14,15]. Current hypothermic preservation fluids suffer from this 
rewarming damage; whilst effective at low temperature, they do not 
prevent severe cell damage upon rewarming [16]. Additionally, the 
chemical composition of commercially available hypothermic 
preservation fluids differs vastly from the chemical composition of 
culture media, which might induce undesirable dedifferentiation of 
cells or failure of a tissue engineered construct [17,18]. 
Consequently, hypothermic storage warrants strategies to alleviate 
these deleterious effects of hypothermia and rewarming, while 
reliably and consistently maintaining the key characteristics of cells, 
including viability, phenotype, and, in the case of ASC, differentiation 
potential. 
Substituted 6-chromanols represent a novel class of pharmacological 
compounds that preserve cell viability under a number of conditions 
[19-21]. Here, we describe the identification of a 6-chromanol 
derivate (SUL-109), a single molecule cell culture additive, as a 
preservation agent that protects human ASC from hypothermia and 
rewarming damage without affecting their subsequent 
differentiation capacity.
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Materials and Methods 
ASC isolation and culture  Human subcutaneous adipose tissue 
samples from healthy human subjects with (BMI< 30) were obtained 
after liposuction surgery (Bergman Clinics, The Netherlands). All 
donors provided informed consent and all procedures were 
performed in accordance to national and institutional guidelines as 
well as with the ethical rules for human experimentation as stated in 
the Declaration of Helsinki. 
Lipoaspirates were enzymatically digested with 0.1% Collagenase A 
(Roche Diagnostic, Mannheim, Germany) in PBS, containing 1% 
bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MI) at 37°C for 
90 mins. Centrifugation (300g, 4°C, 20 mins) separated adipocytes 
and lipid content from the stromal cell fraction. The stromal cell 
fraction was subjected to Lymphoprep (Axis-Shield PoC, Oslo, 
Norway) density gradient centrifugation (300g, 20°C, 30 mins). The 
cells from the interface were collected and cultured in DMEM (Lonza 
#707F, Breda, The Netherlands) containing 10% Fetal Bovine Serum 
(FBS, GE LifeSciences #SH30071, Pittsburg, PA), 1% 
Penicillin/Streptomycin (Sigma-Aldrich #P4333, St. Louis, MI) and 2 
mM L-glutamine (Life Technologies #25030, Carlsbad, CA). ASC at 
passage 1 were routinely checked for the expression of pericyte and 
mesenchymal cell markers according to [22] and had the following 
phenotype: CD10+, CD13+, CD31-, CD34-, CD44+, CD45-, CD73+, 
CD90+ and CD105+. At 80% confluence, ASC were dissociated using 
0.12% Trypsin, 0.02% EDTA solution in PBS (#59430, Sigma-Aldrich, 
St. Louis, MI) pelleted by centrifugation (300g, 4°C, 5 mins), and re-
seeded at a density of 10.000 cells/cm2. ASC at passage 3 were used 




Cell viability, adherence and proliferation  Alpha-Tocopherol (10 
µM, #T1539 Sigma-Aldrich, St. Louis, MI), TROLOX (10 µM, # 
10011659, Cayman Chemical, Ann Arbor, MI) or SUL-109 (10 µM; 
#Rokepie-01, Sulfateq BV, Groningen, The Netherlands) were added 
to the ASC culture medium. After 2 hours culturing at 37°C, ASC 
cultures were placed under hypothermic conditions (4°C) in a 
standard laboratory refrigerator for 48 hours. Thereafter, ASC were 
re-warmed for 2 hours under normal cell culture conditions (37°C 
and 5% CO2). Viability was assessed using the Apoptosis & Necrosis 
Kit (Promokine #PK-CA707-30018, Heidelberg, Germany) as by 
manufacturer’s instructions. In short, ASC were dissociated using 
Trypsin-EDTA solution and suspended in 1X AnnexinV-binding buffer 
at a concentration of 2·106 cells/ml. Next, ASC were incubated with 
5 µl fluorescein-conjugated AnnexinV and 5 µl Ethidium 
Homeodimer III in the dark at room temperature for 15 min. 
Fluorescence was recorded on a BD FACSCalibur (BD Bioscience, 
Franklin Lakes, NJ) by a skilled operator at the UMCG Flow Cytometry 
Core Facility within 1 hour of staining. 
To assess the adherence capacity of ASC, hypothermic preserved ASC 
were dissociated using Trypsin-EDTA in 0.9% NaCl and fluorescently 
labeled with the CFDA SE Cell Tracer (ThermoFisher #V12883, 
Waltham, MA) according to manufacturer’s instructions. Next, 
fluorescently-labeled ASC were plated at a density of 5·103 cells/cm2 
in standard 96-well culture plates (Corning #CLS3596, St. Louis, MI) 
and allowed to adhere under standard culture conditions (37°C and 
5% CO2) for 15-240 min. Following extensive washing with PBS to 
remove non-adhered cells, fluorescence of adherent cells was 
recorded on a Varioskan spectrofluorometer at Ex/Em 492/520 nm.  
To assess cell proliferation, ASC were fixed using 2% 
paraformaldehyde (Sigma-Aldrich #P6148, St. Louis, MI) in PBS for 20 
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min. Next, samples were permeabilized using 0.5% Triton X100 (Life 
Technologies #85112, Carlsbad, CA) in PBS and incubated in 5% 
rabbit normal goat serum (Jackson Immunoresearch #005-000-121, 
Suffolk, UK) at room temperature to block non-specific antibody 
binding for 10 min. Samples were incubated with polyclonal 
antibodies to Ki67 (Monosan #PSX1028, San Diego, CA) at a 
concentration of 2.5 µg/ml. After extensive washing in PBS/Tween-
20 (0.1%), samples were incubated with AlexaFluor555-conjugated 
antibodies to rabbit IgG (Life Technologies #A-21428, Carlsbad, CA) 
at a dilution of 1:300 in PBS containing 5 µM DAPI (4',6-Diamidino-2-
Phenylindole, Life Technologies #D1306, Carlsbad, CA) at room 
temperature for 30 min. Samples were mounted in citifluor (Citifluor 
Ltd #AP-1, London, UK) and visualized on a Zeiss AxioObserver Z1 
microscope. Total cell number and Ki67-positive cells were 
quantified using automated fluorescence microscopy software 
(TissueFaxs, TissueGnostics, Vienna, Austria). 
 
Multipotency of ASC  ASC were subjected to hypothermia and 
rewarming as described above, after which the culture media was 
changed for differentiation media. To induce multi-lineage 
differentiation of ASC, cells were cultured in adipogenic medium 
(DMEM containing 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-
glutamine, Dexamethasone (0.1 µM, Sigma-Aldrich #D4903, St. Louis, 
MI), Insulin (1 nM, Sigma-Aldrich #I2643, St. Louis, MI) and IBMX (0.5 
mM, Sigma-Aldrich #I7018, St. Louis, MI)), osteogenic medium 
(DMEM containing 10% FBS, 1% Penicillin/Streptomycin and 2 mM L-
glutamine, Dexamethasone (0.1 µM), β-glycerophosphate (10 mM, 
Sigma-Aldrich #G9422, St. Louis, MI) and L-ascorbic acid (0.5 mM, 
Sigma-Aldrich #A5960, St. Louis, MI)), or myogenic medium (DMEM 
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containing 10% FBS, 1% Penicillin/Streptomycin and 2 mM L-
glutamine and TGF-β1 (10 ng/ml, Peprotech #100-21, Rocky Hill, NJ)) 
for 21 days. To assess differentiation, ASC were fixed using 2% 
paraformaldehyde (Sigma-Aldrich, #P6148) in PBS for 20 min and 
phenotyped using (immuno)histological stains. For adipogenesis, ASC 
were rinsed with 60% isopropanol and stained with Oil Red O (0.5%, 
Sigma-Aldrich #O0625, St. Louis, MI) at room temperature for 15 
mins. For osteogenesis, samples were stained in Alizarin Red (0.5%, 
Sigma-Aldrich #A5533, St. Louis, MI) at room temperature for 10 
mins. Samples were counterstained using hematoxylin and mounted 
in Kaisers Glycerin.  
To assess myogenic differentiation, ASC were permeabilized with 
0.5% Triton X100 (Life Technologies #85112, Carlsbad, CA) in PBS and 
incubated with polyclonal antibodies to SM22 alpha (2.5 µg/ml, 
#ab14106, Abcam, Cambridge, UK) for 60 mins. After extensive 
washing in PBS/Tween-20 (0.1%), samples were incubated with 
AlexaFluor555-conjugated antibodies to rabbit IgG (2.0 µg/ml, Life 
Technologies #A-21428, Carlsbad, CA) in PBS containing 5 µM DAPI 
(4',6-Diamidino-2-Phenylindole, Life Technologies #D1306, Carlsbad, 
CA) at room temperature for 30 min. Samples were mounted in 
citifluor (Citifluor Ltd #AP-1, London, UK) and visualized on a Zeiss 
AxioObserver Z1 microscope in fluorescence mode. 
 
Antioxidant assays  5 µM 2’7’-dichlorodihydrofluorescein diacetate 
(DCF, Sigma-Aldrich #D6883, St. Louis, MI) was dissolved in Hanks 
Balanced Salt Solution (#H1641, Sigma-Aldrich, St. Louis, MI) and 
supplemented with α-tocopherol, TROLOX, or SUL-109 at 
concentrations ranging from 10-9 to 10-3 M. 3 µM hydrogen peroxide 
(H2O2, MerckMillipore #107209, Darmstadt, Germany) was added as 
reactive oxygen donor and samples were incubated at room 
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temperature for 1 hour. Fluorescence was recorded on a Varioskan 
spectrofluorometer (ThermoScientific, Waltham, MA) at 488/525 nm 
(Ex/Em). 
 
Metabolic state, mitochondrial structure and mitochondrial 
membrane potential analyses  The oxygen consumption rate (OCR) 
and extracellular acidification rate (ECAR) of hypothermically 
preserved ASC were determined after rewarming in the presence or 
absence of SUL-109 for 2 hours, using the Seahorse Bioscience 
Extracellular Flux analyzer (Seahorse Bioscience, Billerica, MA). In 
short, changes in extracellular oxygen tension and pH were 
determined on the XF24 Extracellular Flux Analyzer (Seahorse 
Bioscience, Billerica, MA). 
 After steady state oxygen consumption and basal extracellular 
acidification rates were obtained, 2 µM Oligomycin (ATP Synthase 
inhibitor, Seahorse Bioscience #9634398, Billerica, MA) and 5 µM 
carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, 
mitochondrial uncoupler, Seahorse Bioscience #9634398, Billerica, 
MA) were sequentially added through the reagent delivery chambers 
of the flux analyzer to measure the maximum oxygen consumption 
rates and maximum acidification rates. Finally, a mixture of 2 µM 
Rotenone and 2 µM Antimycin A was used to block mitochondrial 
electron transport. As OCR and ECAR reflect the metabolic activity of 
cells and are influenced by cell number, OCR and ECAR values were 
normalized to total protein content in a sample. 
Mitochondrial morphology was assessed using a mitochondrial 
membrane potential-independent dye (i.e. MitoTracker-Green, 
ThermoFisher Scientific #M7514, Waltham, MA). In short, ASC were 
incubated with 120 nM MitoTracker-Green at 37°C in a 5% CO2 
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humidified chamber for 45 min. Next, cells were analyzed by live cell 
imaging on a confocal microscope (Leica TCS SP2 Confocal 
Microscope, Wetzlar, Germany) with a 63x oil immersion objective 
using an excitation wavelength of 488 nm and emission was 
recorded through a band pass 500 to 550 nm filters. ASC were kept 
at 37°C in a 5% CO2 humidified microscope stage chamber 
throughout the analysis. The mitochondrial membrane potential was 
assessed using the JC-1 MitoProbe (ThermoFisher Scientific 
#M34152, Waltham, MA). ASC were dissociated using Trypsin-EDTA 
in 0.9% NaCl and suspended at 1106 cells/mL in warm medium 
containing 2 µM JC-1. Membrane potential-dependent JC-1 
accumulation in the mitochondria (indicated by a fluorescence 
emission shift from green (~529 nm) to red (~590 nm)) was recorded 
by flow cytometry on a FACS Calibur (BD Biosciences, Franklin Lakes, 
NJ). To depolarize the mitochondrial membrane, 50 μM carbonyl 
cyanide 3-chlorophenylhydrazone (CCCP) was added for 15 mins 
prior to JC-1 loading. 
 
 
Mitochondrial Complex I-V activity measurements  ASC-derived 
mitochondria were isolated using density gradient centrifugation 
using the MitoCheck® Mitochondrial Isolation Kit (Cayman Chemical 
#701010, Ann Arbor, MI) according to manufacturer’s instructions 
and assessed for the activities of mitochondrial complex I-V. In all 
activity measurements, isolated ASC-derived mitochondria were pre-
incubated with a concentration series of SUL-109 (10-9-10-4M) at 
room temperature for 15 mins. Mitochondrial complex I (NADH 
oxidase/co-enzyme Q reductase) activity was determined by 
measuring the decrease in NADH oxidation, which is reflected by a 
decreased in absorbance at 340nm (Cayman Chemical #700930, Ann 
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Arbor, MI) in the presence of 2mM potassium cyanide (KCN) to 
prevent the oxidation of Q.  
Activity of mitochondrial complex II (Succinate dehydrogenase/co-
enzyme Q reductase) was assessed by the rate of reduction of DCPIP, 
which is protonated by reduced co-enzyme Q (Cayman Chemical 
#700940, Ann Arbor, MI), and is reflected by a decrease in 
absorbance at 600nm. To prevent interference of mitochondrial 
complexes I, III and IV, complex II activity measurements were 
performed in the presence of 1µM Rotenone, 10µM Antimycin A and 
2mM KCN (all Sigma-Aldrich (#R8875, #A8674, #60178), St. Louis, 
MI), respectively. Mitochondrial Complex III (Co-enzyme Q 
cytochrome c oxidoreductase) activity was determined by the rate of 
cytochrome c reduction, which is reflected by increased absorbance 
at 550nm (Cayman Chemical #700950, Ann Arbor, MI). To prevent 
backflow of electrons through complex I and the reduction of 
cytochrome c by complex IV, activity measurements were performed 
in the presence of 1µM Rotenone and 2mM KCN. The activity of 
Mitochondrial Complex IV (cytochrome c oxidase) was determined 
by measuring the rate of oxidation of cytochrome c, which is 
reflected by a decrease in absorbance at 550nm (Cayman Chemical 
#700990, Ann Arbor, MI). The activity of Mitochondrial Complex V 
(F1F0 ATP Synthase) was determined by the rate of NADH oxidation, 
which can be monitored at 340nm (Cayman Chemical #701000, Ann 
Arbor, MI). Under physiologic conditions, mitochondrial complex V 
uses the proton gradient generated by complexes I-IV to generate 
ATP from ADP in the presence of Pi. However, complex V can also 
run in reverse [23]. In the determination of complex V activity, ATP is 
converted in ADP by complex V, which is used for the conversion of 
phosphoenolpyruvate into pyruvate by pyruvate kinase. Pyruvate is 
subsequently reduced to lactate in the presence of lactate 
dehydrogenase and NADH. Hence, complex V activity is reflected by 
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the rate of NADH oxidation, which can be measured by a change in 
absorption at 340nm. To prevent interference of mitochondrial 
complex I, which also oxidizes NADH, all complex V activity 
measurements were performed in the presence of 1µM Rotenone.   
 
Measurement of ATP and ROS production  To assess the ATP 
production of human ASC, we used the ATP Determination Kit 
(ThermoFisher Scientific #A22066, Carlsbad, CA). In short, ASC were 
treated with SUL-109 (10-9-10-4M), 0.1µM Rotenone, 1µM KCN or a 
combination of SUL-109 and the Mitochondrial Complex I or IV 
inhibitors for 1 hour. Next, cells were lysed in a Tris/Glycine buffer 
(25mM, pH 7.8, 5mM MgSO4, 0.1mM EDTA and 0.1mM sodium 
azide) that contained 0.5mM D-luciferin, 1.25µg/ml firefly luciferase 
and 1mM DTT. ATP production was assessed as luminescence 
measured on a Luminoskan (ThermoFisher Scientific, Carlsbad, CA) 
set to an integration time of 500ms at 1200mV. To assess ROS 
production, ASC were treated with SUL-109 (10-9-10-4M), 0.1µM 
Rotenone, 1µM KCN or a combination of SUL-109 and the 
Mitochondrial Complex I or IV inhibitors for 1 hour. Next, cells were 
incubated with the fluorescent ROS-indicator DHE (1µM, Life 
technologies #D11347, Carlsbad, CA) for 30 mins. Fluorescence was 
recorded on a Varioskan spectrofluorometer  (TheroScientific, 
Waltham, MA) at Ex/Em 518/605. 
 
Statistical analysis  Data are expressed as average ± SEM and relative 
to vehicle controls of at least 3 independent experiments. Statistical 
evaluation was performed using ANOVA followed by Bonferroni post 
hoc analysis. P-values <0.05 were considered statistically significant. 




(Modified) 6-chromanols are water soluble α-tocopherol 
derivatives. Alpha-tocopherol, TROLOX and SUL-109 (fig.1) belong to 
chemical class of 6-chromanols. SUL-109 and TROLOX differ from α-
tocopherol by the absence of the large hydrophobic side chain. In 
contrast to the hydrophobic α-tocopherol (logP = 9.98), TROLOX and 
SUL-109 are hydrophilic compounds (logP=3.19 and 2.25, 
respectively). Consequently, the water solubility at room 
temperature ranges from α-tocopherol (S=63.1 nM) < TROLOX (S= 




Figure 1. (Modified) 6-chromanols are water soluble α-tocopherol 
derivatives. Structural and chemical properties of the compounds under 
investigation; (a) α-tocopherol (vitamin E), (b) TROLOX, and (c) SUL-109. 
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SUL-109 improves ASC viability, adhesion and proliferation after 
hypothermic damage.  
A hypothermic challenge (4°C, 48h) reduced ASC viability to ~7% 
(p<0.001, fig.2a). Pretreatment of ASC with α-tocopherol marginally 
increased cell viability (viability ~16%, p<0.05) whereas SUL-109 
completely rescued cell viability (viability ~84%, p<0.001, fig.2a).  
Moreover, viability of ASC that received a hypothermic challenge in 
the presence of SUL-109 did not differ from ASC that were 
maintained at 37°C under standard cell culture conditions or ASC 
that were preserved using cryopreservation (fig.2a).  
Cell death resulting from hypothermia was primarily induced by 
necrosis (~66%, p<0.001 compared to ASC maintained at 37°C, fig.2c) 
and to a lesser extent by apoptosis (~27%, p<0.001, fig.2b). 
Consistent with the improved cell viability, SUL-109 completely 
blocked the initiation of apoptosis and necrosis following the 
hypothermia (figs.2b,c), whereas α-tocopherol did not reduce 
apoptosis and necrosis (maximum ~10% reduction, p=0.10, fig.2b,c). 
Further, hypothermic preservation of ASC using SUL-109 was 
effective with full preservation of viability (~88%, fig.2d) over a 
period of four days. 
As tissue engineering and regenerative medicine strategies require 
ASC to readily adhere and grow at the treatment site following 
injection or implantation, we assessed the effects of 6-chromanols 
on their adhesion capacity and growth potential after hypothermic 
treatment (figs.2e-g).  
Hypothermia challenged ASC had a decreased adherence capacity 
(~4-fold, p<0.001) compared to ASC that were maintained under 
standard culture conditions over a period of 4 hours post-seeding 
(fig.2d).  
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Pretreatment with the 6-chromanols α-tocopherol and TROLOX did 
not attenuate the loss in adherence capacity (fig.2d). In contrast, ASC 
that were treated with SUL-109 prior to the hypothermic 
preservation, adhered to the same extent as ASC maintained at 37°C 
throughout the experiment (fig.2d).  
The growth potential of ASC that underwent hypothermic 
preservation was investigated by Ki67 expression. ASC that were 
exposed to hypothermia were devoid of Ki67 expression (fig.2f) for 
as long as 48h after rewarming (fig.2f), indicating prolonged growth 
arrest. Pretreatment with the 6-chromanols increased ASC 
proliferation to 25% (α-tocopherol, p<0.05), 40% (TROLOX, p<0.001) 
and 62% (SUL-109, p<0.001, fig.2g). Notably, ASC pretreated with 
SUL-109 had a growth potential equal to cryopreserved and 
normothermic ASC (figs.2f,g).  
Thus, pretreatment of ASC with SUL-109 fully preserves cell viability, 







Figure 2. SUL-109 protects ASC from hypothermic damage. Hypothermia 
strongly reduces cell viability (a). Hypothermia-induced cell death was 
both caused by apoptosis (~27% Annexin V-positive cells; b) and necrosis 
(~66% Ethidium Homeodimer III-positive cells; c). Alpha-tocopherol and 
TROLOX do not inhibit hypothermia-induced cell death, but SUL-109 
abrogates both the apoptotic and necrotic cell death responses of ASC 
during hypothermic preservation (b,c). SUL-109 maintains ASC viability 
during hypothermic preservation for 4 days (d). Cells that encountered 
hypothermic damage for 48h followed by 2h re-warming show poor 
adherence during 240mins post-seeding (e), whereas ASC treated with SUL-
109 prior to hypothermia adhered at a similar rate as ASC that were 
maintained at 37°C (e). Hypothermia slows metabolic activity and cell cycle 
progression resulting in failure to undergo the G2/M transition after 
cooling from 37°C to 4°C (g). ASC show cell cycle arrest (absence of Ki67; f) 
after hypothermic preservation despite 48h of rewarming (f). In contrast, 
hypothermically stored ASC that were treated with α-tocopherol, TROLOX 
or SUL-109 (e,f) maintained their cycling activity and SUL-109-treated ASC 
proliferated at a similar rate to control cells (g) that were maintained at 
37°C . TOCO = α-tocopherol, N2 = liquid nitrogen cryopreservation, * 
p<0.05, ** p<0.01, *** p<0.001, N2 = liquid nitrogen cryopreservation.  
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ASC maintain their multipotent differentiation capacity after 
hypothermic damage.  
The ability of ASC to differentiate into multiple cell types under 
lineage-specific culture conditions holds promise for tissue 
engineering and regenerative medicine.  
Hence, preservation protocols should have minimal interference 
with these characteristics and must maintain the multipotency of 
ASC. Hypothermic preserved ASC readily differentiated along the 
adipogenic (Oil Red O), osteogenic (Alizarin Red) or myogenic 
(SM22α) lineage (fig.3). Although hypothermia causes a large 
decrease in available cell numbers, ASC exposed to hypothermia did 
not display any signs of decreased multilineage specialization (fig.3).  
Moreover, the adipogenic, osteogenic and myogenic differentiation 
capacity of ASC treated with α-tocopherol, TROLOX or SUL-109 prior 
to hypothermia did not differ from ASC that were maintained under 






Figure 3. Hypothermia does not reduce the multipotency of ASC. ASC 
differentiation into the adipogenic (Oil Red O-positive cells), osteogenic 
(Alizarin Red-positive cells) and myogenic (SM22α-positive cells) lineage. 
Naive ASC differentiate efficiently into the three lineages when treated 
with the appropriate stimuli. ASC that survived the hypothermic challenge 
maintained their differentiation capacity and treatment with the 6-
chromanols did not affect multilineage differentiation. 
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Cell survival is not associated with the antioxidant capacity of 
(modified) 6-chromanols.  
Hypothermic damage is associated with a drastic increase in reactive 
oxygen species (ROS) and can be reduced by antioxidants [24]. 
Therefore we investigated in a test-tube setting if the 6-chromanol 
derivate SUL-109 (fig.1a) possessed antioxidant properties [19, 20] 
using the fluorescent ROS sensor 2’7’-dichlorodihydrofuorecein 
diacetate (DCF).  
The oxidation of DCF by H2O2 was strongly inhibited by the co-
incubation with α-tocopherol (IC50=0.40 µM, TROLOX-equivalent 
antioxidant capacity (TEAC)=0.98±0.05) and TROLOX (IC50=0.32 µM, 
TEAC=1.0±0.11), whereas SUL-109 only inhibited DCF oxidation at 
concentration above 10-5M (IC50=229 µM, TEAC=0.53±0.06, fig.4a). 
ASC survival during hypothermia increased dose-dependently with 
the addition of (modified) 6-chromanols (fig.4b). Alpha-tocopherol 
provided protection against hypothermia at concentrations above 
10-3 M (EC50= 5.40 mM), whereas the modified 6-chromanols 
TROLOX (EC50=306.20 µM) and SUL-109 (EC50=2.65 µM) showed a 
higher potency (fig.4b) with effective concentrations in the 
micromole range.  
These data imply that the protective effects of 6-chromanols are not 
derived from their antioxidant capacity, but from their interference 
with specific cellular processes. Indeed, the TEAC of α-tocopherol, 
TROLOX and SUL-109 shows a positive correlation with ASC viability, 
whereas a negative correlation would be expected if antioxidant 







Figure 4. ROS-scavenging by 6-chromanols does not associate with cell 
survival. Dose-response of the antioxidant capacities of α-tocopherol, 
TROLOX and SUL-109 (a). Alpha-tocopherol and TROLOX are strong 
antioxidants with and IC50 for H2O2-induced DCF fluorescence of 0.40 µM 
and 0.32 µM, respectively. SUL-109 is a weak antioxidant (TEAC 0.56) with 
an IC50 of 229 µM for H2O2-induced DCF fluorescence. Dose-response of 6-
chromanols on the viability of hypothermia-challenged ASC (b). Alpha-
tocopherol and TROLOX increase cell viability after hypothermia only at 
high concentrations. Alpha-tocopherol had an EC50 of 2.2 mM, TROLOX had 
an EC50 of 0.3 mM. In comparison, SUL-109 readily increases cell viability 
with an EC50 of 2.6 µM. Association between antioxidant capacity and cell 
viability (c). TOCO = α-tocopherol, TEAC = TROLOX-equivalent antioxidant 
capacity. 
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SUL-109 maintains mitochondrial integrity, mitochondrial 
membrane potential and ATP production by activation of 
mitochondrial complexes I and IV.  
As cell death and the induction of growth arrest are both highly 
influenced by cellular redox state and mitochondrial function [25, 
26], we investigated if 6-chromanols influenced the mitochondrial 
function of hypothermically preserved ASC (fig.5).  
Hypothermia induces a drastic decrease in mitochondrial respiration 
through oxidative phosphorylation as observed by the decrease in 
basal oxygen consumption rate (OCR, ~2.6-fold, p<0.001, fig.5a,c), 
without changing the extracellular acidification rate (ECAR, fig.5b,c).  
TROLOX and SUL-109 pretreatment maintained basal mitochondrial 
respiration, normalizing the OCR to the level of normothermic 
controls (fig.5a,c). Further, in contrast to α-tocopherol and TROLOX, 
SUL-109 fully prevented the drop in FCCP-induced maximal OCR of 
hypothermically preserved ASC (figs.5a,d), indicative of increased 
mitochondrial reserve capacity and increased mitochondrial coupling 
[27] compared to hypothermia-treated ASC and ASC pretreated with 
α-tocopherol or TROLOX (Fig.5a,d).  
Notably, the SUL-109-induced increase in mitochondrial respiration 
was only observed for oxidative phosphorylation (OCR, fig.5d) and 
not for glycolysis (ECAR), indicating that SUL-109 preserves 
mitochondrial coupling.  
Indeed, the dense network of fused mitochondria observed in 
normothermic ASC became fragmented following hypothermia 
(fig.5e). Pretreatment of ASC with α-tocopherol did not prevent 
mitochondrial fragmentation, whereas TROLOX only partially 
inhibited the fission of the mitochondrial networks. SUL-109 
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pretreatment fully blocked the hypothermia-induced fragmentation, 
as ASC maintained a dense network of fused mitochondria (fig.5e).  
Corroboratively, hypothermic storage for 48h induced a complete 
loss of the mitochondrial membrane potential, whereas α-
tocopherol and TROLOX only partially prevented the collapse in 
mitochondrial membrane potential (fig.5f).  
ASC that received SUL-109 treatment prior to hypothermic 
preservation maintained their mitochondrial membrane potential at 
the level of normothermic ASC (fig.5f). Concurrent with the loss in 
mitochondrial membrane potential, hypothermic ASC, as well as α-
tocopherol and TROLOX-treated ASC showed an increase in 
mitochondrial superoxide production (fig.5g), which is associated 
with cell death [28]. SUL-109-treated ASC did not show excessive 
mitochondrial superoxide formation (fig.5g). 
  





Figure 5. SUL-109 maintains mitochondrial function and integrity and 
function during hypothermic damage. Assessment of mitochondrial 
oxidative phosphorylation  
(a) and glycolysis (b) in hypothermia challenged ASC. Hypothermia reduces 
the basal oxygen consumption rate (OCR) of ASC, which is normalized by 
treatment with TROLOX or SUL-109 (c). During forced respiration,  SUL-109 
maintains the mitochondrial OCR, but does not affect glycolysis (d). 6-
chromanols protect against hypothermia-induced fission of mitochondria 
with different efficacies (e) and maintain the mitochondrial membrane 
potential (f). Concurrently, mitochondrial Superoxide production is reduced 
(g). TOCO = α-tocopherol, OCR = Oxygen Consumption Rate, ECAR = 
Extracellular Acidification Rate, FCCP = Carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone, CCCP = Carbonyl cyanide m-
chlorophenyl hydrazone, N2 = liquid nitrogen cryopreservation, *** 
p<0.001. 
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As SUL-109 maintained mitochondrial spare capacity in ASC following 
hypothermia/rewarming, we questioned at what level SUL-109 
influenced mitochondrial respiration and performed activity 
measurements for mitochondrial complexes I-V on isolated ASC-
derived mitochondria (fig.6). SUL-109 dose-dependently increased 
the activity of mitochondrial complexes I and IV (1.1-fold and 2.1-
fold (p<0.05), respectively, figs.6a,e) but did not affect the activity of 
mitochondrial complexes II, III and V (suppl.fig.1).  
Concurrently, SUL-109 at a concentration of 1 µM inhibited the 
rotenone-induced reduction of complex I activity (fig.6b) and the 
potassium cyanide (KCN)-induced reduction of complex IV activity 
(fig.6f).  
Given the maintenance of mitochondrial function by SUL-109, we 
next investigated whether it also preserved ATP production and 
inhibited mitochondrial ROS production in ASC following damage. To 
this end we treated mitochondria isolated from ASC with either 
rotenone or KCN to inhibit ATP production and induce ROS 
generation. Indeed, SUL-109 treatment almost completely restored 
ATP production in rotenone-treated ASC (fig.6c) and normalized their 
mitochondrial ROS production (fig.6d) to baseline levels.  
Likewise, SUL-109 treatment dose-dependently restored ATP 
production (fig.6g) and inhibited ROS generation (fig.6h) in KCN-
treated ASC. These data imply that SUL-109 protects cells from 
oxidative stress by maintenance of the mitochondrial function 





Figure 6. SUL-109 activates mitochondrial complex I and IV to maintain 
ATP production and inhibit ROS formation. SUL-109 activates 
mitochondrial complex I (a) and dose-dependently limits the rotenone-
induced inhibition of complex I activity (b) in isolated ASC-derived 
mitochondria. Resulting from its effects on complex I, SUL-109 dose-
dependently increases ATP production in rotenone-treated ASC (c) and 
reduces mitochondrial ROS formation (d). Besides, SUL-109 activates 
mitochondrial complex IV (e) and dose-dependently limits the KCN-induced 
inhibition of complex IV activity (f) in isolated ASC-derived mitochondria. 
Resulting from its effects on complex IV, SUL-109 dose-dependently 
increases ATP production in KCN-treated ASC (g) and reduces 
mitochondrial ROS formation (h). * p<0.05, ** p<0.01, *** p<0.001, KCN = 
potassium cyanide. 




Supplemental figure 1. SUL-109 does not affect the activity of 
mitochondrial complexes II, III and V. SUL-109 does not alter the activity of 
mitochondrial complex II (a), III (b) and V (c) activity, nor does it limit the 
reduction of complex II, III and IV activity by 2-TTFA (d), Antimycin A (e) and 




Here we describe the efficacy of the novel pharmacologic compound, 
(6-hydroxyl-2,5,7,8-tetramethylchroman-2-yl)(4-(2-
hydroxyethyl)piperazin-1-yl)methanone (SUL-109), that protects ASC 
from hypothermic damage and cell death during cell preservation 
without affecting their multipotency.  
SUL-109 conveys its protective effect by preserving the 
mitochondrial network structure and activating mitochondrial 
complexes I and IV, therefore maintaining ATP production and 
preventing ROS formation. SUL-109 protects ASC from damage 
associated with hypothermic cell preservation and simplifies the 
application of ASC in cell therapy and tissue engineering by removing 
the major limitations of cell death and dysfunction encountered 
during the manufacturing process. 
Despite the encouraging progress in experimental regenerative 
medicine applications of stem cells for the treatment of chronic 
diseases [3, 4, 8, 9], clinically acceptable methods of cell preservation 
are poorly developed [11, 29-31].  
Current advances in cell therapy and tissue engineering thus create 
the need for standardized procedures for short term cell 
preservation that void the necessity of using expensive 
cryopreservation or vitrification equipment and laborious protocols 
[11] or the usage of cell preservation reagents that are toxic to cells 
at ambient temperatures (e.g. dimethyl sulfoxide) [32-34], to allow 
for proper quality control and transport of cells from their 
manufacturing facility to their clinical destination. Low- temperature 
cell pausing, or hypothermic preservation of cells in their specialized 
culture media, holds great potential as short-term cell storage in 
these respects [11, 35].  
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Low temperatures have a wide range of beneficial effects in the 
context of cell preservation, i.e. a reduction of energy-dependent 
processes such as cell cycle progression and protein synthesis [36-
39], but may also induce cell damage. The hypothermia-induced 
reduction in ATP production causes an influx of sodium ions that is 
no longer counteracted by the Na+-K+-ATPase, which is followed by 
an influx of water and the concomitant cell swelling results in 
necrotic cell damage [40, 41].  
Additionally, the generation of ROS during the rewarming phase 
causes a significant apoptotic response [42-44], wherein only slight 
changes in temperature (~5°C) can have detrimental effects on stem 
cell survival [45]. The addition of antioxidants to cell preservation 
media is reported to reduce the hypothermia-induced apoptosis [14, 
46], but fails to limit the necrosis induction as ATP production is 
limited during hypothermia. Moreover, some cell preservation 
solutions are reported to be toxic to ASC [REF], stressing the urgency 
of developing a cell culture additive that can void the hypothermic 
damage. Notably, SUL-109 maintained ATP production under 
hypothermic conditions and inhibited the generation of ROS upon 
rewarming. Concurrently, SUL-109 inhibited both the hypothermia-
induced apoptosis and necrosis. Hypothermic cell preservation 
induces cell cycle arrest due to the reduction of available ATP in the 
cold phase and the accumulation of ROS-induced DNA damage 
during the rewarming phase [25, 36, 37]. We show hypothermia to 
induce growth arrest which is maintained in ASC 48h post-
rewarming. Alpha-tocopherol, TROLOX and SUL-109 maintained cell 
cycle activity, whereas proliferation of SUL-109-treaded cells was 
similar to ASC that had not encountered a hypothermia challenge. 
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Hypothermia and cryopreservation protocols can also limit the 
multipotency or induce differentiation of stem cells [47, 48]. 
Therefore, we investigated the multilineage differentiation of ASC 
that were subjected to a hypothermic challenge for 48h. ASC that 
survived the hypothermic challenge maintained their differentiation 
capacity towards adipocytes, osteoblasts and muscle cells regardless 
of their treatment.  
We explored the mechanisms-of-action by which SUL-109 could 
protect the ASC from damage encountered during hypothermic 
preservation and rewarming and found that the protective effects 
were not derived from the ROS-scavenging capability of 6-
chromanols [19, 20, 49], as antioxidant capacity did not associate 
with cell survival. Rather, SUL-109 increases the activity of 
mitochondrial complexes I and IV, thereby maintaining the 
mitochondrial membrane potential, ATP production and 
minimalizing ROS generation. 6-chromanols might form Quinones 
[49, 50], the electron acceptor substrate for mitochondrial 
complexes I and II, upon oxidation. Therefore, it seems conceivable 
that such mechanism underlies the increase in mitochondrial 
complex I activity by SUL-109 following hypothermia [51-53]. 
Notably, short-chain Quinones are able to bypass a deficiency in 
complex I by shuttling electrons directly from the cytoplasm to 
complex III of the mitochondrial respiratory chain to maintain ATP 
production [54]. 
Cytochrome c-mediated lipid peroxidation, resulting in a decreased 
mitochondrial membrane potential and decreased ATP production, is 
highly influenced by ROS and hypothermia [55-57]. Cytochrome c 
acts as an electron shuttle between mitochondrial complexes III and 
IV [58], which facilitates oxidative phosphorylation and thus ATP 
production. ROS or hypothermia-induced conformational changes in 
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cytochrome c, facilitate its binding to cardiolipin and the resulting 
partial unfolding of cytochrome c [59], enable its lipid peroxidation 
activity while decreasing the amount of cytochrome c available for 
oxidative phosphorylation [60-62]. Hence, this conformational 
change in cytochrome c might contribute to the mitochondrial 
dysfunction observed during hypothermia. Pentamethyl-6-
chromanol (PMC), another vitamin E analogue with structural 
similarity to SUL-109, reduces cytochrome c-mediated lipid 
peroxidation [62] by a mechanism that is currently not elucidated. 
Therefore, we postulate that SUL-109 also preserves the 
conformational state of cytochrome c, which thereby remains 
available for oxidative phosphorylation and ATP production. 
Although this mechanism might explain how SUL-109 maintains the 
mitochondrial membrane potential and ATP production by complex 
IV following hypothermia, it does not clarify why SUL-109 raises the 
activity of mitochondrial complex IV in normothermic cells. Shuttling 
of electrons from the cytoplasm to mitochondrial complex III [54] 
and the concomitant increase in oxidized cytochrome c represent 
potential mechanisms, but this effect of SUL-109 needs further 
biochemical exploration. 
In conclusion, here we describe the efficacy of SUL-109, a 6-
chromanol derivate that protects ASC against hypothermic cell 
damage during preservation. The protective effects of SUL-109 
against hypothermia are twofold; (1) SUL-109 has an antioxidant 
capacity, and (2) SUL-109 maintains the integrity of the mitochondria 
and activates mitochondrial complexes I and IV, which conserved 
ATP production and mitigates ROS production. Therefore, SUL-109 
represents a single molecule cell preservation agent that protects 
ASC from hypothermic damage associated with short-term cell 
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Diabetes mellitus (DM) is one of the world's fastest growing diseases. 
In fact, it is a heterogeneous set of metabolic disorders that all 
feature hyperglycemia [1]. Diabetic retinopathy (DR) influences one 
third of individuals who experience the effects of DM [2].  In the 
early phases of DR, hyperglycemia causes pericyte demise and 
thickening of the basement membrane, which compromises the 
integrity of retinal vessels and the increases the permeability of the 
blood-retinal barrier [3]. The subsequent collapse of retinal vessels is 
unequivocally connected with the consequence of ischemia and 
results in the release of angiogenic factors in the affected area. This 
advances the DR to the proliferative phase (PDR) where adverse and 
aberrant neovascularization occurs. Accumulation of liquid follows 
due to fragile dysfunctional vessels inside the retina, named macular 
edema, and strongly contributes the loss of vision. PDR is the main 
source of visual impairment among adults in the working age [4-6]. 
The retinal vessels are excessively covered with pericytes. As a 
matter of fact, the EC to pericyte ratio is the highest in the body i.e. 
1: 1. This also means that loss of pericytes not only is an early 
pathological marker for developing DR but also that the ramifications 
are expectedly serious and warrant the development of pericyte 
replacement therapy to treat DR [7]. A great part of the work from 
our research lab and others brings forward that the retinal 
restorative angiovasculogenesis process should include pericyte 
replacement to stabilize and normalize the function of the retinal 
vasculature [8-11].  
This approach is intended to target early phases of DR to improve 
vascular regeneration, diminish inflammatory stimulations, adjust 
hypoxia and ischemia and anticipate advancement to the late phases 
of DR. Adipose tissue-derived stromal cells (ASC) belong to 




plastic adherent capacity; (b) their expression panel of certain cell 
surface markers (i.e. +CD73, +CD90, +CD105, -CD34, -CD45); and (c) 
their ability to differentiate into osteocytes, chondrocytes and 
adipocytes [12, 13]. These parameters make ASC an alluring choice 
for cell therapy. In co-culture with endothelial cells (EC), ASC prompt 
vascular network formation. The particular confinement of ASC on 
the abluminal side of EC enhances the stability of vascular network 
[8, 10, 11, 14]. Cultured ASC have phenotypic and functional 
similarities with perivascular pericytes and either share the similar 
surface markers including NG2, CD140a, and CD140b (PDGFR α and 
β) [14, 15]. Injected ASC into diabetic rat model procured pericytic 
features. ASC incorporated with the retinal microvasculature and 
could protect retinal proliferative angiogenesis [10, 11]. Therefore, 
ASC-derived pericyte replacement would be an effective 
development in treatment of DR. Type 2 diabetes is clinically 
portrayed by hyperglycemia (HG) combined by relative insulin 
inadequacy [16].  
Although, diabetic retinal pericytes experience hyperglycemic 
condition and oxidative stress-induced apoptosis, ASC-derived 
pericytes onto the diabetic retinal vasculature remains unclear. In 
chapter 2, we showed the impact of HG on ASC in vitro. HG 
stimulates generation of mitochondrial reactive oxygen species 
(ROS), which significantly contributes to the pathogenesis of vascular 
complications of diabetes [17]. HG has impact on retinal EC and 
pericytes, instigated mitochondrial fragmentation which decreased 
mitochondrial function [18, 19].  
HG actuate oxidative stress damage in the inner membrane of 
mitochondria and causes the disability of mitochondria, which 
prompts imbalance in the electron transport chain and therefore 
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overproduction of ROS [20]. We indicated ASC had extensive 
production of intracellular ROS following 7 days culture in HG. HG 
actuates mitochondrial dysfunction in ASC, as shown by a diminished 
mitochondrial membrane potential in HG and adverse morphological 
structural changes of the mitochondrial network. The observed ROS 
overproduction augmented apoptosis and necrosis in ASC. We 
demonstrated that ASC somehow resist this HG-induced 
mitochondrial dysfunction because the proliferation of ASC after 
exposure to HG was not influenced. We demonstrated that 
mitochondrial ASC, in normoglycemia (NG), harbor an extensive and 
extensively branched mitochondrial tubular network. This network is 
essential for mitochondrial function and regulated by fusion and 
fission events [21].  
Interruption of mitochondrial fusion and fission causes 
fragmentation of the mitochondrial network, which brings about 
shorter and rounder mitochondria [22]. Our outcomes indicate that 
HG-induced mitochondrial fragmentation is associated with the 
formation of ROS in HG-challenged ASC. The fact that mitochondria 
under HG show the same basal respiration as under NG, 
demonstrates that ASC manage the HG condition. However, we 
showed that HG caused a reduction of the maximal oxygen 
consumption rate (OCR) and diminished the basal level of 
extracellular acidification. The latter suggest that HG dampens the 
glycolysis rate in ASC. Remarkably, HG caused a huge decrease in 
glucose take-up in ASC.  
We propose that ASC under HG compensate the hyperglycemic 
condition by changing the metabolic limit, as shown by reduced 
glucose uptake, diminished OCR and glycolysis. In spite of these 
bioenergetics changes in ASC under HG, we showed that ASCs’ ability 




maintained. The ROS-incited mitochondrial fragmentation and 
apoptosis only partially influenced the pericytic capacity of ASC. This 
data may depict both their capacities and restrictions regarding 
ASCs’ potential to treat the vasculopathy component of DR. In spite 
of the fact that mitochondria vary in structure and capacity in 
different cell types, they share some basic features.  
Mitochondria are closely confined organelles that comprise a 
complex system of two membranes that are required for the 
majority of energy generation, i.e. generation of ATP and GRP by the 
oxidative phosphorylation [23]. Mitochondria are also the major 
source of cellular ROS and likewise are relevant targets for the 
negative impacts of these oxidants. Prolonged oxidative damage to 
the mitochondrial inner membrane imbalances the electron 
transport chain. This could bring about overproduction of ROS and 
disturb mitochondrial membrane proteins additionally [24]. When 
cytochrome-c is discharged from mitochondria, it serves to activate 
apoptosis via the intracellular, intrinsic, route. Cytochrome-c binds to 
caspase-9, which activates caspase-3 which further upregulates and 
executes apoptosis. Mitochondrial oxidative stress increased in ASC 
under HG [25].  
The retina is highly demanding with regard to energy production and 
consumption. Therefore chronic exposure to oxidative stress renders 
the retina one of the body’s most sensitive organs to mitochondrial 
dysfunction [26]. Mitochondrial inability to accomplish energy 
pathways may cause more severe complications in diabetes [27]. 
Identifying mitochondrial dysfunction is essential for the 
advancement of novel stem cell therapies. In regard to this point, in 
chapter 3, we presented the assessment of energy metabolic 
changes in ASC in details. Our reproducible methods included: 
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isolation of ASC from subcutaneous fat tissue, ASC culturing, 
measuring of apoptosis and necrosis in ASC, detecting intracellular 
and mitochondrial ROS, monitoring mitochondrial health via 
mitochondrial morphology and measuring the mitochondrial 
membrane potential, evaluating ASC bioenergetics profiling using 
Extracellular Flux Analyzer (Seahorse Bioscience) and detecting the 
glucose uptake from ASC as a detector of glycolysis.  
Our methods provided extensive information to evaluate 
bioenergetical changes in ASC cultured under HG condition and more 
upcoming in vitro studies. Above and beyond hyperglycemia, there is 
proof that low level inflammation triggers the vascular complexities 
of DR. Undoubtedly, chronic inflammation is a trademark seen at DR 
which is detectable by elevated TNF-α, IL-1β and activated 
leukocytes [28]. Immunosuppressive capability is imparted to ASC, 
which appear to be extremely efficient in various studies [29-32]. 
Mesenchymal stem/stromal cells (MSC) demonstrate their 
immunomodulatory capacities by direct cell-cell contact and indirect 
paracrine effect via indoleamine-2,3-dioxygenase (IDO), nitric oxide 
(NO), prostaglandin-E2 (PGE-2), IL-10 to mention a few [33-35].  
In chapter 4, we showed the dual efficacy of ASC in promoting the 
vascular network formation in contact with EC in vivo and its 
paracrine immunomodulatory effect on retinal endothelial cells 
under HG-induced inflammatory status. Ultrastructure analysis of 
our ASC-EC coculture underlined the juxtacrine i.e. pericytic role of 
ASC in the maintenance of the vascular architecture. One of the 
working definitions of pericytes is that these are ‘matrix-embedded’ 
cells in contact with endothelial cells. This is corroborated by our 
investigations which show that ASC deposited extracellular matrix 




To confirm our in vitro results, ASC injected intravitreally into 
retinopathy of prematurity (ROP) mouse models. The injected ASC 
are found on angiogenic sprouts and in pericyte-specific extra-
luminal positions in the immature vascular tree. Attachment of ASC 
to EC resulted in increased retinal neovascularization, suggesting 
that ASC also in vivo increased the stability of the vessels. Reduced 
expression of pericyte-derived angiopoietin-1, upregulation of 
angiopoietin-2 alongside with increased VEGFA levels prompts vessel 
destabilization and initiates pathological angiogenesis in the eye 
[36]. The mRNA analysis of ROP retinas which were injected with ASC 
revealed that the total mRNA levels of Angpt1 and Fgf2 were 
increased, while levels of Angpt2 and Vegfa were reduced. In this 
study, ASC injection into the ROP promotes expression of 
inflammatory genes like Tnf, Cxcl15 and Ccl2 in retina which was 
expected due to the applying of early-passage of ASC. ASC in early 
passages express MHCII, CD80, and CD86 which may stimulate APCs 
and trigger the immune reaction. However, by passaging the ASC, 
these APC-related markers are lost [37, 38].  
MSC should be activated by inflammatory mediators (i.e. cytokines) 
to apply their immunomodulatory properties [39]. In this way, the 
inflammatory status at the time of ASC injection is important to get 
the best clinical advantages. In general, HG is considered as a pro-
inflammatory environment which causes upregulation of pro-
inflammatory cytokines in retinal cells [40]. Comparison between 
ASC in acute (seven days) and chronic (several passages) 
hyperglycemic condition showed high upregulation of TNF, IL1A, IL6, 
CXCL8, CCL2, PTGS2, CXCL12, MMP1, IDO1, VEGFA, ANGPT1, SLC2A1, 
RGS5 genes only after acute exposure to HG. In contrast, chronic 
exposure to HG led to decreased levels, even lower than under 
chronic NG mainenance, of secreted PGE2. The action of PGE2 is 
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paradoxal: known as immunosuppressor of macrophage and T cell 
function, it is an important pro-inflammatory activator of EC and 
fibroblasts. The secretion of the chemoattractant CCL2 is also 
normalized under chronic hyperglycemic maintenance of ASC. 
Therefore, we suggest that for vascularization therapy, the 
preculturing of ASC under hyperglycemia should be chronic i.e for 
more than 3 passages, before injecting into hyperglycemic 
environment. ASC conditioned medium (ASC-Cme) produced under 
standardized and reproducible conditions could be an alternative to 
transplantation of (autologous) ASC in cell therapy. We showed that 
ASC-Cme rescues bovine retinal endothelial cells (BREC) from 
hyperglycemia-induced apoptosis and inflammatory activation. This 
impact on BREC was evoked by the ROS-inhibiting ability of ASC-Cme 
as it could decrease the hyperglycemia-induced ROS in culture.  
The antioxidant capacity of ASC-Cme correlated to the reduced NF-
κB activation in the BREC. The BREC under HG activate NF-κB 
pathway followed by pro-inflammatory genes upregulation. ASC-
Cme in HG-treated BREC suppressed main pro-inflammatory 
pathways like COX2/PGE2 and VEGFA as a proangiogenic gene.  
We show that adhesion of adherent THP-1 cells to HG-activated 
BREC was suppressed by ASC-Cme and coincided with the 
downregulation of related genes as VCAM-1, ICAM-1 and SELE. We 
suggest that inhibiting ROS by ASC-Cme can decrease the expression 
of upregulated pro-inflammatory genes besides their production.  
Our findings show a strong therapeutic potential of ASC in DR. 
Presently, all the treatment strategies which are based on temporary 
or permanently cell replacement called cell therapy. Replaced cells 
may use as immunomodulatory mediator or as a new functional 




The field of cell therapy is quickly developing, thusthere are 
numerous challenges that should be tackled before cell therapy is 
broadly embraced. Whereas a significant part of the studies focuses 
on how cells should be adequately isolated, expanded and 
transplanted, only minor consideration has been given to how these 
cells can be well-maintained and transported to their clinical 
destination. Hypothermic storing of cells in their own culture 
medium proposes an interesting option to skip the difficulties of 
liquid nitrogen cryopreservation or commercial preservation 
methods. Anyhow, post-thawing cell death or during the rewarming 
period is likely to occur through the overproduction of ROS. In 
chapter 5, We tested the efficacy of a new pharmacologic 
compound, (6-hydroxyl-2,5,7,8-tetramethylchroman-2-yl)(4-(2-
hydroxyethyl)piperazin-1-yl) methanone (SUL-109), that shields ASC 
during cell preservation from hypothermic cell death without 
influencing their multi-potency capacity.  
We showed that the protective effect of SUL-109 is through 
maintenance of the mitochondrial membrane potential and 
promoting the activation of mitochondrial complexes I and IV, 
consequently sustaining ATP production and preventing the 
overproduction of ROS under hypothermic conditions. In this way, 
SUL-109 inhibited hypothermia-induced apoptosis and necrosis. This 
impact was retained during the rewarming phase as well. We 
showed proliferation of ASC under SUL-109 treatment was 
comparable to ASC that had not been challenged with hypothermia. 
Cryopreservation and hypothermia may constrain the multi-potency 




SUL-109-treated ASC maintained their differentiation capacity into 
adipocytes, osteocytes and smooth muscle cells. We proposed that 
6-chromanols derivate SUL-109 may form quinones, the electron 
acceptor for mitochondrial complexes I and II [43, 44] so, it is 
possible that this mechanism activates mitochondrial complex I 
following hypothermia. Cytochrome-c enables oxidative 
phosphorylation and consequently ATP production via transporting 
electrons among mitochondrial complexes III and IV [45]. We assume 
that SUL-109 decreases cytochrome-c-mediated lipid peroxidation 
and can preserve the conformational state of cytochrome-c, which is 
remained accessible for oxidative phosphorylation and ATP 
production. The protective impact of SUL-109 through its antioxidant 
capacity and mitochondrial function and integrity maintenance, 
effectively eliminating the cell death and dysfunction challenges of 
ASC during hypothermic preservation processes.  
Nonetheless, this is an exciting area of future studies that would 





1. Alam, U., et al., General aspects of diabetes mellitus. Handb Clin Neurol, 2014. 
126: p. 211-22. 
2. Kempen, J.H., et al., The prevalence of diabetic retinopathy among adults in the 
United States. Arch Ophthalmol, 2004. 122(4): p. 552-63. 
3. Frank, R.N., Diabetic retinopathy. N Engl J Med, 2004. 350(1): p. 48-58. 
4. Klein, R., et al., The Wisconsin epidemiologic study of diabetic retinopathy. III. 
Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more 
years. Arch Ophthalmol, 1984. 102(4): p. 527-32. 
5. Moss, S.E., R. Klein, and B.E. Klein, Ten-year incidence of visual loss in a diabetic 
population. Ophthalmology, 1994. 101(6): p. 1061-70. 
6. Thylefors, B., et al., Global data on blindness. Bull World Health Organ, 1995. 
73(1): p. 115-21. 
7. Armulik, A., A. Abramsson, and C. Betsholtz, Endothelial/pericyte interactions. 
Circ Res, 2005. 97(6): p. 512-23. 
8. Hajmousa, G., et al., Hyperglycemia Induces Bioenergetic Changes in Adipose-
Derived Stromal Cells While Their Pericytic Function Is Retained. Stem Cells Dev, 
2016. 25(19): p. 1444-53. 
9. Loffredo, F. and R.T. Lee, Therapeutic vasculogenesis: it takes two. Circ Res, 
2008. 103(2): p. 128-30. 
10. Mendel, T.A., et al., Pericytes derived from adipose-derived stem cells protect 
against retinal vasculopathy. PLoS One, 2013. 8(5): p. e65691. 
11. Rajashekhar, G., et al., Regenerative therapeutic potential of adipose stromal 
cells in early stage diabetic retinopathy. PLoS One, 2014. 9(1): p. e84671. 
12. Bunnell, B.A., et al., Adipose-derived stem cells: isolation, expansion and 
differentiation. Methods, 2008. 45(2): p. 115-20. 
Chapter 6 
254 
13. Dominici, M., et al., Minimal criteria for defining multipotent mesenchymal 
stromal cells. The International Society for Cellular Therapy position statement. 
Cytotherapy, 2006. 8(4): p. 315-7. 
14. Traktuev, D.O., et al., A population of multipotent CD34-positive adipose 
stromal cells share pericyte and mesenchymal surface markers, reside in a 
periendothelial location, and stabilize endothelial networks. Circ Res, 2008. 102(1): 
p. 77-85. 
15. Merfeld-Clauss, S., et al., Adipose tissue progenitor cells directly interact with 
endothelial cells to induce vascular network formation. Tissue Eng Part A, 2010. 
16(9): p. 2953-66. 
16. Mathis, D., L. Vence, and C. Benoist, beta-Cell death during progression to 
diabetes. Nature, 2001. 414(6865): p. 792-8. 
17. Kroemer, G., Mitochondrial implication in apoptosis. Towards an endosymbiont 
hypothesis of apoptosis evolution. Cell Death Differ, 1997. 4(6): p. 443-56. 
18. Trudeau, K., et al., High glucose disrupts mitochondrial morphology in retinal 
endothelial cells: implications for diabetic retinopathy. Am J Pathol, 2010. 177(1): 
p. 447-55. 
19. Trudeau, K., A.J. Molina, and S. Roy, High glucose induces mitochondrial 
morphology and metabolic changes in retinal pericytes. Invest Ophthalmol Vis Sci, 
2011. 52(12): p. 8657-64. 
20. Li, S.Y., Z.J. Fu, and A.C. Lo, Hypoxia-induced oxidative stress in ischemic 
retinopathy. Oxid Med Cell Longev, 2012. 2012: p. 426769. 
21. Karbowski, M. and R.J. Youle, Dynamics of mitochondrial morphology in healthy 
cells and during apoptosis. Cell Death and Differentiation, 2003. 10(8): p. 870-880. 
22. Scorrano, L., Multiple functions of mitochondria-shaping proteins. Novartis 
Found Symp, 2007. 287: p. 47-55; discussion 55-9. 
23. Scheffler, I.E., A century of mitochondrial research: achievements and 




24. Kowluru, R.A., Diabetic retinopathy: mitochondrial dysfunction and retinal 
capillary cell death. Antioxid Redox Signal, 2005. 7(11-12): p. 1581-87. 
25. Kristal, B.S., et al., Oxidant-mediated repression of mitochondrial transcription 
in diabetic rats. Free Radical Biology and Medicine, 1997. 22(5): p. 813-822. 
26. D'Amico, A. and E. Bertini, Metabolic neuropathies and myopathies. Handb Clin 
Neurol, 2013. 113: p. 1437-55. 
27. Patti, M.E. and S. Corvera, The role of mitochondria in the pathogenesis of type 
2 diabetes. Endocr Rev, 2010. 31(3): p. 364-95. 
28. Lutty, G.A., Effects of diabetes on the eye. Invest Ophthalmol Vis Sci, 2013. 
54(14): p. ORSF81-7. 
29. Constantin, G., et al., Adipose-derived mesenchymal stem cells ameliorate 
chronic experimental autoimmune encephalomyelitis. Stem Cells, 2009. 27(10): p. 
2624-35. 
30. Gonzalez, M.A., et al., Treatment of experimental arthritis by inducing immune 
tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum, 
2009. 60(4): p. 1006-19. 
31. Puissant, B., et al., Immunomodulatory effect of human adipose tissue-derived 
adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J 
Haematol, 2005. 129(1): p. 118-29. 
32. Yanez, R., et al., Adipose tissue-derived mesenchymal stem cells have in vivo 
immunosuppressive properties applicable for the control of the graft-versus-host 
disease. Stem Cells, 2006. 24(11): p. 2582-91. 
33. Franquesa, M., M.J. Hoogduijn, and C.C. Baan, The impact of mesenchymal 
stem cell therapy in transplant rejection and tolerance. Curr Opin Organ 
Transplant, 2012. 17(4): p. 355-61. 
Chapter 6 
256 
34. Pourgholaminejad, A., et al., The effect of pro-inflammatory cytokines on 
immunophenotype, differentiation capacity and immunomodulatory functions of 
human mesenchymal stem cells. Cytokine, 2016. 85: p. 51-60. 
35. Ringden, O., et al., Mesenchymal stem cells for treatment of therapy-resistant 
graft-versus-host disease. Transplantation, 2006. 81(10): p. 1390-7. 
36. Cai, J., et al., The angiopoietin/Tie-2 system regulates pericyte survival and 
recruitment in diabetic retinopathy. Invest Ophthalmol Vis Sci, 2008. 49(5): p. 
2163-71. 
37. Lindroos, B., R. Suuronen, and S. Miettinen, The potential of adipose stem cells 
in regenerative medicine. Stem Cell Rev, 2011. 7(2): p. 269-91. 
38. McIntosh, K., et al., The immunogenicity of human adipose-derived cells: 
temporal changes in vitro. Stem Cells, 2006. 24(5): p. 1246-53. 
39. Krampera, M., Mesenchymal stromal cell 'licensing': a multistep process. 
Leukemia, 2011. 25(9): p. 1408-14. 
40. Tang, J. and T.S. Kern, Inflammation in diabetic retinopathy. Prog Retin Eye Res, 
2011. 30(5): p. 343-58. 
41. Mason, C., et al., Cell therapy industry: billion dollar global business with 
unlimited potential. Regen Med, 2011. 6(3): p. 265-72. 
42. Pogozhykh, D., et al., Influence of Factors of Cryopreservation and Hypothermic 
Storage on Survival and Functional Parameters of Multipotent Stromal Cells of 
Placental Origin. PLoS One, 2015. 10(10): p. e0139834. 
43. Erb, M., et al., Features of Idebenone and Related Short-Chain Quinones that 
Rescue ATP Levels under Conditions of Impaired Mitochondrial Complex I. Plos One, 
2012. 7(4). 
44. Karuppagounder, S.S., et al., Quercetin up-Regulates Mitochondrial Complex-I 
Activity to Protect against Programmed Cell Death in Rotenone Model of 




45. Errede, B. and M.D. Kamen, Comparative kinetic studies of cytochromes c in 
reactions with mitochondrial cytochrome c oxidase and reductase. Biochemistry, 
1978. 17(6): p. 1015-27. 
Chapter 6 
258 
Therapeutic actions of ASC in the normalization of 
hyperglycemically challenged retinal endothelial cells: a roadmap 

















Towards adipose tissue derived stromal cells-based 
therapy for diabetic retinopathy 
 
In this thesis we investigated the impact of hyperglycemia as a model 
for diabetes on adipose tissue-derived stromal cells (ASC) as a 
prelude to their use in future therapeutic treatment of diabetic 
retinopathy (DR). DR is a multifactorial complexity characterized by 
incessant and fluctuating hyperglycemia, mild chronic inflammation 
and vascular as well as neuronal dysfunction. Hyperglycemia-
initiated overproduction of reactive oxygen species (ROS) causes 
mitochondrial dysfunction in retinal vascular cells and leads to fragile 
and defective vessels. Hypoxia causes non-perfused vessels and 
brings about the proliferative phase of DR that is associated with 
increased secretion of proangiogenic factors and propelling the 
pathological neovascularization in parallel with the chronic 
inflammation in diabetic retina. Considering the absence of effective 
treatments for DR, cell-based therapy may offer novel strategies by 
supplanting of the lost cells to forestall advanced DR and adjust the 
inflammatory state by means of their anti-inflammatory and anti-
angiogenic paracrine factors as well as juxtacrine interactions 
between stem cells and dysfunctional vessels.  
We showed that ASC may indeed impact progression of DR in 
multiple ways. As indicated by their phenotypic and functional 
similarities with perivascular pericytes, ASC offer suitable swap for 
the pericyte lost in the early phases of DR.  Ultrastructure analysis of 
co-cultured ASC-endothelial cells (EC) featured the juxtacrine i.e. 




combined by deposition of extracellular matrix components that 
separated the ASC from the EC. ASC-derived pericytes under 
hyperglycemic condition still support new formed vascular networks 
by endothelial cells in culture. The ROS-incited mitochondrial 
dysfunction and hyperglycemia-induced apoptosis only partially 
influenced the pericytic ability of ASC. Despite of the diminished 
level of maximal oxygen consumption rate (OCR) and glycolysis, ASC 
under HG showed the same basal respiration as under NG which 
proves that ASC resist the HG condition by changing the metabolic 
limit deprived of altering the proliferation rate. Injected ASC into 
retinopathy of prematurity (ROP) mouse models are found in 
pericytic positions on angiogenic new formed vessels. ASC 
administration upregulated the mRNA level of Angpt1 and Fgf2 and 
reduced the expression of Angpt2 and Vegfa in ROP retinas. 
Preculturing of ASC under hyperglycemia should be ‘chronic’, before 
injecting into hyperglycemic environment. Comparison between ASC 
in acute (seven days) and chronic (several passages) hyperglycemic 
condition showed high upregulation of pro-inflammatory and pro-
angiogenic genes only after acute exposure to HG. Interestingly, 
chronic HG diminished secretion of PGE2 and the chemoattractant 
CCL2 in ASC.  
ASC-conditioned medium (ASC-Cme) delivered from ASC cultured in 
chronically HG protected bovine retinal endothelial cells (BREC) from 
hyperglycemia-induced apoptosis and inflammatory activation. This 
effect on BREC was evoked by the ROS-neutralizing capacity of ASC-
Cme in culture. The antioxidant capacity of ASC-Cme was associated 
with a reduced NF-κB activation in the BREC. We demonstrated that 
inhibition of ROS by ASC-Cme can downmodulate upregulated pro-
inflammatory genes. ASC-Cme in HG-treated BREC suppressed 
principle inflammatory pathways like COX2/PGE2 and prevented the 
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adhesion of adherent THP-1 cells to HG-activated BREC. Our results 
demonstrate a solid restorative capability of ASC in several processes 
associated with DR.  
Towards using the ASC for treatment of DR, we present a new 
hypothermic storing technique of cells in their own culture medium 
to well-maintain and transport the prepared cells to their clinical 
destination. The new pharmacologic compound, (6-hydroxyl-2,5,7,8-
tetramethylchroman-2-yl)(4-(2-hydroxyethyl)piperazin-1-yl) 
methanone (SUL-109) shields ASC during cell preservation from 
hypothermic cell death without influencing their multi-potency 
capacity and proliferation. We showed that the protective effect of 
SUL-109 is through maintenance of the mitochondrial membrane 
potential and promoting the activation of mitochondrial complexes I 
and IV, consequently sustaining ATP production and preventing the 
overproduction of ROS under hypothermic conditions. In this way, 
SUL-109 inhibited hypothermia-induced apoptosis and necrosis in 
ASC. This impact was retained during the rewarming phase as well. 
Our pre-clinical study endorses the medical translational expansion 
of adipose tissue derived stromal cells-based therapy for diabetic 






Op weg naar het gebruik van de uit vetweefsel 
afkomstige stromale cellenals voor therapie van 
diabetische retinopathie 
In dit proefschrift hebben we de impact van hyperglycemie op van 
vetweefsel afgeleide stromale cellen (ASC) onderzocht als een model 
voor diabetes en hun gebruik in toekomstige therapeutische 
behandelingen van diabetische retinopathie (DR). DR is een 
multifactoriële complexe ziekte die wordt gekenmerkt door 
onophoudelijke en fluctuerende hyperglycemie, milde chronische 
ontsteking en vasculaire als mede neuronale disfunctie. 
Hyperglycemie-geïnitieerde overproductie van reactieve 
zuurstofverbindingen (ROS) veroorzaakt mitochondriale disfunctie in 
retinale vasculaire cellen en leidt tot fragiele en defecte bloedvaten. 
Hypoxie veroorzaakt geblokkeerde vaten en brengt de proliferatieve 
fase van DR tot stand die geassocieerd is met verhoogde uitscheiding 
van pro-angiogene factoren die de pathologische neovascularisatie 
voortduwt en is parallel aan de chronische ontsteking in de 
diabetische retina. Gezien de afwezigheid van effectieve 
behandelingen voor DR, kan een cel gebaseerde therapie nieuwe 
strategieën bieden door de verloren cellen te vervangen om 
gevorderde DR te voorkomen en de inflammatoire toestand te 
verminderen. Stamcellen hebben ontstekingsremmende en anti-
angiogene paracriene factoren en juxtacrine interacties tussen 
stamcellen en de disfunctionele vaten.  
We hebben aangetoond dat ASC de progressie van DR inderdaad op 
meerdere manieren kunnen beïnvloeden. Zoals aangegeven, bieden 
ASC een mogelijkheid verloren perivasculaire pericyten te vervangen 
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in de vroege fasen van DR door hun fenotypische en functionele 
overeenkomsten. Ultrastructuuranalyse van ASC in kweek samen 
met endotheelcellen (EC) bevestigde de juxtacrine, dat wil zeggen 
dat de pericytische rol van ASC in het onderhoud van de vasculaire 
architectuur gecombineerd door afzetting van extracellulaire 
matrixcomponenten die het ASC van de EC scheiden. ASC-afgeleide 
pericyten onder hyperglycemische toestand ondersteunen nog 
steeds nieuw gevormde vasculaire netwerken door endotheelcellen 
in kweek. De ROS-geïnduceerde mitochondriale disfunctie en 
hyperglycemie-geïnduceerde apoptose beïnvloedden slechts 
gedeeltelijk het pericytische vermogen van de ASC. Ondanks het 
verminderde niveau van maximale zuurstofconsumptie (OCR) en 
glycolyse, vertoonden ASC onder HG dezelfde basale ademhaling als 
onder NG. Dit bewijst dat ASC de HG-toestand weerstaan door de 
metabole limiet aan te passen zonder de proliferatiesnelheid te 
veranderen. Geïnjecteerde ASC in retinopathie muismodellen (ROP) 
werden teruggevonden in pericytische posities op angiogene nieuw 
gevormde bloedvaten. ASC-toediening reguleerde het mRNA-niveau 
van Angpt 1 en Fgf2 op en verminderde de expressie van Angpt2 en 
Vegfa in ROP-retina’s. ASC moeten onder hyperglycemische condities 
worden geweekt voordat ze in een hyperglycemische omgeving 
worden geïnjecteerd. Vergelijking tussen ASC in acute (zeven dagen) 
en chronische (verschillende passages) hyperglycemische toestand 
toonde een verhoogde expressie van pro-inflammatoire en pro-
angiogene genen na acute blootstelling aan HG. Interessant is dat 
chronische HG de secretie van PGE2 en de chemoattractant CCL2 in 
ASC verminderde.  
ASC-geconditioneerd medium (ASC-Cme) afgeleid van ASC gekweekt 
in chronische HG beschermde endotheelcellen van runderen (BREC) 
van hyperglycemie-geïnduceerde apoptose en inflammatoire 




neutraliserende capaciteit van het ASC-Cme in kweek. Het 
antioxiderende vermogen van ASC-Cme was geassocieerd met een 
verminderde NF-KB-activering in de BREC. We hebben aangetoond 
dat remming van ROS door ASC-Cme verhoogde expressie van pro-
inflammatoire genen kan verminderen. In met HG behandelde BREC 
onderdrukte het ASC-Cme principiële inflammatoire routes zoals 
COX2 / PGE2 en voorkwam het de adhesie van aanhangende THP-1-
cellen aan HG-geactiveerde BREC. Onze resultaten tonen een solide 
herstellend vermogen van ASC in verschillende processen 
geassocieerd met DR.  
Op weg naar het gebruik van de ASC voor de behandeling van DR 
presenteren we een nieuwe hypotherme opslagtechniek van cellen 
in hun eigen kweekmedium om de geprepareerde cellen goed te 
onderhouden en naar hun klinische bestemming te transporteren. 
De nieuwe farmacologische verbinding (6-hydroxyl-2,5,7,8-
tetramethylchroman-2-yl) (4- (2-hydroxyethyl) piperazin-1-yl) 
methanon (SUL-109) beschermt ASC tijdens cel behoud van hypo 
thermische celdood zonder hun vermogen tot multipotentie en 
proliferatie te beïnvloeden. We toonden aan dat het beschermende 
effect van SUL-109 verklaard kan worden door het behoud van het 
mitochondriale membraanpotentieel en het bevorderen van de 
activering van mitochondriale complexen I en IV, waardoor de ATP-
productie wordt ondersteund en de overproductie van ROS onder 
hypotherme omstandigheden wordt voorkomen. Op deze manier 
remde SUL-109 hypothermie-geïnduceerde apoptose en necrose in 
ASC. Deze impact werd ook behouden tijdens de opwarmfase. Onze 
pre-klinische studie onderschrijft de medische translationele 
expansie van uit vetweefsel afkomstige stromale cellenals therapie 
voor diabetische retinopathie om zowel de retinale capillaire 
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